8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 63_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP 1_CD Accounting_NNP policies_NNS of_IN milestone_NN payments_NNS and_CC payments_NNS received_VBD on_IN Year_NN to_TO Year_NN to_TO the_DT signing_NN of_IN new_JJ contracts_NNS ._.
The_DT Companys_NNP future_NN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW General_NNP information_NN cash_NN flows_NNS will_MD also_RB be_VB impacted_VBN by_IN the_DT Companys_NNP SkyePharma_NNP PLC_NNP the_DT Company_NN and_CC its_PRP$ change_NN in_IN strategy_NN as_IN outlined_VBN in_IN the_DT EGM_NNP notice_NN 98.3_CD 32.0_CD subsidiaries_NNS together_RB the_DT Group_NNP is_VBZ a_DT speciality_NN dated_VBN 16_CD February_NNP 2006_CD ,_, principally_RB its_PRP$ stated_VBN aim_NN pharmaceutical_JJ Group_NNP which_WDT uses_VBZ its_PRP$ multiple_JJ drug_NN of_IN moving_VBG to_TO sustainable_JJ profitability_NN in_IN the_DT shortest_JJS 19.1_CD 29.1_CD delivery_NN technologies_NNS to_TO create_VB a_DT product_NN pipeline_NN possible_JJ time_NN and_CC its_PRP$ refocus_VB to_TO concentrate_VB on_IN oral_JJ 80.0_CD for_IN out-licensing_JJ to_TO marketing_VBG partners_NNS ._.
Consequently_RB the_DT Groups_NNS 0.3_CD near_IN term_NN working_VBG capital_NN requirements_NNS are_VBP uncertain_JJ 5.8_CD 5.9_CD The_DT Company_NN is_VBZ incorporated_VBN and_CC domiciled_VBN in_IN United_NNP and_CC sensitive_JJ to_TO the_DT timing_NN of_IN a_DT number_NN of_IN initiatives_NNS 14.2_CD 12.0_CD Kingdom_NNP ,_, with_IN its_PRP$ registered_JJ office_NN at_IN 105_CD Piccadilly_NNP ,_, required_VBN to_TO provide_VB the_DT financial_JJ flexibility_NN to_TO implement_VB 0.3_CD London_NNP W1J_NNP 7NJ_NNP ._.
These_DT initiatives_NNS include_VBP the_DT licensing_NN 0.9_CD 3.7_CD of_IN Flutiform_NNP in_IN Europe_NNP ,_, the_DT divestment_NN of_IN its_PRP$ injectable_JJ 7.3_CD 5.3_CD The_DT principal_JJ accounting_NN policies_NNS adopted_VBN in_IN business_NN interests_NNS ,_, which_WDT is_VBZ expected_VBN to_TO require_VB the_DT preparation_NN of_IN these_DT consolidated_JJ financial_JJ shareholder_NN approval_NN ,_, and_CC the_DT delay_NN of_IN certain_JJ statements_NNS are_VBP set_VBN out_RP below_IN ._.
licensing_NN discussions_NNS ,_, such_JJ as_IN US_NNP licensing_NN for_IN 1.0_CD 0.4_CD DepoBupivacaine_NNP pending_VBG the_DT divestment_NN of_IN its_PRP$ 7.0_CD 11.0_CD a_DT Basis_NN of_IN preparation_NN injectables_NNS business_NN ._.
13.3_CD 15.9_CD In_IN accordance_NN with_IN EU_NNP regulations_NNS ,_, SkyePharma_NNP is_VBZ required_VBN to_TO prepare_VB statutory_JJ financial_JJ statements_NNS The_DT Directors_NNS have_VBP reviewed_VBN the_DT working_VBG capital_NN which_WDT comply_VBP with_IN the_DT International_NNP Financial_NNP requirements_NNS of_IN the_DT Group_NNP for_IN the_DT next_JJ twelve_CD months_NNS Reporting_NNP Standards_NNPS adopted_VBD for_IN use_NN in_IN the_DT European_JJ and_CC have_VB a_DT reasonable_JJ expectation_NN that_WDT sufficient_JJ Union_NNP IFRS_NNP starting_VBG from_IN the_DT financial_JJ year_NN ended_VBD funds_NNS will_MD be_VB raised_VBN from_IN these_DT initiatives_NNS and_CC have_VBP 31_CD December_NNP 2005_CD ,_, being_VBG the_DT first_JJ financial_JJ year_NN ,_, therefore_RB prepared_VBD the_DT financial_JJ information_NN contained_VBD commencing_VBG after_IN 1_CD January_NNP 2005_CD ._.
herein_NN on_IN a_DT going_VBG concern_NN basis_NN which_WDT assumes_VBZ that_IN the_DT Company_NN will_MD continue_VB in_IN operational_JJ existence_NN The_DT International_NNP Financial_NNP Reporting_NNP Standards_NNPS for_IN the_DT foreseeable_JJ future_NN ._.
The_DT financial_JJ statements_NNS adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP are_VBP similar_JJ do_VBP not_RB reflect_VB any_DT adjustments_NNS that_WDT would_MD be_VB required_VBN with_IN the_DT International_NNP Financial_NNP Reporting_NNP Standards_NNPS to_TO be_VB made_VBN if_IN they_PRP were_VBD to_TO be_VB prepared_VBN on_IN a_DT basis_NN as_IN issued_VBN by_IN the_DT IASB_NNP ,_, except_IN for_IN certain_JJ provisions_NNS other_JJ than_IN the_DT going_VBG concern_NN basis_NN ._.
concerning_VBG fair_JJ value_NN accounting_NN for_IN financial_JJ liabilities_NNS and_CC hedge_JJ accounting_NN ,_, which_WDT have_VBP no_DT Use_NN of_IN estimates_NNS impact_NN on_IN the_DT financial_JJ statements_NNS of_IN the_DT Group_NNP ._.
The_DT preparation_NN of_IN the_DT financial_JJ statements_NNS ,_, Consequently_RB ,_, the_DT consolidated_JJ IFRS_NNP financial_JJ in_IN conformity_NN with_IN IFRS_NNP ,_, requires_VBZ the_DT use_NN of_IN statements_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN are_VBP compliant_JJ with_IN both_DT the_DT International_NNP Financial_NNP amounts_NNS of_IN assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN Reporting_NNP Standards_NNPS as_IN issued_VBN by_IN IASB_NNP and_CC the_DT the_DT financial_JJ statements_NNS and_CC the_DT reported_VBN amounts_NNS version_NN adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP ._.
of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Although_IN these_DT estimates_NNS are_VBP based_VBN on_IN These_DT consolidated_JJ financial_JJ statements_NNS have_VBP managements_NNS best_JJS knowledge_NN of_IN the_DT amount_NN ,_, been_VBN prepared_VBN in_IN accordance_NN with_IN IFRS_NNP and_CC ,_, event_NN or_CC actions_NNS ,_, actual_JJ results_NNS may_MD ultimately_RB the_DT interpretations_NNS issued_VBN by_IN the_DT International_NNP differ_VBP from_IN those_DT estimates_NNS ._.
The_DT areas_NNS involving_VBG Financial_JJ Reporting_NNP Interpretations_NNPS Committee_NNP higher_JJR degree_NN of_IN judgement_NN or_CC complexity_NN ,_, or_CC IFRIC_NNP and_CC with_IN those_DT parts_NNS of_IN the_DT Companies_NNS Act_NNP areas_NNS where_WRB assumptions_NNS and_CC estimates_NNS are_VBP 1985_CD applicable_JJ to_TO companies_NNS reporting_VBG under_IN IFRS_NNP ._.
significant_JJ to_TO the_DT consolidated_JJ financial_JJ statements_NNS The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN are_VBP disclosed_VBN in_IN Note_NN 3_CD :_: Critical_JJ accounting_NN the_DT historical_JJ cost_NN convention_NN ,_, as_IN modified_VBN by_IN the_DT estimates_NNS and_CC judgements_NNS ._.
revaluation_NN of_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS ._.
Company_NN income_NN statement_NN The_DT Companys_NNPS working_VBG capital_NN requirements_NNS In_IN accordance_NN with_IN the_DT provisions_NNS of_IN section_NN 230_CD continue_VBP to_TO be_VB affected_VBN by_IN the_DT timing_NN and_CC receipt_NN of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, no_DT separate_JJ income_NN SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 63_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 64_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD statement_NN has_VBZ been_VBN presented_VBN for_IN the_DT Company_NN ._.
Share-Based_NNP Payments_NNS to_TO equity_NN instruments_NNS that_WDT The_DT results_NNS for_IN the_DT Company_NN are_VBP also_RB presented_VBN were_VBD granted_VBN on_IN or_CC before_IN 7_CD November_NNP 2002_CD and_CC under_IN IFRS_NNP ._.
The_DT Company_NN elected_VBN to_TO adopt_VB full_JJ retrospective_NN application_NN of_IN IFRS_NNP 2_CD ,_, b_NN IFRS_NNS 1_CD exemptions_NNS not_RB taking_VBG advantage_NN of_IN the_DT IFRS_NNP 1_CD exemption_NN ._.
IFRS_NNS 1_CD :_: First-time_JJ Adoption_NN of_IN International_NNP Financial_NNP Reporting_NNP Standards_NNP has_VBZ been_VBN applied_VBN in_IN preparing_VBG Cumulative_JJ translation_NN differences_NNS :_: A_DT first-time_JJ these_DT financial_JJ statements_NNS ._.
IFRS_NNS 1_CD sets_VBZ out_RP the_DT adopter_NN need_MD not_RB comply_VB retrospectively_RB with_IN the_DT procedures_NNS that_IN the_DT Group_NNP must_MD follow_VB when_WRB it_PRP requirements_NNS in_IN IAS_NNP 21_CD :_: The_DT Effects_NNPS of_IN Changes_NNS adopts_VBZ IFRS_NNP for_IN the_DT first_JJ time_NN ._.
in_IN Foreign_NNP Exchange_NNP Rates_NNP to_TO classify_VB translation_NN differences_NNS as_IN a_DT separate_JJ component_NN of_IN equity_NN The_DT Group_NNP has_VBZ established_VBN its_PRP$ IFRS_NNP accounting_NN related_VBN to_TO foreign_JJ operations_NNS and_CC recycle_VB them_PRP policies_NNS for_IN the_DT year_NN ending_VBG 31_CD December_NNP 2005_CD and_CC through_IN the_DT income_NN statement_NN on_IN disposal_NN of_IN the_DT applied_VBN these_DT standards_NNS retrospectively_RB to_TO determine_VB foreign_JJ operations_NNS ._.
The_DT Group_NNP elected_VBD not_RB to_TO take_VB the_DT IFRS_NNP opening_NN balance_NN sheet_NN at_IN its_PRP$ date_NN of_IN transition_NN ,_, advantage_NN of_IN this_DT exemption_NN ._.
1_CD January_NNP 2004_CD ,_, except_IN where_WRB permitted_VBN or_CC required_VBN by_IN IFRS_NNP 1_CD or_CC other_JJ applicable_JJ standards_NNS ._.
Financial_NNP instruments_NNS :_: In_IN its_PRP$ first_JJ IFRS_NNP financial_JJ statements_NNS a_DT first_JJ time_NN adopter_NN need_MD not_RB restate_VB Except_IN as_IN noted_VBN below_IN ,_, at_IN the_DT date_NN of_IN transition_NN to_TO the_DT comparative_JJ information_NN in_IN compliance_NN with_IN IFRS_NNP ,_, the_DT Group_NNP recognized_VBD all_DT assets_NNS and_CC liabilities_NNS IAS_NNP 32_CD :_: Financial_NNP Instruments_NNPS :_: Disclosure_NN and_CC as_IN required_VBN by_IN IFRS_NNP and_CC derecognised_VBD all_DT assets_NNS and_CC presentation_NN and_CC IAS_NNP 39_CD :_: Financial_NNP Instruments_NNPS :_: liabilities_NNS not_RB permitted_VBN by_IN IFRS_NNP ._.
Assets_NNS and_CC liabilities_NNS Recognition_NN and_CC Measurement_NNP ._.
The_DT Company_NN were_VBD all_DT measured_VBN in_IN accordance_NN with_IN IFRS_NNP ._.
elected_VBN not_RB to_TO take_VB advantage_NN of_IN this_DT exemption_NN ._.
The_DT impact_NN of_IN transition_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP on_IN c_NN Consolidation_NN the_DT Groups_NNS shareholders_NNS funds_NNS as_IN at_IN 1_CD January_NNP 2004_CD The_DT underlying_VBG financial_JJ statements_NNS comprise_VBP a_DT and_CC 31_CD December_NNP 2004_CD ,_, and_CC on_IN the_DT Groups_NNS income_NN consolidation_NN of_IN the_DT accounts_NNS of_IN the_DT Company_NN and_CC all_DT statement_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD its_PRP$ subsidiaries_NNS and_CC includes_VBZ the_DT Groups_NNS share_NN of_IN the_DT is_VBZ discussed_VBN in_IN Note_NN 37_CD :_: Transition_NN from_IN accounting_NN results_NNS and_CC net_JJ assets_NNS of_IN its_PRP$ associates_NNS ._.
The_DT accounts_NNS practices_NNS generally_RB accepted_VBN in_IN the_DT UK_NNP to_TO of_IN the_DT Groups_NNS subsidiaries_NNS and_CC associates_NNS are_VBP made_VBN International_NNP Financial_NNP Reporting_NNP Standards_NNPS ._.
The_DT adoption_NN of_IN the_DT provisions_NNS set_VBN out_RP in_IN IFRS_NNP 1_CD Subsidiaries_NNPS are_VBP outlined_VBN below_IN ._.
Subsidiaries_NNS are_VBP all_DT entities_NNS over_IN which_WDT the_DT Group_NNP has_VBZ control_NN ._.
Control_NNP is_VBZ achieved_VBN where_WRB the_DT Company_NNP Business_NNP combinations_NNS :_: A_DT first-time_JJ adopter_NN may_MD has_VBZ the_DT power_NN to_TO govern_VB the_DT financial_JJ and_CC operating_VBG elect_VB not_RB to_TO apply_VB IFRS_NNP 3_CD :_: Business_NNP Combinations_NNPS policies_NNS of_IN an_DT entity_NN so_RB as_IN to_TO obtain_VB benefits_NNS from_IN its_PRP$ retrospectively_RB to_TO business_NN combinations_NNS that_WDT activities_NNS ._.
Subsidiaries_NNS are_VBP fully_RB consolidated_VBN from_IN occurred_VBN before_IN the_DT date_NN of_IN transition_NN to_TO IFRS_NNP ._.
the_DT date_NN on_IN which_WDT control_NN is_VBZ transferred_VBN to_TO the_DT Group_NNP ._.
The_DT Company_NN elected_VBN to_TO take_VB advantage_NN of_IN this_DT They_PRP are_VBP fide-consolidated_VBN from_IN the_DT date_NN on_IN which_WDT exemption_NN ,_, not_RB applying_VBG IFRS_NNP 3_CD to_TO the_DT business_NN control_NN ceases_VBZ ._.
The_DT results_NNS of_IN subsidiaries_NNS acquired_VBN combinations_NNS that_WDT occurred_VBD before_IN the_DT date_NN of_IN or_CC disposed_VBN during_IN the_DT year_NN are_VBP included_VBN in_IN the_DT transition_NN ._.
Any_DT unamortised_JJ goodwill_NN at_IN 1_CD January_NNP consolidated_JJ income_NN statement_NN from_IN the_DT effective_JJ 2004_CD ,_, calculated_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP ,_, date_NN of_IN acquisition_NN or_CC up_RB to_TO the_DT effective_JJ date_NN of_IN has_VBZ been_VBN recognized_VBN in_IN the_DT IFRS_NNP accounts_NNS at_IN disposal_NN ,_, as_IN appropriate_JJ ._.
depreciated_VBN cost_NN after_IN taking_VBG into_IN account_NN potential_JJ adjustments_NNS required_VBN to_TO comply_VB with_IN IFRS_NNP The_NNP Group_NNP uses_VBZ the_DT purchase_NN method_NN to_TO account_VB measurement_NN principles_NNS ._.
for_IN the_DT acquisition_NN of_IN subsidiaries_NNS ._.
The_DT cost_NN of_IN an_DT acquisition_NN is_VBZ measured_VBN as_IN the_DT fair_JJ value_NN of_IN the_DT Share-based_JJ payments_NNS :_: A_DT first-time_JJ adopter_NN is_VBZ assets_NNS given_VBN ,_, equity_NN instruments_NNS issued_VBN and_CC liabilities_NNS encouraged_VBD ,_, but_CC not_RB required_VBN ,_, to_TO apply_VB IFRS_NNP 2_CD :_: incurred_VBN or_CC assumed_VBN at_IN the_DT date_NN of_IN exchange_NN ,_, plus_CC 64_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 65_CD Payments_NNS to_TO equity_NN instruments_NNS that_WDT costs_VBZ directly_RB attributable_JJ to_TO the_DT acquisition_NN ._.
Identifiable_JJ Associates_NNPS accounting_NN policies_NNS have_VBP been_VBN changed_VBN on_IN or_CC before_IN 7_CD November_NNP 2002_CD and_CC assets_NNS acquired_VBN and_CC liabilities_NNS and_CC contingent_NN where_WRB necessary_JJ to_TO ensure_VB consistency_NN with_IN the_DT January_NNP 2005_CD ._.
The_DT Company_NN elected_VBN liabilities_NNS assumed_VBD in_IN a_DT business_NN combination_NN policies_NNS adopted_VBN by_IN the_DT Group_NNP ._.
etrospective_JJ application_NN of_IN IFRS_NNP 2_CD ,_, are_VBP measured_VBN initially_RB at_IN their_PRP$ fair_JJ values_NNS at_IN the_DT antage_NN of_IN the_DT IFRS_NNP 1_CD exemption_NN ._.
acquisition_NN date_NN ,_, irrespective_RB of_IN the_DT extent_NN of_IN any_DT d_SYM Foreign_JJ currency_NN translation_NN minority_NN interest_NN ._.
The_DT excess_NN of_IN the_DT cost_NN of_IN acquisition_NN Functional_NNP and_CC presentation_NN currency_NN anslation_NN differences_NNS :_: A_DT first-time_JJ over_IN the_DT fair_JJ value_NN of_IN the_DT Groups_NNS share_NN of_IN the_DT Items_NNS included_VBD in_IN the_DT financial_JJ statements_NNS of_IN each_DT of_IN not_RB comply_VB retrospectively_RB with_IN the_DT identifiable_JJ net_JJ assets_NNS acquired_VBN is_VBZ recorded_VBN as_IN the_DT Groups_NNS entities_NNS are_VBP measured_VBN using_VBG the_DT currency_NN in_IN IAS_NNP 21_CD :_: The_DT Effects_NNPS of_IN Changes_NNS goodwill_NN ._.
If_IN the_DT cost_NN of_IN acquisition_NN is_VBZ less_JJR than_IN the_DT of_IN the_DT primary_JJ economic_JJ environment_NN in_IN which_WDT hange_NN Rates_NNS to_TO classify_VB translation_NN fair_JJ value_NN of_IN the_DT groups_NNS share_NN of_IN the_DT net_JJ assets_NNS of_IN the_DT entity_NN operates_VBZ the_DT functional_JJ currency_NN ._.
a_DT separate_JJ component_NN of_IN equity_NN the_DT subsidiary_NN acquired_VBN ,_, the_DT difference_NN is_VBZ recognized_VBN The_DT consolidated_JJ financial_JJ statements_NNS are_VBP presented_VBN ign_NN operations_NNS and_CC recycle_VB them_PRP directly_RB in_IN the_DT income_NN statement_NN ._.
in_IN pound_NN sterling_NN ,_, which_WDT is_VBZ the_DT Companys_NNP functional_JJ come_VBN statement_NN on_IN disposal_NN of_IN the_DT and_CC presentation_NN currency_NN ._.
The_DT Group_NNP elected_VBD not_RB to_TO take_VB Inter-company_JJ transactions_NNS ,_, balances_NNS and_CC unrealised_JJ his_PRP$ exemption_NN ._.
gains_NNS on_IN transactions_NNS between_IN Group_NNP companies_NNS are_VBP Transactions_NNS and_CC balances_NNS eliminated_VBN ._.
Unrealised_JJ losses_NNS are_VBP also_RB eliminated_VBN Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS ruments_NNS :_: In_IN its_PRP$ first_JJ IFRS_NNP financial_JJ unless_IN the_DT transaction_NN provides_VBZ evidence_NN of_IN an_DT are_VBP translated_VBN in_IN the_DT functional_JJ currency_NN at_IN the_DT irst_NN time_NN adopter_NN need_MD not_RB restate_VB impairment_NN of_IN the_DT asset_NN transferred_VBN ._.
Subsidiaries_NNS exchange_NN rate_NN prevailing_VBG at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
five_CD information_NN in_IN compliance_NN with_IN accounting_NN policies_NNS have_VBP been_VBN changed_VBN where_WRB Foreign_JJ exchange_NN gains_NNS and_CC losses_NNS resulting_VBG from_IN ial_JJ Instruments_NNPS :_: Disclosure_NN and_CC necessary_JJ to_TO ensure_VB consistency_NN with_IN the_DT policies_NNS the_DT settlement_NN of_IN such_JJ transactions_NNS and_CC from_IN the_DT nd_NN IAS_NNP 39_CD :_: Financial_NNP Instruments_NNPS :_: adopted_VBN by_IN the_DT Group_NNP ._.
translation_NN at_IN year-end_JJ exchange_NN rates_NNS of_IN monetary_JJ nd_NN Measurement_NNP ._.
The_DT Company_NN assets_NNS and_CC liabilities_NNS denominated_VBN in_IN foreign_JJ currencies_NNS take_VBP advantage_NN of_IN this_DT exemption_NN ._.
Associates_NNPS are_VBP recognized_VBN in_IN the_DT income_NN statement_NN ,_, except_IN when_WRB Associates_NNS are_VBP all_DT entities_NNS over_IN which_WDT the_DT Group_NNP it_PRP relates_VBZ to_TO items_NNS recognized_VBN directly_RB in_IN equity_NN n_NN has_VBZ the_DT power_NN to_TO exercise_VB significant_JJ influence_NN but_CC e._FW g._FW equities_NNS classified_VBN as_IN available_JJ for_IN sale_NN ,_, the_DT financial_JJ statements_NNS comprise_VBP a_DT not_RB control_VB generally_RB accompanying_VBG a_DT shareholding_NN exchange_NN component_NN of_IN that_DT gain_NN or_CC loss_NN will_MD be_VB the_DT accounts_NNS of_IN the_DT Company_NN and_CC all_DT of_IN between_IN 20_CD %_NN and_CC 50_CD %_NN of_IN the_DT voting_NN rights_NNS ._.
and_CC includes_VBZ the_DT Groups_NNS share_NN of_IN the_DT Investments_NNPS in_IN associates_NNS are_VBP accounted_VBN for_IN by_IN assets_NNS of_IN its_PRP$ associates_NNS ._.
The_DT accounts_NNS the_DT equity_NN method_NN of_IN accounting_NN and_CC are_VBP initially_RB Group_NNP companies_NNS ubsidiaries_NNS and_CC associates_NNS are_VBP made_VBN recognized_VBN at_IN cost_NN ._.
The_DT Groups_NNS investment_NN in_IN The_DT results_NNS and_CC financial_JJ position_NN of_IN all_PDT the_DT Group_NNP ber_NN ._.
associates_NNS includes_VBZ goodwill_NN identified_VBN on_IN acquisition_NN ._.
entities_NNS that_WDT have_VBP a_DT functional_JJ currency_NN different_JJ from_IN the_DT presentation_NN currency_NN are_VBP translated_VBN into_IN the_DT The_DT Groups_NNS share_NN of_IN its_PRP$ associates_NNS post-acquisition_JJ presentation_NN currency_NN as_IN follows_VBZ :_: all_DT entities_NNS over_IN which_WDT the_DT Group_NNP profits_NNS or_CC losses_NNS is_VBZ recognized_VBN in_IN the_DT income_NN trol_NN is_VBZ achieved_VBN where_WRB the_DT Company_NN statement_NN ,_, and_CC its_PRP$ share_NN of_IN post-acquisition_JJ i_FW assets_NNS and_CC liabilities_NNS for_IN each_DT balance_NN sheet_NN o_NN govern_VBP the_DT financial_JJ and_CC operating_VBG movements_NNS in_IN reserves_NNS is_VBZ recognized_VBN in_IN reserves_NNS ._.
presented_VBN are_VBP translated_VBN at_IN the_DT closing_NN rate_NN tity_NN so_RB as_IN to_TO obtain_VB benefits_NNS from_IN its_PRP$ The_DT cumulative_JJ post-acquisition_NN movements_NNS are_VBP at_IN the_DT date_NN of_IN the_DT balance_NN sheet_NN :_: iaries_NNS are_VBP fully_RB consolidated_VBN from_IN adjusted_VBN against_IN the_DT carrying_VBG amount_NN of_IN the_DT h_NN control_NN is_VBZ transferred_VBN to_TO the_DT Group_NNP ._.
When_WRB the_DT Groups_NNS share_NN of_IN losses_NNS in_IN ii_JJ income_NN and_CC expenses_NNS for_IN each_DT income_NN statement_NN solidated_VBN from_IN the_DT date_NN on_IN which_WDT an_DT associate_NN or_CC joint_JJ venture_NN equals_VBZ or_CC exceeds_VBZ its_PRP$ are_VBP translated_VBN at_IN average_JJ exchange_NN rates_NNS :_: and_CC The_DT results_NNS of_IN subsidiaries_NNS acquired_VBN interest_NN or_CC participation_NN ,_, including_VBG any_DT other_JJ ng_NN the_DT year_NN are_VBP included_VBN in_IN the_DT unsecured_JJ long-term_JJ receivables_NN ,_, the_DT Group_NNP does_VBZ iii_VB all_DT resulting_VBG exchange_NN differences_NNS are_VBP recognized_VBN ome_NN statement_NN from_IN the_DT effective_JJ not_RB recognize_VB further_JJ losses_NNS ,_, unless_IN it_PRP has_VBZ incurred_VBN as_IN a_DT separate_JJ component_NN of_IN equity_NN ._.
on_IN or_CC up_IN to_TO the_DT effective_JJ date_NN of_IN obligations_NNS or_CC made_VBN payments_NNS on_IN behalf_NN ropriate_NN ._.
of_IN the_DT associate_NN or_CC joint_JJ venture_NN ._.
On_IN consolidation_NN ,_, exchange_NN differences_NNS arising_VBG from_IN the_DT translation_NN of_IN the_DT net_JJ investment_NN in_IN foreign_JJ the_DT purchase_NN method_NN to_TO account_VB Unrealised_JJ gains_NNS on_IN transactions_NNS between_IN the_DT Group_NNP entities_NNS ,_, are_VBP taken_VBN to_TO shareholders_NNS equity_NN ._.
The_DT cost_NN of_IN an_DT and_CC its_PRP$ associates_NNS are_VBP eliminated_VBN to_TO the_DT extent_NN of_IN the_DT easured_VBN as_IN the_DT fair_JJ value_NN of_IN the_DT Groups_NNS interest_NN in_IN the_DT associates_NNS ._.
Unrealised_JJ losses_NNS Goodwill_NNP and_CC fair_JJ value_NN adjustments_NNS arising_VBG on_IN the_DT uity_NN instruments_NNS issued_VBN and_CC liabilities_NNS are_VBP also_RB eliminated_VBN unless_IN the_DT transaction_NN provides_VBZ acquisition_NN of_IN a_DT foreign_JJ entity_NN are_VBP treated_VBN as_IN assets_NNS med_VBN at_IN the_DT date_NN of_IN exchange_NN ,_, plus_CC evidence_NN of_IN an_DT impairment_NN of_IN the_DT asset_NN transferred_VBN ._.
and_CC liabilities_NNS of_IN the_DT foreign_JJ entity_NN and_CC translated_VBN SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 65_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 66_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD at_IN the_DT closing_NN rate_NN ._.
On_IN disposal_NN of_IN a_DT foreign_JJ entity_NN ,_, Royalty_NN income_NN accumulated_VBN exchange_NN differences_NNS are_VBP recognized_VBN Royalty_NN income_NN is_VBZ recognized_VBN on_IN an_DT accruals_NNS basis_NN in_IN the_DT income_NN statement_NN in_IN the_DT same_JJ period_NN in_IN which_WDT and_CC represents_VBZ income_NN earned_VBD as_IN a_DT percentage_NN of_IN the_DT gain_NN or_CC loss_NN on_IN disposal_NN is_VBZ recognized_VBN ._.
product_NN sales_NNS in_IN accordance_NN with_IN the_DT substance_NN of_IN the_DT relevant_JJ agreement_NN ._.
e_LS Segment_NNP reporting_VBG The_DT Groups_NNS primary_JJ segment_NN for_IN IFRS_NNP segment_NN Manufacturing_NNP and_CC distribution_NN reporting_NN is_VBZ the_DT business_NN segment_NN ._.
A_DT business_NN Manufacturing_NNP and_CC distribution_NN revenues_NNS principally_RB segment_NN is_VBZ a_DT group_NN of_IN assets_NNS and_CC operations_NNS engaged_VBD comprise_VB contract_NN manufacturing_NN fees_NNS invoiced_VBD to_TO in_IN providing_VBG products_NNS or_CC services_NNS that_WDT are_VBP subject_JJ to_TO third_JJ parties_NNS and_CC income_NN from_IN product_NN sales_NNS ._.
Revenues_NNS risks_NNS and_CC returns_NNS that_WDT are_VBP different_JJ from_IN those_DT of_IN are_VBP recognized_VBN upon_IN transfer_NN to_TO the_DT customer_NN of_IN other_JJ business_NN segments_NNS ._.
significant_JJ risks_NNS and_CC rewards_NNS ,_, usually_RB upon_IN despatch_NN of_IN goods_NNS shipped_VBN where_WRB the_DT sales_NNS price_NN is_VBZ agreed_VBN Geographical_NNP regions_NNS are_VBP the_DT secondary_JJ reporting_NN and_CC collectability_NN is_VBZ reasonably_RB assured_VBN ._.
A_DT geographic_JJ segment_NN is_VBZ engaged_VBN in_IN providing_VBG products_NNS or_CC services_NNS within_IN a_DT particular_JJ g_NN Intangible_JJ assets_NNS economic_JJ environment_NN that_WDT are_VBP subject_JJ to_TO risks_NNS and_CC Goodwill_NNP return_NN that_WDT are_VBP different_JJ from_IN those_DT of_IN components_NNS Goodwill_NNP represents_VBZ the_DT excess_NN of_IN the_DT cost_NN of_IN an_DT operating_NN in_IN other_JJ economic_JJ environments_NNS ._.
acquisition_NN over_IN the_DT fair_JJ value_NN of_IN the_DT Groups_NNS share_NN of_IN the_DT net_JJ identifiable_JJ assets_NNS of_IN the_DT acquired_VBN subsidiary_NN Segment_NN reporting_NN reflects_VBZ the_DT internal_JJ management_NN at_IN the_DT date_NN of_IN acquisition_NN ._.
Goodwill_NN is_VBZ tested_VBN annually_RB reporting_VBG structure_NN and_CC the_DT way_NN the_DT business_NN for_IN impairment_NN and_CC carried_VBD at_IN cost_NN less_JJR accumulated_VBN is_VBZ managed_VBN ._.
Goodwill_NN is_VBZ allocated_VBN to_TO cash_VB generating_VBG units_NNS for_IN the_DT purpose_NN of_IN impairment_NN testing_NN ._.
f_LS Revenue_NN recognition_NN Each_DT of_IN those_DT cash_NN generating_VBG units_NNS represents_VBZ the_DT Revenue_NN comprises_VBZ the_DT fair_JJ value_NN for_IN the_DT sale_NN of_IN Groups_NNS investment_NN in_IN each_DT country_NN of_IN operation_NN ._.
goods_NNS and_CC services_NNS ,_, net_NN of_IN sales_NNS taxes_NNS ,_, rebates_NNS and_CC discounts_NNS and_CC after_IN eliminating_VBG sales_NNS within_IN Intellectual_NNP property_NN the_DT Group_NNP ._.
Revenue_NN is_VBZ recognized_VBN as_IN follows_VBZ :_: Intellectual_NNP property_NN comprises_VBZ acquired_VBN patents_NNS ,_, trade_NN marks_NNS ,_, know-how_NN and_CC other_JJ similarly_RB identified_VBN Contract_NNP development_NN and_CC licensing_NN rights_NNS ._.
These_DT are_VBP recorded_VBN at_IN their_PRP$ fair_JJ value_NN at_IN Contract_NNP development_NN and_CC licensing_NN income_NN acquisition_NN date_NN and_CC are_VBP amortised_VBN on_IN a_DT straight_JJ line_NN represents_VBZ amounts_NNS earned_VBN for_IN services_NNS rendered_VBN basis_NN over_IN their_PRP$ estimated_VBN useful_JJ economic_JJ lives_NNS from_IN under_IN development_NN and_CC licensing_NN agreements_NNS ,_, the_DT time_NN they_PRP are_VBP available_JJ for_IN use_NN ._.
The_DT period_NN over_IN including_VBG up-front_JJ payments_NNS ,_, milestone_NN payments_NNS ,_, which_WDT the_DT Group_NNP expects_VBZ to_TO derive_VB economic_JJ benefits_NNS technology_NN access_NN fees_NNS and_CC research_NN and_CC does_VBZ not_RB exceed_VB 20_CD years_NNS ._.
Revenues_NNS are_VBP recognized_VBN where_WRB they_PRP are_VBP non-refundable_JJ ,_, the_DT Research_NNP and_CC development_NN Groups_NNS obligations_NNS related_VBN to_TO the_DT revenues_NNS have_VBP been_VBN Research_NNP expenditure_NN is_VBZ charged_VBN to_TO the_DT income_NN discharged_VBN and_CC their_PRP$ collection_NN is_VBZ reasonably_RB assured_VBN ._.
statement_NN in_IN the_DT period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Refundable_JJ contract_NN revenue_NN is_VBZ treated_VBN as_IN deferred_VBN Development_NNP expenditure_NN is_VBZ capitalized_VBN when_WRB the_DT until_IN such_JJ time_NN that_IN it_PRP is_VBZ no_RB longer_RBR refundable_JJ ._.
criteria_NNS for_IN recognizing_VBG as_IN an_DT asset_NN are_VBP met_VBN In_IN general_JJ up-front_JJ payments_NNS are_VBP deferred_VBN and_CC when_WRB it_PRP is_VBZ probable_JJ that_IN the_DT project_NN will_MD be_VB a_DT success_NN ,_, amortised_VBN on_IN a_DT systematic_JJ basis_NN over_IN the_DT period_NN of_IN considering_VBG its_PRP$ commercial_JJ and_CC technological_JJ development_NN to_TO filing_NN ._.
Milestone_NN payments_NNS related_VBN to_TO feasibility_NN and_CC costs_NNS can_MD be_VB measured_VBN reliably_RB ._.
scientific_JJ or_CC technical_JJ achievements_NNS are_VBP recognized_VBN Regulatory_NNP and_CC other_JJ uncertainties_NNS generally_RB mean_VBP as_IN income_NN when_WRB the_DT milestone_NN is_VBZ accomplished_VBN ._.
that_IN such_JJ criteria_NNS are_VBP not_RB met_VBN ._.
Where_WRB development_NN costs_NNS are_VBP capitalized_VBN they_PRP are_VBP amortised_VBN over_IN their_PRP$ useful_JJ economic_JJ lives_NNS from_IN product_NN launch_NN ._.
Prior_RB to_TO product_NN launch_NN the_DT asset_NN is_VBZ tested_VBN annually_RB for_IN impairment_NN ._.
66_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 67_CD Computer_NNP software_NN is_VBZ written_VBN down_RP immediately_RB to_TO its_PRP$ recoverable_JJ s_PRP recognized_VBD on_IN an_DT accruals_NNS basis_NN Costs_NNS that_WDT are_VBP directly_RB associated_VBN with_IN the_DT purchase_NN amount_NN if_IN the_DT assets_NNS carrying_VBG amount_NN is_VBZ greater_JJR than_IN ncome_NN earned_VBN as_IN a_DT percentage_NN of_IN and_CC implementation_NN of_IN identifiable_JJ and_CC unique_JJ its_PRP$ estimated_VBN recoverable_JJ amount_NN ._.
accordance_NN with_IN the_DT substance_NN of_IN software_NN products_NNS by_IN the_DT Group_NNP are_VBP recognized_VBN as_IN eement_NN ._.
Expenditures_NNS that_WDT enhance_VBP and_CC Gains_NNS and_CC losses_NNS on_IN disposals_NNS are_VBP determined_VBN by_IN extend_VBP the_DT benefits_NNS of_IN computer_NN software_NN programs_NNS comparing_VBG the_DT disposal_NN proceeds_NNS with_IN the_DT carrying_VBG nd_NN distribution_NN beyond_IN their_PRP$ original_JJ specifications_NNS and_CC lives_NNS are_VBP amount_NN and_CC are_VBP included_VBN in_IN the_DT income_NN statement_NN ._.
nd_JJ distribution_NN revenues_NNS principally_RB recognized_VBN as_IN a_DT capital_NN improvement_NN and_CC added_VBD to_TO ct_VB manufacturing_NN fees_NNS invoiced_VBD to_TO the_DT original_JJ cost_NN of_IN the_DT software_NN ._.
Direct_JJ costs_NNS include_VBP i_FW Impairment_NN of_IN assets_NNS income_NN from_IN product_NN sales_NNS ._.
Revenues_NNS the_DT software_NN development_NN employee_NN costs_NNS and_CC an_DT Assets_NNS that_WDT have_VBP an_DT indefinite_JJ useful_JJ life_NN are_VBP not_RB pon_VB transfer_NN to_TO the_DT customer_NN of_IN appropriate_JJ portion_NN of_IN relevant_JJ overheads_NNS ._.
Software_NNP subject_NN to_TO amortisation_NN and_CC are_VBP tested_VBN annually_RB for_IN and_CC rewards_NNS ,_, usually_RB upon_IN despatch_NN costs_NNS are_VBP amortised_VBN over_IN their_PRP$ useful_JJ economic_JJ lives_NNS ,_, impairment_NN ._.
Assets_NNS that_WDT are_VBP subject_JJ to_TO amortisation_NN d_SYM where_WRB the_DT sales_NNS price_NN is_VBZ agreed_VBN generally_RB a_DT period_NN of_IN 3_CD to_TO 5_CD years_NNS ._.
or_CC depreciation_NN are_VBP reviewed_VBN for_IN impairment_NN y_NN is_VBZ reasonably_RB assured_VBN ._.
whenever_WRB events_NNS or_CC changes_NNS in_IN circumstances_NNS h_VBP Property_NN ,_, plant_NN and_CC equipment_NN indicate_VBP that_IN the_DT carrying_VBG amount_NN may_MD not_RB be_VB sets_NNS Property_NN ,_, plant_NN and_CC equipment_NN are_VBP stated_VBN at_IN the_DT recoverable_JJ ._.
An_DT impairment_NN loss_NN is_VBZ recognized_VBN for_IN cost_NN of_IN purchase_NN or_CC construction_NN less_RBR provision_NN for_IN the_DT amount_NN by_IN which_WDT the_DT assets_NNS carrying_VBG amount_NN ents_VBZ the_DT excess_NN of_IN the_DT cost_NN of_IN an_DT depreciation_NN and_CC impairment_NN ._.
The_DT cost_NN of_IN property_NN ,_, exceeds_VBZ its_PRP$ recoverable_JJ amount_NN ._.
The_DT recoverable_JJ the_DT fair_JJ value_NN of_IN the_DT Groups_NNS share_NN of_IN plant_NN and_CC equipment_NN includes_VBZ acquisition_NN costs_NNS and_CC amount_NN is_VBZ the_DT higher_JJR of_IN an_DT assets_NNS fair_JJ value_NN less_RBR ble_JJ assets_NNS of_IN the_DT acquired_VBN subsidiary_NN labor_NN and_CC overhead_NN costs_NNS arising_VBG directly_RB from_IN the_DT costs_NNS to_TO sell_VB and_CC value_NN in_IN use_NN ._.
Goodwill_NN is_VBZ tested_VBN annually_RB construction_NN or_CC acquisition_NN of_IN an_DT item_NN of_IN property_NN ,_, is_VBZ charged_VBN to_TO the_DT income_NN statement_NN in_IN the_DT year_NN and_CC carried_VBD at_IN cost_NN less_JJR accumulated_VBN plant_NN and_CC equipment_NN ._.
For_IN the_DT purposes_NNS of_IN assessing_VBG impairment_NN ,_, es_VBZ ._.
Goodwill_NN is_VBZ allocated_VBN to_TO cash_VB assets_NNS are_VBP grouped_VBN at_IN the_DT lowest_JJS levels_NNS for_IN which_WDT for_IN the_DT purpose_NN of_IN impairment_NN testing_NN ._.
Subsequent_JJ costs_NNS are_VBP included_VBN in_IN the_DT assets_NNS carrying_VBG there_EX are_VBP separately_RB identifiable_JJ cash_NN in_IN flows_NNS cashsh_VBP generating_VBG units_NNS represents_VBZ the_DT amount_NN or_CC recognized_VBN as_IN a_DT separate_JJ asset_NN ,_, as_IN generating_VBG units_NNS ._.
ent_NN in_IN each_DT country_NN of_IN operation_NN ._.
appropriate_JJ ,_, only_RB when_WRB it_PRP is_VBZ probable_JJ that_IN future_JJ economic_JJ benefits_NNS associated_VBN with_IN the_DT item_NN will_MD flow_VB The_DT expected_JJ cash_NN flows_VBZ generated_VBN by_IN the_DT assets_NNS are_VBP erty_JJ to_TO the_DT Group_NNP and_CC the_DT cost_NN of_IN the_DT item_NN can_MD be_VB discounted_VBN using_VBG asset_NN specific_JJ discount_NN rates_NNS which_WDT erty_VBP comprises_VBZ acquired_VBN patents_NNS ,_, measured_VBN reliably_RB ._.
All_DT other_JJ repairs_NNS and_CC maintenance_NN reflect_VBP the_DT risks_NNS associated_VBN with_IN the_DT groups_NNS of_IN assets_NNS ._.
ow-how_NN and_CC other_JJ similarly_RB identified_VBN expenditures_NNS are_VBP charged_VBN to_TO the_DT income_NN statement_NN These_DT risks_NNS vary_VBP with_IN the_DT nature_NN and_CC the_DT location_NN of_IN e_SYM recorded_VBN at_IN their_PRP$ fair_JJ value_NN at_IN during_IN the_DT financial_JJ period_NN in_IN which_WDT they_PRP are_VBP incurred_VBN ._.
and_CC are_VBP amortised_VBN on_IN a_DT straight_JJ line_NN estimated_VBN useful_JJ economic_JJ lives_NNS from_IN Depreciation_NN is_VBZ not_RB provided_VBN on_IN freehold_JJ land_NN or_CC j_NN Investments_NNP e_SYM available_JJ for_IN use_NN ._.
The_DT period_NN over_IN projects_NNS under_IN construction_NN ._.
On_IN other_JJ property_NN ,_, plant_NN The_DT Group_NNP classifies_VBZ its_PRP$ investments_NNS according_VBG to_TO expects_VBZ to_TO derive_VB economic_JJ benefits_NNS and_CC equipment_NN ,_, depreciation_NN is_VBZ provided_VBN on_IN the_DT the_DT purpose_NN for_IN which_WDT the_DT investments_NNS were_VBD 20_CD years_NNS ._.
difference_NN between_IN the_DT cost_NN of_IN an_DT item_NN and_CC its_PRP$ acquired_VBN ._.
Management_NNP determines_VBZ the_DT classification_NN estimated_VBN residual_JJ value_NN ,_, in_IN equal_JJ annual_JJ instalments_NNS of_IN investments_NNS at_IN initial_JJ recognition_NN and_CC re-evaluates_VBZ evelopment_NN over_IN the_DT estimated_VBN useful_JJ lives_NNS of_IN the_DT assets_NNS as_IN follows_VBZ :_: the_DT designation_NN at_IN every_DT reporting_NN date_NN ._.
The_DT Group_NNP diture_NN is_VBZ charged_VBN to_TO the_DT income_NN has_VBZ the_DT following_VBG categories_NNS of_IN investments_NNS :_: Freehold_NNP buildings_NNS 2_CD %_NN 5_CD %_NN period_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Laboratory_NN equipment_NN and_CC machines_NNS 10_CD %_NN 33_CD %_NN penditure_NN is_VBZ capitalized_VBN when_WRB the_DT Available-for-sale_JJ financial_JJ assets_NNS Office_NNP and_CC other_JJ equipment_NN 10_CD %_NN 33_CD %_NN nising_NN as_IN an_DT asset_NN are_VBP met_VBN Available-for-sale_JJ financial_JJ assets_NNS are_VBP non-derivatives_JJ Motor_NNP vehicles_NNS 20_CD %_NN ble_NN that_IN the_DT project_NN will_MD be_VB a_DT success_NN ,_, that_WDT are_VBP not_RB acquired_VBN to_TO generate_VB profit_NN from_IN shortShort_NNP leasehold_VBD property_NN period_NN of_IN the_DT lease_NN ommercial_JJ and_CC technological_JJ term_NN fluctuations_NNS in_IN price_NN ._.
They_PRP are_VBP included_VBN in_IN nonsts_NNS can_MD be_VB measured_VBN reliably_RB ._.
current_JJ assets_NNS unless_IN management_NN intends_VBZ to_TO other_JJ uncertainties_NNS generally_RB mean_VBP Assets_NNS in_IN the_DT course_NN of_IN construction_NN are_VBP depreciated_VBN dispose_VB of_IN the_DT asset_NN within_IN 12_CD months_NNS of_IN the_DT balance_NN a_DT are_VBP not_RB met_VBN ._.
Where_WRB development_NN when_WRB they_PRP have_VBP been_VBN brought_VBN into_IN operational_JJ use_NN ._.
ised_VBN they_PRP are_VBP amortised_VBN over_IN their_PRP$ lives_NNS from_IN product_NN launch_NN ._.
The_DT assets_NNS residual_JJ values_NNS and_CC useful_JJ lives_NNS are_VBP Available-for-sale_JJ investments_NNS are_VBP initially_RB recorded_VBN launch_NN the_DT asset_NN is_VBZ tested_VBN annually_RB reviewed_VBN ,_, and_CC adjusted_VBN if_IN appropriate_JJ ,_, at_IN each_DT at_IN cost_NN ,_, being_VBG the_DT fair_JJ value_NN of_IN consideration_NN given_VBN ,_, balance_NN sheet_NN date_NN ._.
An_DT assets_NNS carrying_VBG amount_NN plus_CC transaction_NN costs_NNS ._.
Subsequently_RB ,_, available-for-sale_JJ SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 67_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 68_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD investments_NNS comprising_VBG marketable_JJ equity_NN securities_NNS is_VBZ made_VBN for_IN obsolete_JJ ,_, slow-moving_JJ or_CC defective_JJ items_NNS that_WDT are_VBP traded_VBN in_IN active_JJ markets_NNS are_VBP carried_VBN at_IN their_PRP$ where_WRB appropriate_JJ ._.
fair_JJ value_NN as_IN of_IN each_DT balance_NN sheet_NN date_NN ._.
l_NN Trade_NNP receivables_NN Unrealised_JJ gains_NNS and_CC losses_NNS arising_VBG from_IN changes_NNS Trade_NNP receivables_NNS are_VBP non-derivative_JJ financial_JJ assets_NNS in_IN the_DT fair_JJ value_NN of_IN non-monetary_JJ securities_NNS classified_VBN with_IN fixed_VBN or_CC determinable_JJ payments_NNS that_WDT are_VBP not_RB as_IN available-for-sale_JJ investments_NNS are_VBP recognized_VBN in_IN quoted_VBN in_IN an_DT active_JJ market_NN ._.
They_PRP arise_VBP when_WRB the_DT equity_NN ._.
When_WRB available-for-sale_JJ investments_NNS are_VBP sold_VBN Group_NNP provides_VBZ money_NN ,_, goods_NNS or_CC services_NNS directly_RB to_TO or_CC impaired_VBN ,_, the_DT accumulated_VBN fair_JJ value_NN adjustments_NNS a_DT debtor_NN with_IN no_DT intention_NN of_IN trading_VBG the_DT receivable_NN ._.
in_IN equity_NN are_VBP recycled_VBN into_IN the_DT income_NN statement_NN as_IN They_PRP are_VBP included_VBN in_IN current_JJ assets_NNS ,_, except_IN for_IN gains_NNS and_CC losses_NNS from_IN investment_NN securities_NNS ._.
maturities_NNS greater_JJR than_IN 12_CD months_NNS after_IN the_DT balance_NN sheet_NN date_NN ._.
These_DT are_VBP classified_VBN as_IN non-current_JJ The_NNP Group_NNP assesses_VBZ at_IN each_DT balance_NN sheet_NN date_NN assets_NNS ._.
Trade_NNP receivables_NNS are_VBP recognized_VBN initially_RB at_IN whether_IN there_EX is_VBZ objective_JJ evidence_NN that_IN a_DT financial_JJ fair_JJ value_NN less_RBR provision_NN for_IN impairment_NN ._.
A_DT provision_NN asset_NN or_CC a_DT group_NN of_IN financial_JJ assets_NNS is_VBZ impaired_VBN ._.
for_IN impairment_NN of_IN trade_NN receivables_NN is_VBZ established_VBN If_IN any_DT such_JJ evidence_NN exists_VBZ for_IN available-for-sale_NN when_WRB there_EX is_VBZ objective_JJ evidence_NN that_IN the_DT Group_NNP will_MD financial_JJ assets_NNS ,_, the_DT cumulative_JJ loss_NN measured_VBN as_IN not_RB be_VB able_JJ to_TO collect_VB all_DT amounts_NNS due_JJ according_VBG to_TO the_DT difference_NN between_IN the_DT acquisition_NN cost_NN and_CC the_DT the_DT original_JJ terms_NNS of_IN the_DT receivables_NN ._.
current_JJ fair_JJ value_NN ,_, less_JJR any_DT impairment_NN loss_NN on_IN that_DT financial_JJ asset_NN previously_RB recognized_VBN is_VBZ removed_VBN m_NN Cash_NN and_CC cash_NN equivalents_NNS from_IN equity_NN and_CC recognized_VBN in_IN the_DT income_NN statement_NN ._.
Cash_NN and_CC cash_NN equivalents_NNS are_VBP highly_RB liquid_JJ Impairment_NN losses_NNS recognized_VBN in_IN the_DT income_NN investments_NNS that_WDT are_VBP readily_RB convertible_JJ to_TO known_VBN statement_NN on_IN equity_NN instruments_NNS are_VBP not_RB reversed_JJ amounts_NNS of_IN cash_NN and_CC which_WDT are_VBP subject_JJ to_TO an_DT through_IN the_DT income_NN statement_NN ._.
insignificant_JJ risk_NN of_IN changes_NNS in_IN value_NN ._.
Cash_NN and_CC cash_NN equivalents_NNS are_VBP carried_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN ._.
Financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN For_IN the_DT purposes_NNS of_IN the_DT cash_NN flow_NN statement_NN ,_, cash_NN The_DT Group_NNP classifies_VBZ investments_NNS in_IN this_DT category_NN and_CC cash_NN equivalents_NNS comprise_VBP cash_NN at_IN bank_NN and_CC if_IN acquired_VBN principally_RB for_IN the_DT purpose_NN of_IN selling_NN in_IN in_IN hand_NN ,_, short_JJ term_NN deposits_NNS ,_, marketable_JJ securities_NNS the_DT short_JJ term_NN or_CC if_IN so_RB designated_VBN by_IN management_NN ._.
Bank_NNP overdrafts_NNS are_VBP included_VBN within_IN Financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN borrowings_NNS in_IN current_JJ liabilities_NNS on_IN the_DT balance_NN sheet_NN ._.
are_VBP initially_RB recorded_VBN ,_, and_CC subsequently_RB carried_VBD ,_, at_IN fair_JJ value_NN ._.
Realised_VBN and_CC unrealised_JJ gains_NNS and_CC losses_NNS n_VBP Borrowings_NNS arising_VBG from_IN changes_NNS in_IN the_DT fair_JJ value_NN of_IN assets_NNS held_VBN in_IN Borrowings_NNS are_VBP recognized_VBN initially_RB at_IN fair_JJ value_NN ,_, this_DT category_NN are_VBP included_VBN in_IN the_DT income_NN statement_NN net_NN of_IN transaction_NN costs_NNS incurred_VBN ._.
Borrowings_NNS are_VBP in_IN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
Financial_JJ assets_NNS at_IN subsequently_RB stated_VBN at_IN amortised_JJ cost_NN ,_, any_DT difference_NN fair_JJ value_NN through_IN profit_NN or_CC loss_NN are_VBP classified_VBN as_IN between_IN proceeds_NNS net_NN of_IN transaction_NN costs_NNS and_CC current_JJ assets_NNS if_IN they_PRP are_VBP either_RB held_VBN for_IN trading_VBG the_DT redemption_NN value_NN is_VBZ recognized_VBN in_IN the_DT income_NN or_CC are_VBP expected_VBN to_TO be_VB realized_VBN within_IN 12_CD months_NNS statement_NN over_IN the_DT period_NN of_IN the_DT borrowings_NNS using_VBG of_IN the_DT balance_NN sheet_NN date_NN ._.
Borrowings_NNS are_VBP classified_VBN as_IN current_JJ liabilities_NNS unless_IN the_DT Group_NNP has_VBZ an_DT k_NN Inventories_NNS unconditional_JJ right_NN to_TO defer_VB settlement_NN of_IN the_DT liability_NN Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_NN for_IN at_IN least_JJS 12_CD months_NNS after_IN the_DT balance_NN sheet_NN date_NN ._.
Cost_NN is_VBZ determined_VBN using_VBG the_DT firstin-first-out_JJ FIFO_NNP method_NN ._.
The_DT cost_NN of_IN finished_JJ o_NN Convertible_JJ bonds_NNS goods_NNS and_CC work_NN in_IN progress_NN comprises_VBZ raw_JJ On_IN issue_NN the_DT debt_NN and_CC equity_NN components_NNS of_IN a_DT materials_NNS ,_, direct_JJ labor_NN ,_, other_JJ direct_JJ costs_NNS and_CC convertible_JJ bond_NN are_VBP separated_VBN and_CC recorded_VBN at_IN fair_JJ an_DT appropriate_JJ proportion_NN of_IN related_JJ production_NN value_NN net_NN of_IN issue_NN costs_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT liability_NN overheads_NNS ,_, based_VBN on_IN the_DT normal_JJ level_NN of_IN production_NN portion_NN is_VBZ determined_VBN by_IN applying_VBG a_DT market_NN interest_NN capacity_NN ._.
Net_JJ realisable_JJ value_NN is_VBZ the_DT estimated_VBN selling_NN rate_NN for_IN an_DT equivalent_JJ non-convertible_JJ bond_NN to_TO the_DT price_NN in_IN the_DT ordinary_JJ course_NN of_IN business_NN ,_, less_JJR forecast_NN cash_NN flows_VBZ under_IN the_DT convertible_JJ bond_NN applicable_JJ variable_JJ selling_NN expenses_NNS ._.
This_DT amount_NN is_VBZ recorded_VBN as_IN a_DT liability_NN 68_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 69_CD olete_NN ,_, slow-moving_JJ or_CC defective_JJ items_NNS on_IN an_DT amortised_JJ cost_NN basis_NN until_IN extinguished_VBN on_IN recorded_VBN in_IN the_DT income_NN statement_NN ,_, together_RB with_IN te_NN ._.
conversion_NN or_CC maturity_NN of_IN the_DT bonds_NNS ._.
The_DT remainder_NN any_DT changes_NNS in_IN the_DT fair_JJ value_NN of_IN the_DT hedged_JJ asset_NN of_IN the_DT proceeds_NNS of_IN the_DT bond_NN is_VBZ allocated_VBN to_TO the_DT or_CC liability_NN that_WDT are_VBP attributable_JJ to_TO the_DT hedged_VBN risk_NN ._.
bles_NNS conversion_NN option_NN which_WDT is_VBZ recognized_VBN and_CC included_VBN s_PRP are_VBP non-derivative_JJ financial_JJ assets_NNS in_IN shareholders_NNS equity_NN ,_, net_NN of_IN income_NN tax_NN effects_NNS ._.
Cash_NN flow_NN hedge_NN erminable_JJ payments_NNS that_WDT are_VBP not_RB The_DT value_NN of_IN the_DT conversion_NN option_NN is_VBZ not_RB changed_VBN The_DT effective_JJ portion_NN of_IN changes_NNS in_IN the_DT fair_JJ value_NN of_IN five_CD market_NN ._.
They_PRP arise_VBP when_WRB the_DT in_IN subsequent_JJ periods_NNS ._.
derivatives_NNS that_WDT are_VBP designated_VBN and_CC qualify_VB as_IN cash_NN money_NN ,_, goods_NNS or_CC services_NNS directly_RB to_TO flow_VB hedges_NNS are_VBP recognized_VBN in_IN equity_NN ._.
The_DT gain_NN or_CC intention_NN of_IN trading_VBG the_DT receivable_NN ._.
p_NN Paul_NNP Capital_NNP funding_VBG liabilities_NNS loss_NN relating_VBG to_TO the_DT ineffective_JJ portion_NN is_VBZ recognized_VBN d_SYM in_IN current_JJ assets_NNS ,_, except_IN for_IN The_DT Group_NNP entered_VBD into_IN two_CD transactions_NNS with_IN Paul_NNP immediately_RB in_IN the_DT income_NN statement_NN ._.
er_JJR than_IN 12_CD months_NNS after_IN the_DT balance_NN Capital_NN Royalty_NNP Acquisition_NNP Fund_NNP Paul_NNP Capital_NNP in_IN Amounts_NNP deferred_VBN in_IN equity_NN are_VBP recycled_VBN in_IN the_DT e_SYM are_VBP classified_VBN as_IN non-current_JJ 2000_CD and_CC 2002_CD ._.
Under_IN these_DT transactions_NNS Paul_NNP Capital_NNP income_NN statement_NN in_IN the_DT periods_NNS when_WRB the_DT hedged_VBN ceivables_NNS are_VBP recognized_VBN initially_RB at_IN provided_VBN a_DT total_NN of_IN $_$ 60m_CD in_IN return_NN for_IN the_DT sale_NN of_IN a_DT item_NN will_MD affect_VB profit_NN or_CC loss_NN ._.
A_DT provision_NN portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN of_IN trade_NN receivables_NN is_VBZ established_VBN streams_NNS on_IN a_DT selection_NN of_IN the_DT Groups_NNS products_NNS ._.
Derivatives_NNS that_WDT do_VBP not_RB qualify_VB for_IN hedge_JJ accounting_NN jective_NN evidence_NN that_IN the_DT Group_NNP will_MD The_DT proceeds_NNS received_VBD from_IN Paul_NNP Capital_NNP meet_VBP the_DT Changes_NNS in_IN the_DT fair_JJ value_NN of_IN any_DT derivative_JJ instruments_NNS llect_VBP all_DT amounts_NNS due_JJ according_VBG to_TO definition_NN of_IN a_DT financial_JJ liability_NN under_IN IAS_NNP 39_CD ,_, and_CC are_VBP that_IN do_VBP not_RB qualify_VB for_IN hedge_JJ accounting_NN are_VBP ms_NNS of_IN the_DT receivables_NN ._.
treated_VBN as_IN such_JJ and_CC recorded_VBN in_IN borrowings_NNS at_IN the_DT recognized_VBN immediately_RB in_IN the_DT income_NN statement_NN ._.
net_JJ present_JJ value_NN of_IN royalties_NNS expected_VBN to_TO be_VB paid_VBN to_TO sh_VB equivalents_NNS Paul_NNP Capital_NNP over_IN the_DT term_NN of_IN the_DT agreements_NNS at_IN the_DT r_NN Leases_VBZ quivalents_NNS are_VBP highly_RB liquid_JJ effective_JJ interest_NN rates_NNS at_IN inception_NN of_IN the_DT arrangements_NNS ._.
Lease_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP t_NN are_VBP readily_RB convertible_JJ to_TO known_VBN Interest_NN is_VBZ charged_VBN on_IN the_DT liability_NN and_CC royalties_NNS paid_VBD substantially_RB all_PDT the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN and_CC which_WDT are_VBP subject_JJ to_TO an_DT to_TO Paul_NNP Capital_NNP are_VBP treated_VBN as_IN repayment_NN of_IN the_DT liability_NN ._.
of_IN an_DT asset_NN are_VBP classified_VBN as_IN finance_NN leases_NNS ._.
Finance_NNP of_IN changes_NNS in_IN value_NN ._.
Cash_NN and_CC cash_NN leases_NNS are_VBP capitalized_VBN at_IN the_DT inception_NN of_IN the_DT lease_NN carried_VBD in_IN the_DT balance_NN sheet_NN at_IN cost_NN ._.
q_NN Derivative_JJ financial_JJ instruments_NNS at_IN the_DT lower_JJR of_IN the_DT fair_JJ value_NN of_IN the_DT leased_VBN property_NN ,_, s_VBZ of_IN the_DT cash_NN flow_NN statement_NN ,_, cash_NN The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO plant_NN and_CC equipment_NN or_CC the_DT present_JJ value_NN of_IN minimum_JJ lents_NNS comprise_VBP cash_NN at_IN bank_NN and_CC manage_VB its_PRP$ exposure_NN to_TO fluctuations_NNS in_IN interest_NN and_CC lease_NN payments_NNS ._.
Each_DT lease_NN payment_NN is_VBZ allocated_VBN rm_NN deposits_NNS ,_, marketable_JJ securities_NNS foreign_JJ exchange_NN rates_NNS ._.
Specifically_RB ,_, the_DT Group_NNP uses_VBZ between_IN the_DT liability_NN and_CC finance_NN charges_NNS so_RB as_IN to_TO Bank_NNP overdrafts_NNS are_VBP included_VBN within_IN interest_NN rate_NN swaps_NNS ,_, forward_RB currency_NN contracts_NNS and_CC achieve_VB a_DT constant_JJ rate_NN on_IN the_DT finance_NN balance_NN rrent_JJ liabilities_NNS on_IN the_DT balance_NN sheet_NN ._.
The_DT corresponding_JJ rental_JJ obligations_NNS ,_, net_NN of_IN finance_NN charges_NNS ,_, are_VBP included_VBN in_IN other_JJ longDerivatives_NNS are_VBP initially_RB recognized_VBN at_IN fair_JJ value_NN on_IN term_NN payables_NNS ._.
These_DT payments_NNS are_VBP split_VBN between_IN recognized_VBN initially_RB at_IN fair_JJ value_NN ,_, the_DT date_NN a_DT derivative_JJ contract_NN is_VBZ entered_VBN into_IN and_CC capital_NN and_CC interest_NN elements_NNS using_VBG the_DT annuity_NN n_NN costs_NNS incurred_VBN ._.
Borrowings_NNS are_VBP are_VBP subsequently_RB re-measured_JJ at_IN their_PRP$ fair_JJ value_NN ._.
The_DT interest_NN element_NN of_IN the_DT lease_NN rental_NN is_VBZ ated_VBN at_IN amortised_JJ cost_NN ,_, any_DT difference_NN The_DT Group_NNP designates_VBZ certain_JJ derivatives_NNS as_IN either_DT :_: included_VBN in_IN the_DT income_NN statement_NN ._.
Assets_NNS held_VBN under_IN ds_NNS net_NN of_IN transaction_NN costs_NNS and_CC hedges_NNS of_IN the_DT fair_JJ value_NN of_IN recognized_VBN assets_NNS or_CC finance_NN leases_NNS are_VBP depreciated_VBN on_IN a_DT basis_NN consistent_JJ value_NN is_VBZ recognized_VBN in_IN the_DT income_NN liabilities_NNS fair_JJ value_NN hedge_NN :_: or_CC with_IN similar_JJ owned_VBN assets_NNS or_CC the_DT lease_NN term_NN if_IN shorter_JJR ._.
he_PRP period_NN of_IN the_DT borrowings_NNS using_VBG hedges_NNS of_IN highly_RB probable_JJ forecast_NN transactions_NNS rest_VBP method_NN ._.
Borrowings_NNS are_VBP classified_JJ cash_NN flow_NN hedges_NNS ._.
All_DT other_JJ leases_NNS are_VBP classified_VBN as_IN operating_VBG leases_NNS ._.
ties_NNS unless_IN the_DT Group_NNP has_VBZ an_DT Payments_NNS made_VBN under_IN operating_VBG leases_NNS ,_, net_NN of_IN lease_NN ght_NN to_TO defer_VB settlement_NN of_IN the_DT liability_NN For_IN relationships_NNS where_WRB hedge_JJ accounting_NN is_VBZ applied_VBN incentives_NNS or_CC premiums_NNS received_VBD ,_, are_VBP charged_VBN to_TO the_DT onths_NNS after_IN the_DT balance_NN sheet_NN date_NN ._.
the_DT Group_NNP documents_NNS at_IN the_DT inception_NN of_IN the_DT income_NN statement_NN on_IN a_DT straight_JJ line_NN basis_NN over_IN the_DT transaction_NN the_DT relationship_NN between_IN hedging_VBG period_NN of_IN the_DT lease_NN ._.
bonds_NNS instruments_NNS and_CC hedged_VBN items_NNS ,_, as_RB well_RB as_IN its_PRP$ risk_NN bt_NN and_CC equity_NN components_NNS of_IN a_DT management_NN objective_NN and_CC strategy_NN for_IN undertaking_VBG s_PRP Employee_NN benefits_NNS are_VBP separated_VBN and_CC recorded_VBN at_IN fair_JJ various_JJ hedge_NN transactions_NNS and_CC reviews_NNS this_DT Pension_NN obligations_NNS e_LS costs_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT liability_NN documentation_NN on_IN an_DT ongoing_JJ basis_NN ._.
The_DT Group_NNP operates_VBZ various_JJ defined_VBN contribution_NN mined_VBN by_IN applying_VBG a_DT market_NN interest_NN plans_NNS for_IN its_PRP$ employees_NNS in_IN the_DT UK_NNP and_CC US_NNP ._.
alent_JJ non-convertible_JJ bond_NN to_TO the_DT Fair_NNP value_NN hedge_NN The_DT Groups_NNS contributions_NNS to_TO these_DT plans_NNS are_VBP charged_VBN ws_NNS under_IN the_DT convertible_JJ bond_NN Changes_NNS in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS that_WDT are_VBP to_TO the_DT income_NN statement_NN in_IN the_DT period_NN to_TO which_WDT they_PRP amount_NN is_VBZ recorded_VBN as_IN a_DT liability_NN designated_VBN and_CC qualify_VB as_IN fair_JJ value_NN hedges_NNS are_VBP relate_VB ,_, and_CC the_DT assets_NNS are_VBP held_VBN in_IN separate_JJ trustee_NN SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 69_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 70_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD administered_VBN funds_NNS ._.
The_DT Group_NNP has_VBZ no_DT further_JJ payment_NN Non-market_NN vesting_VBG conditions_NNS are_VBP included_VBN in_IN obligations_NNS once_IN the_DT contributions_NNS have_VBP been_VBN paid_VBN ._.
estimates_NNS about_IN the_DT number_NN of_IN options_NNS that_WDT are_VBP expected_VBN to_TO become_VB exercisable_JJ ._.
The_DT Group_NNP operates_VBZ a_DT funded_JJ defined_VBN benefit_NN scheme_NN in_IN respect_NN of_IN its_PRP$ employees_NNS in_IN Switzerland_NNP and_CC an_DT The_NNP Group_NNP provides_VBZ finance_NN to_TO an_DT employee_NN share_NN unfunded_JJ defined_VBN benefit_NN scheme_NN in_IN respect_NN of_IN its_PRP$ ownership_NN trust_NN to_TO purchase_VB company_NN shares_NNS on_IN employees_NNS in_IN France_NNP ._.
the_DT open_JJ market_NN to_TO meet_VB the_DT Groups_NNS obligation_NN to_TO provide_VB shares_NNS when_WRB employees_NNS exercise_VBP their_PRP$ The_DT liability_NN recognized_VBN in_IN the_DT balance_NN sheet_NN in_IN options_NNS or_CC awards_NNS ._.
The_DT costs_NNS of_IN running_VBG the_DT employee_NN respect_NN of_IN the_DT defined_VBN benefit_NN pension_NN plans_NNS is_VBZ the_DT share_NN ownership_NN trust_NN are_VBP charged_VBN to_TO the_DT income_NN present_JJ value_NN of_IN the_DT defined_VBN benefit_NN obligations_NNS at_IN the_DT statement_NN as_IN they_PRP accrue_VBP ._.
Shares_NNS held_VBN by_IN the_DT balance_NN sheet_NN date_NN less_RBR the_DT fair_JJ value_NN of_IN plan_NN assets_NNS ,_, employee_NN share_NN ownership_NN trust_NN are_VBP deducted_VBN from_IN together_RB with_IN adjustments_NNS for_IN unrecognised_JJ past_JJ shareholders_NNS equity_NN ._.
Defined_VBN benefit_NN obligations_NNS for_IN the_DT schemes_NNS are_VBP calculated_VBN annually_RB by_IN independent_JJ At_IN each_DT balance_NN sheet_NN date_NN ,_, the_DT entity_NN revises_VBZ its_PRP$ actuaries_NNS using_VBG the_DT projected_VBN unit_NN credit_NN method_NN ._.
estimates_NNS of_IN the_DT number_NN of_IN options_NNS that_WDT are_VBP expected_VBN The_DT present_JJ value_NN of_IN the_DT defined_VBN benefit_NN obligations_NNS to_TO become_VB exercisable_JJ ._.
It_PRP recognizes_VBZ the_DT impact_NN are_VBP determined_VBN by_IN discounting_VBG the_DT estimated_JJ future_NN of_IN the_DT revision_NN of_IN original_JJ estimates_NNS ,_, if_IN any_DT ,_, in_IN the_DT cash_NN outflows_NNS using_VBG interest_NN rates_NNS of_IN high_JJ quality_NN income_NN statement_NN ,_, and_CC a_DT corresponding_JJ adjustment_NN corporate_JJ bonds_NNS that_WDT are_VBP denominated_VBN in_IN the_DT currency_NN to_TO equity_NN over_IN the_DT remaining_VBG vesting_JJ period_NN ._.
in_IN which_WDT the_DT benefits_NNS will_MD be_VB paid_VBN ,_, and_CC that_DT have_VBP terms_NNS to_TO maturity_NN approximating_NN to_TO the_DT terms_NNS of_IN the_DT t_NN Provisions_NNS related_VBN pension_NN liability_NN ._.
Service_NNP costs_NNS are_VBP included_VBN in_IN Provisions_NNS are_VBP recognized_VBN when_WRB the_DT Group_NNP has_VBZ a_DT staff_NN costs_NNS and_CC charged_VBN to_TO income_NN statement_NN over_IN the_DT present_JJ legal_JJ or_CC constructive_JJ obligation_NN as_IN a_DT result_NN remaining_VBG average_JJ expected_JJ service_NN lives_NNS of_IN employees_NNS ._.
of_IN past_JJ events_NNS ,_, if_IN it_PRP is_VBZ probable_JJ that_IN an_DT outflow_NN of_IN resources_NNS will_MD be_VB required_VBN to_TO settle_VB the_DT obligation_NN Actuarial_JJ gains_NNS and_CC losses_NNS arising_VBG from_IN experience_NN and_CC the_DT amount_NN can_MD be_VB reliably_RB estimated_VBN ._.
adjustments_NNS and_CC changes_NNS actuarial_JJ assumptions_NNS Restructuring_NN charges_NNS are_VBP provided_VBN in_IN the_DT period_NN are_VBP charged_VBN or_CC credited_VBN to_TO equity_NN in_IN the_DT Consolidated_NNP in_IN which_WDT management_NN has_VBZ committed_VBN to_TO a_DT plan_NN and_CC Statement_NN of_IN Recognised_NNP Income_NNP and_CC Expense_NNP in_IN it_PRP is_VBZ probable_JJ that_IN an_DT obligation_NN has_VBZ been_VBN incurred_VBN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
that_WDT can_MD be_VB reliably_RB estimated_VBN ._.
Provisions_NNS are_VBP not_RB recognized_VBN for_IN future_JJ operating_NN losses_NNS ._.
The_DT Group_NNP recognizes_VBZ actuarial_JJ gains_NNS and_CC losses_NNS arising_VBG from_IN experience_NN adjustments_NNS and_CC changes_NNS in_IN u_JJ Taxation_NNP actuarial_JJ assumptions_NNS directly_RB in_IN equity_NN ,_, in_IN the_DT period_NN Current_JJ tax_NN is_VBZ the_DT expected_JJ tax_NN payable_JJ on_IN the_DT taxable_JJ they_PRP have_VBP occurred_VBN ,_, in_IN accordance_NN to_TO the_DT alternative_JJ income_NN for_IN the_DT year_NN using_VBG the_DT tax_NN rates_NNS and_CC laws_NNS that_WDT treatment_NN allowed_VBN by_IN the_DT amendment_NN to_TO IAS_NNP 19_CD :_: have_VB been_VBN enacted_VBN or_CC substantially_RB enacted_VBN at_IN the_DT Employee_NN benefits_NNS Actuarial_JJ gains_NNS and_CC losses_NNS ,_, balance_NN sheet_NN date_NN ,_, and_CC any_DT adjustment_NN to_TO tax_NN group_NN plans_NNS and_CC disclosures_NNS ._.
payable_JJ in_IN respect_NN of_IN previous_JJ years_NNS ._.
Share-based_JJ compensation_NN Deferred_JJ income_NN tax_NN is_VBZ provided_VBN in_IN full_JJ ,_, using_VBG the_DT Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO liability_NN method_NN ,_, on_IN temporary_JJ differences_NNS arising_VBG employees_NNS under_IN share_NN option_NN ,_, share_NN purchase_NN between_IN the_DT tax_NN bases_NNS of_IN assets_NNS and_CC liabilities_NNS and_CC and_CC long_JJ term_NN incentive_NN plans_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT their_PRP$ carrying_VBG amounts_NNS in_IN the_DT consolidated_JJ financial_JJ employee_NN services_NNS received_VBN in_IN exchange_NN for_IN the_DT grant_NN statements_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN to_TO of_IN the_DT options_NNS and_CC rewards_NNS is_VBZ recognized_VBN as_IN an_DT the_DT extent_NN that_IN it_PRP is_VBZ probable_JJ that_IN future_JJ taxable_JJ expense_NN ._.
The_DT total_JJ amount_NN to_TO be_VB expensed_VBN over_IN the_DT profits_NNS will_MD be_VB available_JJ against_IN which_WDT the_DT temporary_JJ vesting_JJ period_NN is_VBZ determined_VBN by_IN reference_NN to_TO the_DT fair_JJ differences_NNS can_MD be_VB utilised_VBN ._.
Deferred_JJ income_NN tax_NN is_VBZ value_NN of_IN the_DT options_NNS granted_VBN ,_, which_WDT excludes_VBZ the_DT determined_VBN using_VBG tax_NN rates_NNS that_WDT have_VBP been_VBN enacted_VBN impact_NN of_IN any_DT non-market_JJ vesting_NN conditions_NNS for_IN or_CC substantially_RB enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
example_NN ,_, profitability_NN and_CC sales_NNS growth_NN targets_NNS ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
70_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 71_CD ting_NN conditions_NNS are_VBP included_VBN in_IN v_NN Deferred_JJ consideration_NN Interest_NN rate_NN risk_VB the_DT number_NN of_IN options_NNS that_WDT are_VBP Provisions_NNS for_IN deferred_JJ consideration_NN comprise_VBP the_DT The_NNP Group_NNP borrows_VBZ at_IN fixed_VBN and_CC floating_VBG rates_NNS of_IN ome_NN exercisable_JJ ._.
fair_JJ value_NN of_IN contingent_JJ consideration_NN arising_VBG from_IN interest_NN as_IN deemed_VBN appropriate_JJ for_IN its_PRP$ circumstances_NNS ._.
The_DT eventual_JJ outcome_NN is_VBZ subject_JJ to_TO the_DT Where_WRB necessary_JJ the_DT Group_NNP uses_VBZ interest_NN rate_NN swaps_NNS des_FW finance_NN to_TO an_DT employee_NN share_NN Groups_NNS future_JJ performance_NN and_CC certain_JJ contractual_JJ to_TO achieve_VB the_DT desired_VBN interest_NN rate_NN profile_NN ._.
to_TO purchase_VB company_NN shares_NNS on_IN terms_NNS ._.
Provisions_NNS are_VBP reviewed_VBN annually_RB by_IN the_DT to_TO meet_VB the_DT Groups_NNS obligation_NN Directors_NNS ,_, and_CC changes_NNS to_TO the_DT estimated_VBN fair_JJ value_NN Credit_NN risk_NN s_VBZ when_WRB employees_NNS exercise_VBP their_PRP$ of_IN the_DT contingent_JJ consideration_NN are_VBP recorded_VBN as_IN an_DT The_NNP Group_NNP is_VBZ exposed_VBN to_TO credit_NN related_VBN losses_NNS in_IN the_DT s._NN The_DT costs_NNS of_IN running_VBG the_DT employee_NN adjustment_NN to_TO goodwill_NN or_CC the_DT underlying_JJ asset_NN value_NN ._.
event_NN of_IN non-performance_JJ by_IN third_JJ parties_NNS to_TO financial_JJ trust_NN are_VBP charged_VBN to_TO the_DT income_NN instruments_NNS ._.
The_DT Group_NNP does_VBZ not_RB expect_VB any_DT third_JJ ey_NN accrue_VBP ._.
Shares_NNS held_VBN by_IN the_DT 2_CD Financial_NNP risk_NN management_NN parties_NNS to_TO fail_VB to_TO meet_VB their_PRP$ obligations_NNS given_VBN the_DT policy_NN ownership_NN trust_NN are_VBP deducted_VBN from_IN of_IN selecting_VBG only_RB parties_NNS with_IN high_JJ credit_NN ratings_NNS and_CC uity_NN ._.
Financial_NNP risk_NN factors_NNS minimizing_VBG its_PRP$ exposure_NN to_TO any_DT one_CD institution_NN ._.
The_DT Group_NNP holds_VBZ financial_JJ instruments_NNS to_TO finance_VB sheet_NN date_NN ,_, the_DT entity_NN revises_VBZ its_PRP$ its_PRP$ operations_NNS and_CC to_TO manage_VB the_DT currency_NN risk_NN that_WDT Price_NNP risk_NN number_NN of_IN options_NNS that_WDT are_VBP expected_VBN arises_VBZ from_IN these_DT operations_NNS ._.
It_PRP is_VBZ the_DT Groups_NNS policy_NN The_DT Group_NNP is_VBZ exposed_VBN to_TO equity_NN securities_NNS price_NN risk_NN isable_JJ ._.
It_PRP recognizes_VBZ the_DT impact_NN that_IN no_DT speculative_JJ trading_NN in_IN financial_JJ instruments_NNS because_IN of_IN investments_NNS which_WDT have_VBP been_VBN classified_VBN original_JJ estimates_NNS ,_, if_IN any_DT ,_, in_IN the_DT shall_MD be_VB undertaken_VBN ._.
The_DT Group_NNP finances_VBZ its_PRP$ operations_NNS on_IN the_DT consolidated_JJ balance_NN sheet_NN as_IN at_IN fair_JJ value_NN nt_NN ,_, and_CC a_DT corresponding_JJ adjustment_NN through_IN a_DT combination_NN of_IN equity_NN ,_, convertible_JJ bonds_NNS ,_, through_IN profit_NN or_CC loss_NN ._.
bank_NN loans_NNS and_CC other_JJ borrowings_NNS ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT Groups_NNS financial_JJ instruments_NNS are_VBP Fair_NNP value_NN estimation_NN liquidity_NN risk_NN ,_, foreign_JJ currency_NN risk_NN ,_, interest_NN rate_NN risk_NN ,_, The_DT fair_JJ value_NN of_IN financial_JJ instruments_NNS traded_VBN in_IN ecognised_VBN when_WRB the_DT Group_NNP has_VBZ a_DT credit_NN risk_NN and_CC price_NN risk_NN ._.
active_JJ markets_NNS such_JJ as_IN trading_NN and_CC obligation_NN as_IN a_DT result_NN sale_NN securities_NNS is_VBZ based_VBN on_IN quoted_VBN market_NN prices_NNS it_PRP is_VBZ probable_JJ that_IN an_DT outflow_NN of_IN Liquidity_NN risk_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT quoted_VBN market_NN price_NN e_SYM required_VBN to_TO settle_VB the_DT obligation_NN The_DT Groups_NNS policy_NN is_VBZ to_TO maintain_VB continuity_NN of_IN funding_NN used_VBN for_IN financial_JJ assets_NNS held_VBN by_IN the_DT Group_NNP is_VBZ the_DT can_MD be_VB reliably_RB estimated_VBN ._.
through_IN a_DT mixture_NN of_IN long-term_JJ debt_NN and_CC bank_NN loans_NNS ,_, current_JJ bid_NN price_NN ._.
Quoted_VBN market_NN prices_NNS or_CC dealer_NN harges_NNS are_VBP provided_VBN in_IN the_DT period_NN raised_VBD to_TO cover_VB specific_JJ projects_NNS ,_, and_CC through_IN the_DT quotes_NNS for_IN similar_JJ instruments_NNS are_VBP used_VBN for_IN other_JJ ement_NN has_VBZ committed_VBN to_TO a_DT plan_NN and_CC issue_NN of_IN shares_NNS to_TO collaborative_JJ partners_NNS ,_, where_WRB financial_JJ instruments_NNS ._.
The_DT fair_JJ value_NN of_IN forward_RB t_VB an_DT obligation_NN has_VBZ been_VBN incurred_VBN necessary_JJ ,_, to_TO finance_VB development_NN contracts_NNS ._.
Shortforeign_NNP exchange_NN contracts_NNS is_VBZ determined_VBN using_VBG bly_RB estimated_VBN ._.
Provisions_NNS are_VBP not_RB term_NN flexibility_NN is_VBZ provided_VBN through_IN the_DT use_NN of_IN overdrafts_NNS ._.
forward_RB exchange_NN market_NN rates_NNS at_IN the_DT balance_NN sheet_NN uture_NN operating_NN losses_NNS ._.
The_DT nominal_JJ value_NN less_RBR estimated_JJ credit_NN Foreign_JJ currency_NN risk_NN adjustments_NNS of_IN trade_NN receivables_NNS and_CC payables_NNS are_VBP All_DT of_IN the_DT Groups_NNS operations_NNS are_VBP based_VBN overseas_RB in_IN assumed_VBN to_TO approximate_JJ their_PRP$ fair_JJ values_NNS ._.
The_DT fair_JJ e_SYM expected_VBN tax_NN payable_JJ on_IN the_DT taxable_JJ Continental_NNP Europe_NNP and_CC North_NNP America_NNP giving_VBG rise_NN value_NN of_IN the_DT liabilities_NNS for_IN the_DT disclosure_NN purposes_NNS ear_NN using_VBG the_DT tax_NN rates_NNS and_CC laws_NNS that_WDT to_TO exposures_NNS to_TO changes_NNS in_IN foreign_JJ exchange_NN rates_NNS is_VBZ estimated_VBN by_IN discounting_VBG the_DT future_JJ cash_NN flows_VBZ ed_VBN or_CC substantially_RB enacted_VBN at_IN the_DT notably_RB the_DT Swiss_JJ Franc_NN ,_, Euro_NNP and_CC US_NNP Dollar_NNP ._.
at_IN the_DT current_JJ market_NN interest_NN rates_NNS that_WDT is_VBZ available_JJ ate_VBD ,_, and_CC any_DT adjustment_NN to_TO tax_NN To_TO minimize_VB the_DT impact_NN of_IN any_DT fluctuations_NNS ,_, the_DT to_TO the_DT Group_NNP for_IN similar_JJ financial_JJ instruments_NNS ._.
Groups_NNS policy_NN has_VBZ historically_RB been_VBN to_TO maintain_VB natural_JJ hedges_NNS by_IN relating_VBG the_DT structure_NN of_IN 3_CD Critical_JJ accounting_NN estimates_NNS and_CC judgements_NNS e_LS tax_NN is_VBZ provided_VBN in_IN full_JJ ,_, using_VBG the_DT borrowings_NNS to_TO the_DT trading_NN cash_NN flows_VBZ that_IN generate_VB on_IN temporary_JJ differences_NNS arising_VBG them_PRP ._.
Where_WRB subsidiaries_NNS are_VBP funded_VBN centrally_RB ,_, this_DT is_VBZ The_DT preparation_NN of_IN the_DT Consolidated_NNP Financial_NNP bases_NNS of_IN assets_NNS and_CC liabilities_NNS and_CC achieved_VBN by_IN the_DT use_NN of_IN long-term_JJ loans_NNS ,_, the_DT exchange_NN Statements_NNP requires_VBZ the_DT Group_NNP to_TO make_VB estimates_NNS mounts_NNS in_IN the_DT consolidated_JJ financial_JJ differences_NNS on_IN which_WDT are_VBP taken_VBN to_TO reserves_NNS ._.
and_CC judgements_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN erred_VBN tax_NN assets_NNS are_VBP recognized_VBN to_TO Where_WRB it_PRP has_VBZ not_RB been_VBN possible_JJ to_TO use_VB natural_JJ assets_NNS ,_, liabilities_NNS ,_, revenues_NNS and_CC expenses_NNS ,_, and_CC related_VBN is_VBZ probable_JJ that_IN future_JJ taxable_JJ hedges_NNS ,_, currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS ._.
ailable_JJ against_IN which_WDT the_DT temporary_JJ and_CC forward_JJ currency_NN contracts_NNS are_VBP used_VBN ._.
The_DT Group_NNP The_NNP Group_NNP bases_VBZ its_PRP$ estimates_NNS and_CC judgements_NNS on_IN be_VB utilised_VBN ._.
Deferred_JJ income_NN tax_NN is_VBZ has_VBZ used_VBN these_DT financial_JJ instruments_NNS during_IN the_DT historical_JJ experience_NN and_CC on_IN various_JJ other_JJ assumptions_NNS g_VBP tax_NN rates_NNS that_WDT have_VBP been_VBN enacted_VBN year_NN to_TO minimize_VB the_DT currency_NN exposure_NN on_IN that_IN it_PRP considers_VBZ to_TO be_VB reasonable_JJ ._.
Actual_JJ results_NNS may_MD enacted_VBN by_IN the_DT balance_NN sheet_NN date_NN ._.
differ_VBP from_IN these_DT estimates_NNS under_IN different_JJ assumptions_NNS ets_VBZ and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 71_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 72_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD Revenue_NN recognition_NN reviewed_VBN annually_RB by_IN the_DT Directors_NNS ,_, who_WP make_VBP The_DT Groups_NNS revenue_NN comprises_VBZ revenues_NNS from_IN significant_JJ judgments_NNS as_IN to_TO the_DT estimated_VBN fair_JJ value_NN contract_NN development_NN and_CC licensing_NN ,_, royalties_NNS and_CC of_IN the_DT contingent_JJ consideration_NN ._.
Based_VBN on_IN these_DT manufacturing_NN and_CC distribution_NN ._.
The_DT Group_NNP enters_VBZ judgments_NNS ,_, changes_NNS to_TO the_DT estimated_VBN fair_JJ value_NN of_IN a_DT wide_JJ variety_NN of_IN collaborative_JJ arrangements_NNS with_IN the_DT consideration_NN are_VBP recorded_VBN ._.
its_PRP$ partners_NNS from_IN which_WDT it_PRP may_MD earn_VB all_DT ,_, or_CC some_DT of_IN ,_, these_DT revenue_NN streams_NNS ._.
The_DT application_NN of_IN the_DT Contingent_NNP Liabilities_NNPS Groups_NNS revenue_NN recognition_NN policy_NN set_VBN out_RP earlier_JJR Provisions_NNS for_IN contingent_JJ liabilities_NNS are_VBP dependent_JJ in_IN this_DT note_NN to_TO its_PRP$ complex_JJ collaboration_NN agreements_NNS upon_IN estimates_NNS and_CC assessments_NNS of_IN whether_IN the_DT requires_VBZ significant_JJ estimates_NNS and_CC judgement_NN ._.
criteria_NNS for_IN recognition_NN have_VBP been_VBN met_VBN ,_, including_VBG In_IN particular_JJ ,_, in_IN arrangements_NNS with_IN multiple_JJ estimates_NNS by_IN the_DT Directors_NNS as_IN to_TO the_DT probable_JJ outcome_NN deliverables_NNS ,_, there_EX may_MD be_VB significant_JJ judgement_NN in_IN and_CC the_DT amount_NN of_IN the_DT potential_JJ cost_NN of_IN resolution_NN ._.
separating_VBG the_DT different_JJ revenue_NN generating_VBG activities_NNS ._.
Any_DT estimate_NN for_IN such_JJ an_DT accrual_NN would_MD be_VB developed_VBN in_IN consultation_NN with_IN external_JJ legal_JJ advisors_NNS handling_VBG Paul_NNP Capital_NNP funding_VBG liabilities_NNS the_DT Groups_NNS defense_NN in_IN these_DT matters_NNS and_CC would_MD be_VB The_DT proceeds_NNS received_VBD from_IN Paul_NNP Capital_NNP are_VBP treated_VBN based_VBN upon_IN an_DT analysis_NN of_IN potential_JJ outcomes_NNS ._.
as_IN a_DT liability_NN under_IN IAS_NNP 39_CD and_CC are_VBP recorded_VBN within_IN borrowings_NNS at_IN the_DT net_JJ present_JJ value_NN of_IN royalties_NNS Pensions_NNS expected_VBN to_TO be_VB paid_VBN to_TO Paul_NNP Capital_NNP at_IN the_DT effective_JJ The_DT Group_NNP recognizes_VBZ actuarial_JJ gains_NNS and_CC losses_NNS interest_NN rate_NN at_IN inception_NN of_IN the_DT agreement_NN ._.
arising_VBG from_IN experience_NN adjustments_NNS and_CC changes_NNS in_IN Therefore_RB in_IN order_NN to_TO be_VB able_JJ to_TO record_VB the_DT funding_NN actuarial_JJ assumptions_NNS directly_RB in_IN equity_NN ,_, in_IN the_DT period_NN liability_NN significant_JJ estimation_NN of_IN certain_JJ of_IN the_DT they_PRP have_VBP occurred_VBN ,_, in_IN accordance_NN to_TO the_DT alternative_NN Groups_NNS future_JJ cash_NN flows_VBZ is_VBZ required_VBN ._.
Royalty_NN cash_NN treatment_NN allowed_VBN by_IN the_DT amendment_NN to_TO IAS_NNP 19_CD :_: flows_NNS are_VBP periodically_RB reassessed_VBN to_TO determine_VB the_DT Employee_NN benefits_NNS Actuarial_JJ gains_NNS and_CC losses_NNS ,_, estimated_VBN funding_NN liability_NN ._.
In_IN addition_NN such_JJ flows_NNS group_NN plans_NNS and_CC disclosures_NNS ._.
The_DT costs_NNS are_VBP assessed_VBN are_VBP subject_JJ to_TO foreign_JJ exchange_NN movements_NNS ._.
in_IN accordance_NN with_IN advice_NN received_VBN from_IN independent_JJ actuaries_NNS ._.
These_DT assumptions_NNS include_VBP inflation_NN rate_NN ,_, Impairment_NN of_IN goodwill_NN rate_NN of_IN increase_NN in_IN salaries_NNS ,_, discount_NN rate_NN and_CC The_DT Group_NNP tests_NNS annually_RB whether_IN goodwill_NN has_VBZ suffered_VBN expected_VBN return_NN on_IN plan_NN assets_NNS and_CC are_VBP disclosed_VBN any_DT impairment_NN ,_, in_IN accordance_NN with_IN the_DT accounting_NN in_IN Note_NN 27_CD :_: Retirement_NNP benefit_NN obligations_NNS ._.
policy_NN stated_VBD earlier_RBR in_IN this_DT note_NN ._.
The_DT recoverable_JJ The_DT selection_NN of_IN different_JJ assumptions_NNS could_MD affect_VB amounts_NNS of_IN cash-generating_JJ units_NNS have_VBP been_VBN the_DT future_JJ results_NNS of_IN the_DT Group_NNP ._.
determined_VBN based_VBN on_IN value-in-use_JJ calculations_NNS ._.
These_DT calculations_NNS require_VBP the_DT use_NN of_IN estimates_NNS ._.
The_DT estimates_NNS Share_NN based_VBN compensation_NN used_VBN in_IN goodwill_NN impairment_NN testing_NN as_IN at_IN 31_CD December_NNP Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO 2005_CD and_CC 2004_CD are_VBP presented_VBN in_IN Note_NN 12_CD :_: Goodwill_NNP ._.
employees_NNS under_IN share_NN option_NN ,_, share_NN purchase_NN and_CC long_JJ term_NN incentive_NN plans_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT Impairment_NN of_IN other_JJ intangible_JJ assets_NNS and_CC property_NN ,_, employee_NN services_NNS received_VBN in_IN exchange_NN for_IN the_DT grant_NN plant_NN ant_NN equipment_NN of_IN the_DT options_NNS and_CC rewards_NNS is_VBZ recognized_VBN as_IN an_DT The_NNP Group_NNP tests_VBZ annually_RB whether_IN other_JJ intangible_JJ expense_NN ._.
The_DT expense_NN is_VBZ based_VBN upon_IN a_DT number_NN of_IN assets_NNS and_CC property_NN ,_, plant_NN ant_NN equipment_NN have_VBP assumptions_NNS disclosed_VBN in_IN Note_NN 28_CD :_: Share_NN capital_NN ._.
suffered_VBN any_DT impairment_NN ,_, in_IN accordance_NN with_IN The_DT selection_NN of_IN different_JJ assumptions_NNS could_MD affect_VB the_DT accounting_NN policy_NN stated_VBN earlier_RBR in_IN this_DT note_NN ._.
the_DT future_JJ results_NNS of_IN the_DT Group_NNP ._.
Amortisation_NNP lives_VBZ Deferred_NNP Consideration_NNP Other_JJ intangible_JJ assets_NNS are_VBP recorded_VBN at_IN their_PRP$ fair_JJ Provisions_NNS for_IN deferred_JJ consideration_NN payable_JJ by_IN value_NN at_IN acquisition_NN date_NN and_CC are_VBP amortised_VBN on_IN the_DT Group_NNP comprise_VBP the_DT fair_JJ value_NN of_IN contingent_NN a_DT straight_JJ line_NN basis_NN over_IN their_PRP$ estimated_VBN useful_JJ consideration_NN arising_VBG from_IN acquisitions_NNS ._.
The_DT eventual_JJ economic_JJ lives_NNS from_IN the_DT time_NN they_PRP are_VBP available_JJ for_IN outcome_NN is_VBZ subject_JJ to_TO the_DT Groups_NNS future_JJ performance_NN use_NN ._.
Any_DT change_NN in_IN the_DT estimated_VBN useful_JJ economic_JJ and_CC certain_JJ contractual_JJ terms_NNS ._.
Provisions_NNS are_VBP lives_NNS could_MD affect_VB the_DT future_JJ results_NNS of_IN the_DT Group_NNP ._.
72_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 73_CD ly_RB by_IN the_DT Directors_NNS ,_, who_WP make_VBP Taxation_NNP ments_NNS as_IN to_TO the_DT estimated_VBN fair_JJ value_NN Current_JJ tax_NN is_VBZ the_DT expected_JJ tax_NN payable_JJ on_IN the_DT taxable_JJ t_NN consideration_NN ._.
Based_VBN on_IN these_DT income_NN for_IN the_DT year_NN using_VBG the_DT tax_NN rates_NNS and_CC laws_NNS that_WDT ges_VBZ to_TO the_DT estimated_VBN fair_JJ value_NN of_IN have_VBP been_VBN enacted_VBN or_CC substantially_RB enacted_VBN at_IN the_DT n_NN are_VBP recorded_VBN ._.
balance_NN sheet_NN date_NN ,_, and_CC any_DT adjustment_NN to_TO tax_NN payable_JJ in_IN respect_NN of_IN previous_JJ years_NNS ._.
The_DT Group_NNP has_VBZ lities_NNS open_JJ tax_NN issues_NNS with_IN a_DT number_NN of_IN revenue_NN authorities_NNS ntingent_JJ liabilities_NNS are_VBP dependent_JJ and_CC ,_, on_IN the_DT basis_NN of_IN external_JJ professional_JJ advice_NN ,_, and_CC assessments_NNS of_IN whether_IN the_DT continues_VBZ to_TO believe_VB that_IN it_PRP has_VBZ made_VBN adequate_JJ nition_NN have_VBP been_VBN met_VBN ,_, including_VBG provision_NN for_IN any_DT liabilities_NNS that_WDT may_MD arise_VB from_IN these_DT Directors_NNS as_IN to_TO the_DT probable_JJ outcome_NN open_JJ assessments_NNS ._.
The_DT ultimate_JJ liability_NN for_IN such_JJ of_IN the_DT potential_JJ cost_NN of_IN resolution_NN ._.
matters_NNS may_MD vary_VB from_IN the_DT amounts_NNS provided_VBN ,_, and_CC such_PDT an_DT accrual_NN would_MD be_VB developed_VBN is_VBZ dependent_JJ upon_IN negotiations_NNS with_IN the_DT relevant_JJ with_IN external_JJ legal_JJ advisors_NNS handling_VBG tax_NN authorities_NNS ._.
nce_NN in_IN these_DT matters_NNS and_CC would_MD be_VB nalysis_NN of_IN potential_JJ outcomes_NNS ._.
4_CD Segment_NN information_NN Primary_JJ reporting_NN format_NN business_NN segments_NNS nises_VBZ actuarial_JJ gains_NNS and_CC losses_NNS Based_VBN on_IN the_DT risks_NNS and_CC returns_NNS of_IN the_DT various_JJ segments_NNS ,_, the_DT Directors_NNS consider_VBP that_IN the_DT Groups_NNS primary_JJ erience_NN adjustments_NNS and_CC changes_NNS in_IN reporting_VBG format_NN is_VBZ by_IN business_NN segment_NN with_IN geographical_JJ reporting_NN being_VBG the_DT secondary_JJ format_NN ._.
The_DT Group_NNP ptions_NNS directly_RB in_IN equity_NN ,_, in_IN the_DT period_NN is_VBZ a_DT speciality_NN pharmaceutical_JJ company_NN ,_, using_VBG its_PRP$ multiple_JJ drug_NN delivery_NN technologies_NNS to_TO create_VB a_DT product_NN ed_VBD ,_, in_IN accordance_NN to_TO the_DT alternative_JJ pipeline_NN for_IN out-licensing_JJ to_TO marketing_VBG partners_NNS ._.
The_DT business_NN segments_NNS consist_VBP of_IN the_DT Injectable_JJ business_NN ed_VBN by_IN the_DT amendment_NN to_TO IAS_NNP 19_CD :_: and_CC the_DT Oral_NNP and_CC Inhalation_NNP business_NN ._.
Business_NNP segment_NN data_NN includes_VBZ an_DT allocation_NN of_IN corporate_JJ costs_NNS to_TO ts_NNS Actuarial_JJ gains_NNS and_CC losses_NNS ,_, each_DT segment_NN on_IN an_DT appropriate_JJ basis_NN ._.
There_EX are_VBP no_DT material_NN inter-segment_NN transfers_NNS ._.
The_DT costs_NNS are_VBP assessed_VBN segments_NNS of_IN UK_NNP ,_, Europe_NNP ,_, North_NNP America_NNP and_CC Rest_VB of_IN the_DT World_NNP reflect_VBP the_DT Groups_NNS most_RBS significant_JJ regional_JJ th_NN advice_NN received_VBD from_IN independent_JJ markets_NNS ._.
Revenue_NN is_VBZ shown_VBN by_IN business_NN segment_NN ,_, revenue_NN stream_NN and_CC location_NN of_IN customer_NN ._.
Other_JJ geographic_JJ assumptions_NNS include_VBP inflation_NN rate_NN ,_, information_NN is_VBZ provided_VBN by_IN location_NN of_IN operation_NN ._.
All_DT Group_NNP activities_NNS are_VBP continuing_VBG operations_NNS ._.
in_IN salaries_NNS ,_, discount_NN rate_NN and_CC on_IN plan_NN assets_NNS and_CC are_VBP disclosed_VBN Revenue_NN by_IN business_NN segment_NN :_: Year_NN ended_VBD Year_NN ended_VBD ement_NN benefit_NN obligations_NNS ._.
31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD different_JJ assumptions_NNS could_MD affect_VB m_FW m_FW s_PRP of_IN the_DT Group_NNP ._.
Injectable_JJ 10.5_CD 25.6_CD Oral_NNP and_CC Inhalation_NNP 50.8_CD 49.6_CD mpensation_NN 61.3_CD 75.2_CD form_NN of_IN shares_NNS are_VBP provided_VBN to_TO r_NN share_NN option_NN ,_, share_NN purchase_NN Revenue_NN earned_VBD can_MD be_VB analyzed_VBN as_IN :_: centive_JJ plans_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT Contract_NNP development_NN and_CC licensing_NN es_VBZ received_VBN in_IN exchange_NN for_IN the_DT grant_NN Milestone_NN payments_NNS 22.1_CD 33.4_CD d_SYM rewards_NNS is_VBZ recognized_VBN as_IN an_DT Research_NN and_CC development_NN costs_NNS recharged_VBD 5.5_CD 6.0_CD pense_NN is_VBZ based_VBN upon_IN a_DT number_NN of_IN 27.6_CD 39.4_CD closed_VBN in_IN Note_NN 28_CD :_: Share_NN capital_NN ._.
Royalties_NNS 21.7_CD 25.9_CD different_JJ assumptions_NNS could_MD affect_VB Manufacturing_NNP and_CC distribution_NN 12.0_CD 9.9_CD s_PRP of_IN the_DT Group_NNP ._.
Total_JJ revenue_NN 61.3_CD 75.2_CD es_NNS assets_NNS are_VBP recorded_VBN at_IN their_PRP$ fair_JJ on_IN date_NN and_CC are_VBP amortised_VBN on_IN asis_NN over_IN their_PRP$ estimated_VBN useful_JJ rom_NN the_DT time_NN they_PRP are_VBP available_JJ for_IN in_IN the_DT estimated_VBN useful_JJ economic_JJ the_DT future_JJ results_NNS of_IN the_DT Group_NNP ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 73_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 74_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD Operating_VBG loss_NN by_IN business_NN segment_NN :_: Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Injectable_FW 18.6_CD 1.4_CD Oral_NNP and_CC Inhalation_NNP 2.5_CD 1.0_CD Operating_NN loss_NN pre_NN exceptional_JJ items_NNS 16.1_CD 0.4_CD Exceptional_JJ items_NNS 21.4_CD 2.7_CD Operating_NN loss_NN 37.5_CD 3.1_CD Share_NN of_IN loss_NN in_IN associate_JJ 0.8_CD Net_JJ interest_NN 12.3_CD 15.3_CD Tax_NNP 0.3_CD 0.2_CD Loss_NN after_IN tax_NN 50.9_CD 18.6_CD Total_JJ assets_NNS by_IN business_NN segment_NN :_: Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN Injectable_NNP 57.1_CD 60.4_CD Oral_NNP and_CC Inhalation_NNP 93.3_CD 95.6_CD Total_JJ operating_VBG assets_NNS 150.4_CD 156.0_CD Investments_NNP in_IN associates_NNS 0.2_CD 14.3_CD Available-for-sale_JJ financial_JJ assets_NNS 1.6_CD 5.2_CD Financial_NNP assets_NNS at_IN fair_JJ value_NN through_IN profit_NN and_CC loss_NN 0.4_CD 1.1_CD Cash_NN and_CC cash_NN equivalents_NNS 34.3_CD 15.3_CD Total_JJ assets_NNS 186.9_CD 191.9_CD Total_JJ liabilities_NNS by_IN business_NN segment_NN :_: Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN Injectable_NNP 40.1_CD 30.5_CD Oral_NNP and_CC Inhalation_NNP 41.4_CD 54.0_CD Total_JJ operating_VBG liabilities_NNS 81.5_CD 84.5_CD Short-term_JJ borrowings_NNS :_: convertible_JJ bonds_NNS 9.4_CD Short-term_JJ borrowings_NNS :_: other_JJ 2.7_CD 3.9_CD Long-term_JJ borrowings_NNS :_: convertible_JJ bonds_NNS 63.6_CD 50.4_CD Long-term_JJ borrowings_NNS :_: other_JJ 7.2_CD 7.2_CD Total_JJ liabilities_NNS 155.0_CD 155.4_CD 74_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 75_CD Property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ assets_NNS by_IN business_NN segment_NN :_: Year_NN ended_VBD Year_NN ended_VBD Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW 18.6_CD 1.4_CD Additions_NNS 2.5_CD 1.0_CD Injectable_NNP 1.8_CD 2.3_CD 16.1_CD 0.4_CD Oral_NNP and_CC Inhalation_NNP 3.3_CD 4.9_CD 21.4_CD 2.7_CD 5.1_CD 7.2_CD 37.5_CD 3.1_CD 0.8_CD Depreciation_NN and_CC Amortisation_NNP 12.3_CD 15.3_CD Injectable_NNP 1.9_CD 1.9_CD 0.3_CD 0.2_CD Oral_NNP and_CC Inhalation_NNP 6.4_CD 6.3_CD 50.9_CD 18.6_CD 8.3_CD 8.2_CD Investments_NNP in_IN associates_NNS by_IN business_NN segment_NN :_: Year_NN ended_VBD Year_NN ended_VBD Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW 57.1_CD 60.4_CD Injectable_JJ 0.2_CD 14.3_CD 93.3_CD 95.6_CD Oral_NNP and_CC Inhalation_NNP 150.4_CD 156.0_CD 0.2_CD 14.3_CD 0.2_CD 14.3_CD Secondary_JJ reporting_NN format_NN geographic_JJ 1.6_CD 5.2_CD 0.4_CD 1.1_CD Revenue_NN by_IN location_NN of_IN customer_NN :_: Year_NN ended_VBD Year_NN ended_VBD 34.3_CD 15.3_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 186.9_CD 191.9_CD m_NN m_NN UK_NNP 23.9_CD 15.2_CD Europe_NNP 23.8_CD 26.0_CD Year_NN ended_VBD Year_NN ended_VBD North_NNP America_NNP 8.7_CD 29.2_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Rest_VB of_IN World_NNP 4.9_CD 4.8_CD 40.1_CD 30.5_CD 61.3_CD 75.2_CD 41.4_CD 54.0_CD 81.5_CD 84.5_CD Total_JJ assets_NNS by_IN location_NN of_IN operation_NN :_: Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 9.4_CD m_NN m_NN 2.7_CD 3.9_CD UK_NNP 37.7_CD 30.0_CD 63.6_CD 50.4_CD Europe_NNP 56.9_CD 89.7_CD 7.2_CD 7.2_CD North_NNP America_NNP 92.3_CD 72.2_CD 155.0_CD 155.4_CD 186.9_CD 191.9_CD Property_NN ,_, plant_NN and_CC equipment_NN and_CC intangible_JJ asset_NN additions_NNS by_IN location_NN of_IN operation_NN :_: Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Europe_NNP 3.3_CD 4.9_CD North_NNP America_NNP 1.8_CD 2.3_CD 5.1_CD 7.2_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 75_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 76_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 5_CD Exceptional_JJ items_NNS Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN Impairments_NNP 19.4_CD 3.5_CD Abortive_JJ transaction_NN costs_NNS 2.0_CD Restructuring_NN costs_NNS 1.2_CD Profit_NN on_IN disposal_NN of_IN available-for-sale_JJ investment_NN 2.0_CD Convertible_JJ bonds_NNS exchange_NN 6.2_CD 21.4_CD 8.9_CD Following_VBG the_DT Strategic_NNP Review_NNP and_CC the_DT Groups_NNS decision_NN to_TO focus_VB on_IN its_PRP$ core_NN oral_JJ and_CC pulmonary_JJ products_NNS and_CC to_TO divest_VB its_PRP$ injectable_JJ business_NN ,_, the_DT Group_NNP no_RB longer_RB views_VBZ its_PRP$ collaborations_NNS with_IN Astralis_NNP ,_, Vital_NNP Living_VBG and_CC Micap_NNP as_IN strategic_JJ and_CC these_DT investments_NNS have_VBP therefore_RB been_VBN impaired_VBN resulting_VBG in_IN an_DT exceptional_JJ charge_NN of_IN 19.4_CD million_CD ._.
See_VB notes_NNS 15_CD :_: Investments_NNP in_IN associates_NNS and_CC 16_CD :_: Available_JJ for_IN sale_NN financial_JJ assets_NNS ._.
During_IN the_DT year_NN the_DT Group_NNP incurred_VBD 2.0_CD million_CD legal_JJ and_CC professional_JJ fees_NNS relating_VBG to_TO an_DT aborted_JJ strategic_JJ transaction_NN ._.
Exceptional_JJ items_NNS for_IN 2004_CD include_VBP a_DT charge_NN of_IN 3.5_CD million_CD relating_VBG to_TO the_DT impairment_NN in_IN the_DT investment_NN in_IN Vital_NNP Living_VBG and_CC 1.2_CD million_CD relating_VBG to_TO the_DT reorganisation_NN of_IN some_DT research_NN and_CC development_NN operations_NNS and_CC other_JJ business_NN functions_NNS ._.
In_IN addition_NN ,_, 2.0_CD million_CD relates_VBZ to_TO the_DT profit_NN on_IN disposal_NN of_IN the_DT Groups_NNS investment_NN in_IN Transition_NN Therapeutics_NNS and_CC a_DT charge_NN of_IN 6.2_CD million_CD relates_VBZ to_TO the_DT exchange_NN of_IN convertible_JJ bonds_NNS ._.
6_CD Operating_NN expenses_NNS Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Cost_NN of_IN sales_NNS 29.2_CD 28.2_CD Selling_NNP ,_, marketing_NN and_CC distribution_NN expenses_NNS 5.9_CD 1.7_CD Depreciation_NN 6.2_CD 6.0_CD Amortisation_NNP 2.1_CD 2.2_CD Research_NNP and_CC development_NN expenses_NNS 26.0_CD 28.0_CD Loss_NN gain_NN on_IN financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN 0.7_CD 0.1_CD Fair_NNP value_NN gain_NN loss_NN on_IN derivative_JJ financial_JJ instruments_NNS 0.3_CD 0.5_CD Profit_NN on_IN disposal_NN of_IN available_JJ for_IN sale_NN financial_JJ assets_NNS 0.3_CD Other_JJ operating_NN expenses_NNS 8.1_CD 9.1_CD Operating_NN expenses_NNS before_IN exceptional_JJ items_NNS 77.6_CD 75.6_CD Impairments_NNP 19.4_CD 3.5_CD Abortive_JJ transaction_NN costs_NNS 2.0_CD Restructuring_NN costs_NNS 1.2_CD Profit_NN on_IN disposal_NN of_IN available_JJ for_IN sale_NN financial_JJ assets_NNS 2.0_CD Total_JJ operating_NN expenses_NNS 99.0_CD 78.3_CD 76_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 77_CD Services_NNPS provided_VBN by_IN the_DT Groups_NNS auditor_NN and_CC network_NN firms_NNS Year_NN ended_VBD Year_NN ended_VBD It_PRP is_VBZ the_DT Groups_NNS policy_NN to_TO employ_VB the_DT auditors_NNS on_IN assignments_NNS additional_JJ to_TO their_PRP$ statutory_JJ audit_NN duties_NNS where_WRB 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW their_PRP$ expertise_NN and_CC experience_NN with_IN the_DT Group_NNP are_VBP important_JJ ,_, principally_RB tax_NN advice_NN and_CC due_JJ diligence_NN reporting_VBG on_IN acquisitions_NNS ,_, or_CC where_WRB they_PRP are_VBP awarded_VBN assignments_NNS on_IN a_DT competitive_JJ basis_NN ._.
During_IN the_DT year_NN the_DT Group_NNP 19.4_CD 3.5_CD including_VBG its_PRP$ overseas_JJ subsidiaries_NNS obtained_VBD the_DT following_JJ services_NNS from_IN the_DT Groups_NNS auditor_NN at_IN costs_NNS detailed_JJ 2.0_CD below_IN :_: 1.2_CD Year_NN ended_VBD Year_NN ended_VBD 2.0_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN 6.2_CD 21.4_CD 8.9_CD Audit_NNP services_NNS statutory_JJ audit_NN 0.4_CD 0.3_CD audit_NN related_VBN regulatory_JJ reporting_NN 0.2_CD 0.2_CD re_NN oral_JJ and_CC pulmonary_JJ products_NNS Further_JJ assurance_NN services_NNS 1.2_CD 1.0_CD orations_NNS with_IN Astralis_NNP ,_, Vital_NNP Living_VBG Tax_NNP services_NNS red_JJ resulting_VBG in_IN an_DT exceptional_JJ charge_NN compliance_NN services_NNS 0.1_CD e_SYM for_IN sale_NN financial_JJ assets_NNS ._.
During_IN the_DT advisory_JJ services_NNS 0.2_CD 0.6_CD o_IN an_DT aborted_JJ strategic_JJ transaction_NN ._.
2.0_CD 2.2_CD impairment_NN in_IN the_DT investment_NN in_IN ch_NN and_CC development_NN operations_NNS and_CC Included_VBN in_IN the_DT analysis_NN above_IN are_VBP audit_NN fees_NNS paid_VBN to_TO the_DT Groups_NNS auditor_NN in_IN the_DT UK_NNP of_IN 227,000_CD 2004_CD :_: 177,000_CD disposal_NN of_IN the_DT Groups_NNS investment_NN of_IN which_WDT 15,000_CD 2004_CD :_: 14,000_CD was_VBD paid_VBN in_IN respect_NN of_IN the_DT parent_NN company_NN ._.
Also_RB included_VBN above_IN are_VBP fees_NNS paid_VBD ange_NN of_IN convertible_JJ bonds_NNS ._.
to_TO the_DT Groups_NNS auditor_NN in_IN respect_NN of_IN non-audit_JJ services_NNS in_IN the_DT UK_NNP of_IN 1,295,000_CD 2004_CD :_: 1,141,000_CD ._.
7_CD Staff_NN costs_NNS Year_NN ended_VBD Year_NN ended_VBD Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW 29.2_CD 28.2_CD Wages_NNS and_CC salaries_NNS 19.7_CD 19.2_CD 5.9_CD 1.7_CD Equity_NNP settled_VBD share_NN based_VBN payments_NNS 1.9_CD 2.9_CD 6.2_CD 6.0_CD Social_NNP security_NN costs_VBZ 2.9_CD 2.9_CD 2.1_CD 2.2_CD Pensions_NNS 26.0_CD 28.0_CD defined_VBN benefit_NN plans_VBZ 0.2_CD 0.7_CD 0.7_CD 0.1_CD defined_VBN contribution_NN plans_VBZ 0.7_CD 1.3_CD 0.3_CD 0.5_CD Other_JJ benefits_NNS 0.8_CD 0.3_CD 26.2_CD 27.0_CD 8.1_CD 9.1_CD 77.6_CD 75.6_CD The_DT average_JJ number_NN of_IN people_NNS ,_, including_VBG executive_JJ directors_NNS ,_, employed_VBN by_IN the_DT Group_NNP during_IN the_DT period_NN was_VBD 19.4_CD 3.5_CD 457_CD persons_NNS 2004_CD :_: 438_CD persons_NNS and_CC the_DT Company_NN numbers_NNS 18_CD persons_NNS 2004_CD :_: 18_CD persons_NNS ._.
2.0_CD 1.2_CD Average_JJ number_NN of_IN employees_NNS by_IN business_NN segment_NN :_: 2.0_CD Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 99.0_CD 78.3_CD Injectable_JJ 129_CD 113_CD Oral_NNP and_CC Inhalation_NNP 328325457438_CD The_DT Groups_NNS key_JJ management_NN comprises_VBZ only_RB Directors_NNS and_CC Director_NNP remuneration_NN for_IN the_DT year_NN is_VBZ shown_VBN in_IN the_DT audited_JJ part_NN of_IN the_DT Remuneration_NNP Report_NNP ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 77_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 78_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 8_CD Other_JJ income_NN and_CC expenses_NNS Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Loss_NN gain_NN on_IN financial_JJ assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN 0.7_CD 0.1_CD Profit_NN on_IN disposal_NN of_IN available-for-sale_JJ investment_NN 0.3_CD 2.0_CD 0.4_CD 2.1_CD 9_CD Finance_NNP costs_NNS and_CC income_NN Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Interest_NN and_CC similar_JJ expense_NN :_: Interest_NN :_: bank_NN borrowings_NNS 0.5_CD 0.7_CD Paul_NNP Capital_NNP arrangements_NNS 12.7_CD 11.3_CD interest_NN on_IN convertible_JJ bonds_NNS 5.8_CD 5.7_CD 19.0_CD 17.7_CD Foreign_JJ exchange_NN on_IN Paul_NNP Capital_NNP arrangements_NNS 3.3_CD Fair_NNP value_NN losses_NNS on_IN financial_JJ instruments_NNS :_: loss_NN on_IN exchange_NN of_IN convertible_JJ bonds_NNS 6.2_CD Total_JJ interest_NN and_CC similar_JJ expense_NN 22.3_CD 23.9_CD Interest_NN and_CC similar_JJ income_NN :_: Paul_NNP Capital_NNP change_NN in_IN estimated_JJ future_JJ payments_NNS 9.0_CD 6.0_CD Other_JJ interest_NN income_NN 1.0_CD 0.8_CD Foreign_JJ exchange_NN on_IN Paul_NNP Capital_NNP arrangements_NNS 1.8_CD Total_JJ interest_NN and_CC similar_JJ income_NN 10.0_CD 8.6_CD 10_CD Income_NNP tax_NN Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Current_JJ income_NN tax_NN expense_NN :_: Foreign_NNP tax_NN 0.3_CD 0.2_CD There_EX was_VBD no_DT deferred_JJ tax_NN component_NN in_IN the_DT tax_NN charge_NN ._.
Foreign_JJ tax_NN relates_VBZ principally_RB to_TO withholding_VBG tax_NN paid_VBN on_IN remittance_NN of_IN royalties_NNS to_TO Switzerland_NNP which_WDT is_VBZ not_RB recoverable_JJ ._.
78_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 79_CD The_DT tax_NN on_IN the_DT Groups_NNS losses_NNS before_IN tax_NN differs_VBZ from_IN the_DT theoretical_JJ amount_NN that_WDT would_MD arise_VB using_VBG Year_NN ended_VBD Year_NN ended_VBD the_DT standard_JJ rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP ._.
The_DT differences_NNS are_VBP explained_VBN below_IN :_: 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Year_NN ended_VBD Year_NN ended_VBD m_FW m_FW 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD %_NN %_NN 0.7_CD 0.1_CD Rate_NN of_IN corporation_NN tax_NN in_IN the_DT UK_NNP 30.0_CD 30.0_CD 0.3_CD 2.0_CD 0.4_CD 2.1_CD Effects_NNPS of_IN :_: Adjustments_NNS in_IN respect_NN of_IN foreign_JJ tax_NN rates_NNS 4.4_CD 17.2_CD Adjustment_NNP to_TO tax_NN in_IN respect_NN of_IN prior_JJ periods_NNS 0.1_CD Year_NN ended_VBD Year_NN ended_VBD Expenses_NNS not_RB deductible_JJ for_IN tax_NN purposes_NNS 7.1_CD 8.2_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Tax_NNP losses_NNS for_IN which_WDT no_DT deferred_JJ tax_NN asset_NN was_VBD recognized_VBN 19.6_CD 40.0_CD m_NN m_NN Tax_NNP losses_NNS utilised_VBD 1.0_CD 1.9_CD Capital_NNP allowances_NNS utilised_VBD 0.2_CD Withholding_NN taxes_NNS 0.6_CD 0.7_CD 0.5_CD 0.7_CD Other_JJ 0.1_CD 1.3_CD 12.7_CD 11.3_CD Effective_JJ tax_NN rate_NN 0.6_CD 1.0_CD 5.8_CD 5.7_CD 19.0_CD 17.7_CD 3.3_CD The_DT Group_NNP has_VBZ estimated_VBN total_JJ tax_NN losses_NNS available_JJ to_TO be_VB set_VBN off_RP against_IN future_JJ taxable_JJ profits_NNS of_IN 280.0_CD million_CD 31_CD December_NNP 2004_CD :_: 271.1_CD million_CD ._.
These_DT losses_NNS arise_VBP primarily_RB in_IN Switzerland_NNP and_CC the_DT US_NNP ._.
Of_IN the_DT 6.2_CD 280.0_CD million_CD of_IN losses_NNS carried_VBD forward_RB ,_, 22.0_CD million_CD expire_VBP in_IN 2006_CD ,_, 65.1_CD million_CD expire_VBP between_IN 2007_CD and_CC 22.3_CD 23.9_CD 2009_CD ,_, 191.6_CD million_CD expire_VBP from_IN 2010_CD onwards_NNS and_CC 1.3_CD million_CD of_IN losses_NNS may_MD be_VB carried_VBN forward_RB indefinitely_RB ._.
The_DT Group_NNP also_RB has_VBZ other_JJ tax_NN allowances_NNS available_JJ of_IN 59.8_CD million_CD 31_CD December_NNP 2004_CD :_: 56.6_CD million_CD 9.0_CD 6.0_CD No_DT deferred_VBN tax_NN asset_NN has_VBZ been_VBN recognized_VBN ,_, given_VBN the_DT uncertainty_NN of_IN the_DT recoverability_NN of_IN the_DT Groups_NNS tax_NN losses_NNS 1.0_CD 0.8_CD carried_VBD forward_RB ._.
1.8_CD 10.0_CD 8.6_CD 11_CD Earnings_NNS per_IN share_NN Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Year_NN ended_VBD Year_NN ended_VBD Attributable_JJ loss_NN before_IN exceptional_JJ items_NNS 29.5_CD 9.7_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Exceptional_JJ items_NNS 21.4_CD 8.9_CD Basic_JJ and_CC diluted_JJ attributable_JJ loss_NN 50.9_CD 18.6_CD 0.3_CD 0.2_CD Number_NNP Number_NNP m_FW m_FW Basic_JJ and_CC diluted_JJ weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN 624.9_CD 615.2_CD yalties_NNS to_TO Switzerland_NNP which_WDT Loss_NN per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS 4.7_CD p_NN 1.6_CD p_NN Exceptional_JJ items_NNS 3.4_CD p_NN 1.4_CD p_NN Basic_JJ and_CC diluted_JJ loss_NN per_IN Ordinary_NNP Share_NNP 8.1_CD p_NN 3.0_CD p_NN There_EX is_VBZ no_DT difference_NN between_IN basic_JJ and_CC diluted_JJ loss_NN per_IN share_NN since_IN in_IN a_DT loss_NN making_VBG year_NN all_DT potential_JJ shares_NNS from_IN convertible_JJ bonds_NNS ,_, stock_NN options_NNS ,_, warrants_NNS and_CC contingent_JJ issuance_NN of_IN shares_NNS are_VBP anti_JJ dilutive_JJ ._.
Shares_NNS held_VBN by_IN the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP have_VBP been_VBN excluded_VBN from_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 79_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 80_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 12_CD Goodwill_NNP As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Group_NNP m_FW m_FW Cost_NN Beginning_NN of_IN the_DT year_NN 82.7_CD 82.7_CD Additions_NNS during_IN the_DT year_NN Exchange_NNP differences_NNS End_NN of_IN the_DT year_NN 82.7_CD 82.7_CD Accumulated_VBN impairment_NN and_CC depreciation_NN Beginning_NN of_IN the_DT year_NN 14.0_CD 14.0_CD Amortisation_NNP charge_NN Exchange_NNP differences_NNS End_NN of_IN the_DT year_NN 14.0_CD 14.0_CD Net_JJ book_NN value_NN Beginning_NN of_IN the_DT year_NN 68.7_CD 68.7_CD End_NN of_IN the_DT year_NN 68.7_CD 68.7_CD Goodwill_NNP arose_VBD on_IN the_DT acquisition_NN of_IN SkyePharma_NNP Inc_NNP 35.6_CD million_CD ,_, SkyePharma_NNP Canada_NNP Inc_NNP 29.2_CD million_CD and_CC SkyePharma_NNP AB_NNP 3.9_CD million_CD and_CC has_VBZ been_VBN allocated_VBN to_TO the_DT following_JJ business_NN segments_NNS cashgenerating_VBG units_NNS :_: As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Injectables_NNPS 38.6_CD 38.6_CD Oral_NNP and_CC Inhalation_NNP 30.1_CD 30.1_CD 68.7_CD 68.7_CD Goodwill_NNP is_VBZ not_RB amortised_VBN but_CC is_VBZ tested_VBN annually_RB for_IN impairment_NN or_CC more_JJR frequently_RB if_IN there_EX are_VBP indications_NNS that_WDT goodwill_NN might_MD be_VB impaired_VBN ._.
Value_NN in_IN use_NN calculations_NNS are_VBP generally_RB utilised_VBN to_TO calculate_VB recoverable_JJ amount_NN ._.
Value_NN in_IN use_NN is_VBZ calculated_VBN as_IN the_DT net_JJ present_JJ value_NN of_IN the_DT projected_VBN risk-adjusted_JJ cash_NN flows_NNS of_IN the_DT cashgenerating_VBG unit_NN to_TO which_WDT goodwill_NN is_VBZ allocated_VBN ._.
The_DT cash_NN flow_NN projections_NNS are_VBP based_VBN on_IN the_DT most_RBS recent_JJ business_NN plans_NNS approved_VBN by_IN management_NN which_WDT cover_VBP a_DT period_NN of_IN 10_CD years_NNS ,_, and_CC are_VBP adjusted_VBN where_WRB necessary_JJ to_TO take_VB account_NN of_IN longer_JJR patent_NN lives_NNS ._.
The_DT discount_NN rate_NN applied_VBD may_MD vary_VB depending_VBG on_IN the_DT risk_NN profile_NN of_IN the_DT asset_NN being_VBG valued_VBN but_CC is_VBZ typically_RB 15_CD %_NN ,_, which_WDT is_VBZ the_DT Groups_NNS average_VBP pre-tax_JJ discount_NN rate_NN derived_VBN from_IN a_DT capital_NN asset_NN pricing_NN model_NN ._.
The_DT key_JJ assumptions_NNS for_IN the_DT value_NN in_IN use_NN calculations_NNS are_VBP those_DT regarding_VBG the_DT launch_NN dates_NNS of_IN products_NNS ,_, their_PRP$ growth_NN rates_NNS ,_, the_DT discount_NN rates_NNS used_VBN and_CC the_DT period_NN over_IN which_WDT the_DT cash_NN flows_NNS are_VBP projected_VBN ._.
The_DT assumptions_NNS made_VBN reflect_VBP past_JJ experience_NN ,_, market_NN research_NN and_CC expectations_NNS of_IN future_JJ market_NN trends_NNS ._.
Goodwill_NN was_VBD tested_VBN for_IN impairment_NN both_DT at_IN 31_CD December_NNP 2005_CD and_CC 31_CD December_NNP 2004_CD ._.
All_DT amortisation_NN charges_NNS in_IN the_DT year_NN have_VBP been_VBN charged_VBN through_IN administrative_JJ expenses_NNS ._.
requently_RB if_IN there_EX are_VBP indications_NNS that_WDT ed_VBD to_TO calculate_VB recoverable_JJ amount_NN ._.
Intellectual_NNP property_NN acquired_VBN during_IN 2005_CD mainly_RB relates_VBZ to_TO the_DT purchase_NN of_IN licenses_NNS to_TO intellectual_JJ property_NN in_IN the_DT area_NN of_IN pulmonary_JJ delivery_NN ._.
djusted_JJ cash_NN flows_NNS of_IN the_DT cashare_JJ based_VBN on_IN the_DT most_RBS recent_JJ Included_VBN within_IN intellectual_JJ property_NN is_VBZ 2.0_CD million_CD of_IN assets_NNS which_WDT are_VBP not_RB yet_RB in_IN use_NN ._.
These_DT assets_NNS have_VBP s_PRP ,_, and_CC are_VBP adjusted_VBN where_WRB necessary_JJ not_RB been_VBN amortised_VBN but_CC have_VBP been_VBN tested_VBN for_IN impairment_NN consistent_JJ with_IN the_DT method_NN set_VBN out_RP for_IN goodwill_NN depending_VBG on_IN the_DT risk_NN profile_NN in_IN note_NN 12_CD ._.
e_LS pre-tax_JJ discount_NN rate_NN derived_VBN g_IN the_DT launch_NN dates_NNS of_IN products_NNS ,_, cash_NN flows_NNS are_VBP projected_VBN ._.
ectations_NNS of_IN future_JJ market_NN trends_NNS ._.
Included_VBN in_IN freehold_NN property_NN is_VBZ an_DT amount_NN of_IN 4.9_CD million_CD 2004_CD :_: 5.1_CD million_CD in_IN respect_NN of_IN land_NN which_WDT is_VBZ not_RB depreciated_VBN ._.
At_IN 31_CD December_NNP 2005_CD ,_, the_DT carrying_VBG amount_NN of_IN the_DT Groups_NNS laboratory_NN equipment_NN and_CC machines_NNS includes_VBZ an_DT amount_NN of_IN Nil_NNP 2004_CD :_: 1.2_CD million_CD and_CC motor_NN vehicles_NNS an_DT amount_NN of_IN 0.1_CD million_CD 2004_CD :_: 0.1_CD million_CD in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN arrangements_NNS ._.
82_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 83_CD At_IN 31_CD December_NNP 2005_CD ,_, the_DT net_JJ book_NN value_NN of_IN the_DT tangible_JJ assets_NNS pledged_VBN as_IN collateral_NN in_IN the_DT framework_NN of_IN various_JJ borrowing_NN agreements_NNS disclosed_VBN in_IN Note_NN 23_CD :_: Borrowings_NNS was_VBD 1.9_CD million_CD 2004_CD :_: 2.1_CD million_CD ._.
Office_NNP and_CC Motor_NNP quipment_NN vehicles_NNS Total_JJ The_DT Group_NNP did_VBD not_RB identify_VB any_DT tangible_JJ assets_NNS temporarily_RB idle_JJ as_IN at_IN the_DT balance_NN sheet_NN date_NN ._.
Impairment_NN 16.3_CD End_NN of_IN the_DT year_NN 0.2_CD 14.3_CD ion_NN in_IN respect_NN of_IN land_NN which_WDT The_DT investment_NN in_IN Astralis_NNP Limited_NNP was_VBD recorded_VBN at_IN 0.2_CD million_CD at_IN 31_CD December_NNP 2005_CD 2004_CD :_: 14.3_CD million_CD and_CC had_VBD a_DT market_NN value_NN of_IN 0.4_CD million_CD 2004_CD :_: 9.6_CD million_CD ._.
Following_VBG the_DT Strategic_NNP Review_NNP and_CC the_DT Groups_NNS pment_NN and_CC machines_NNS includes_VBZ decision_NN to_TO focus_VB on_IN its_PRP$ core_NN oral_JJ and_CC pulmonary_JJ products_NNS and_CC to_TO divest_VB its_PRP$ injectable_JJ business_NN ,_, the_DT Group_NNP 0.1_CD million_CD 2004_CD :_: 0.1_CD million_CD no_DT longer_JJR views_NNS its_PRP$ collaboration_NN with_IN Astralis_NNP as_IN strategic_JJ ._.
This_DT combined_VBN with_IN the_DT current_JJ uncertainties_NNS ments_NNS ._.
concerning_VBG Astralis_NNP financial_JJ position_NN resulted_VBD in_IN the_DT Group_NNP impairing_VBG its_PRP$ investment_NN to_TO its_PRP$ estimated_VBN fair_JJ value_NN ._.
As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Company_NN m_NN m_NN Beginning_NN of_IN the_DT year_NN 14.3_CD Reclassification_NN of_IN investment_NN as_IN associate_JJ 14.2_CD Additions_NNS 3.0_CD 0.1_CD Impairment_NN 17.1_CD End_NN of_IN the_DT year_NN 0.2_CD 14.3_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 83_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 84_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 16_CD Available_JJ for_IN sale_NN financial_JJ assets_NNS As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Group_NNP m_FW m_FW Beginning_NN of_IN the_DT year_NN 5.2_CD 22.0_CD Exchange_NNP 0.1_CD Reclassification_NNP as_IN associate_JJ 14.2_CD Additions_NNS 0.1_CD 2.0_CD Disposal_NNP 1.8_CD 0.6_CD Impairments_NNP 2.6_CD 3.5_CD Revaluation_NNP surplus_NN deficit_NN transfer_NN 0.6_CD 0.5_CD End_NN of_IN the_DT year_NN 1.6_CD 5.2_CD As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Company_NN m_NN m_NN Beginning_NN of_IN the_DT year_NN 3.6_CD 16.3_CD Reclassification_NN as_IN associate_JJ 14.2_CD Additions_NNS 0.1_CD 2.0_CD Disposal_NNP 1.8_CD Revaluation_NNP surplus_NN deficit_NN transfer_NN 0.6_CD 0.5_CD End_NN of_IN the_DT year_NN 1.3_CD 3.6_CD Group_NNP and_CC Company_NNP Available_NNP for_IN sale_NN financial_JJ assets_NNS comprise_VBP the_DT following_VBG unlisted_JJ securities_NNS :_: Vectura_NNP Group_NNP plc_NN Vectura_NNP is_VBZ a_DT UK_NNP emerging_VBG pharmaceutical_JJ company_NN traded_VBN on_IN the_DT Alternative_NNP Investment_NNP Market_NNP ._.
Vectura_NNP is_VBZ developing_VBG a_DT range_NN of_IN inhaled_JJ drugs_NNS for_IN the_DT treatment_NN of_IN lung_NN diseases_NNS and_CC conditions_NNS where_WRB delivery_NN via_IN the_DT lungs_NNS can_MD provide_VB significant_JJ benefits_NNS ,_, such_JJ as_IN rapid_JJ onset_NN of_IN action_NN ,_, improved_VBD efficacy_NN and_CC improved_VBD tolerability_NN compared_VBN with_IN current_JJ therapies_NNS ._.
During_IN 2005_CD the_DT Group_NNP sold_VBD 2_CD million_CD ordinary_JJ shares_NNS in_IN Vectura_NNP for_IN 1.6_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2005_CD the_DT remaining_VBG holding_NN was_VBD 1.2_CD million_CD ordinary_JJ shares_NNS ._.
The_DT investment_NN was_VBD recorded_VBN at_IN 1.0_CD million_CD at_IN 31_CD December_NNP 2005_CD 2004_CD :_: 2.0_CD million_CD ._.
In_IN January_NNP 2006_CD the_DT Group_NNP sold_VBD the_DT remaining_VBG 1.2_CD million_CD ordinary_JJ shares_NNS ._.
Vital_JJ Living_VBG Inc_NNP Vital_NNP Living_VBG primarily_RB develops_VBZ and_CC markets_VBZ evidence-based_JJ nutriceuticals_NNS ._.
These_DT are_VBP developed_VBN for_IN incorporation_NN by_IN physicians_NNS into_IN a_DT standard_JJ physician_NN patient_NN program_NN ,_, supported_VBN by_IN a_DT specially_RB designed_VBN compliance_NN regimen_NN ._.
Vital_JJ Living_VBG is_VBZ based_VBN in_IN the_DT US_NNP ._.
During_IN 2005_CD the_DT Group_NNP received_VBD 2,101,422_CD Vital_JJ Living_VBG common_JJ shares_NNS with_IN a_DT value_NN of_IN 68,000_CD $_$ 120,000_CD in_IN lieu_NN of_IN interest_NN due_JJ on_IN the_DT 12_CD %_NN senior_JJ secured_VBN convertible_JJ notes_NNS ._.
As_IN at_IN 31_CD December_NNP 2005_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 16,993,599_CD common_JJ shares_NNS ,_, 1_CD million_CD series_NN D_NNP convertible_JJ preferred_JJ shares_NNS ,_, $_$ 1_CD million_CD 12_CD %_NN senior_JJ secured_VBN convertible_JJ notes_NNS due_JJ 2008_CD and_CC 4_CD million_CD warrants_NNS expiring_VBG 2008_CD ,_, representing_VBG approximately_RB 17.2_CD %_NN of_IN the_DT common_JJ shares_NNS ._.
The_DT investment_NN in_IN Vital_NNP Living_VBG was_VBD recorded_VBN at_IN 0.4_CD million_CD at_IN 31_CD December_NNP 2005_CD 2004_CD :_: 1.7_CD million_CD ._.
The_DT Company_NN recorded_VBN 0.1_CD million_CD at_IN 31_CD December_NNP 2005_CD 2004_CD :_: 0.1_CD million_CD ._.
Following_VBG the_DT Strategic_NNP Review_NNP and_CC the_DT Groups_NNS decision_NN to_TO focus_VB on_IN its_PRP$ core_NN oral_JJ and_CC pulmonary_JJ products_NNS and_CC to_TO divest_VB its_PRP$ injectable_JJ business_NN ,_, the_DT Group_NNP no_RB longer_RB views_VBZ its_PRP$ collaboration_NN with_IN Vital_JJ Living_VBG as_IN strategic_JJ and_CC this_DT investment_NN has_VBZ therefore_RB been_VBN impaired_VBN ._.
84_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 85_CD Micap_NNP plc_NN As_IN at_IN As_IN at_IN Micap_NNP plc_NN is_VBZ a_DT UK_NNP science-based_JJ technology_NN company_NN traded_VBD on_IN the_DT Alternative_NNP Investment_NNP Market_NNP ._.
As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW 31_CD December_NNP 2005_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 5,238,334_CD ordinary_JJ shares_NNS and_CC 1,830,000_CD convertible_JJ shares_NNS ,_, representing_VBG approximately_RB 9.4_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT investment_NN in_IN Micap_NNP recorded_VBD 5.2_CD 22.0_CD at_IN 0.2_CD million_CD at_IN 31_CD December_NNP 2005_CD 2004_CD :_: 1.5_CD million_CD ._.
Following_VBG the_DT Strategic_NNP Review_NNP and_CC the_DT Groups_NNS 0.1_CD decision_NN to_TO focus_VB on_IN its_PRP$ core_NN oral_JJ and_CC pulmonary_JJ products_NNS and_CC to_TO divest_VB its_PRP$ injectable_JJ business_NN ,_, the_DT Group_NNP 14.2_CD no_DT longer_JJR views_NNS its_PRP$ collaboration_NN with_IN Micap_NNP as_IN strategic_JJ and_CC this_DT investment_NN has_VBZ therefore_RB been_VBN impaired_VBN ._.
0.1_CD 2.0_CD 1.8_CD 0.6_CD Cade_NNP Struktur_NNP Corp_NNP 2.6_CD 3.5_CD Cade_NNP Struktur_NNP was_VBD formerly_RB a_DT drug_NN delivery_NN company_NN engaged_VBD in_IN research_NN and_CC development_NN and_CC worldwide_JJ 0.6_CD 0.5_CD commercialisation_NN of_IN pharmaceutical_JJ formulations_NNS ._.
The_DT current_JJ business_NN is_VBZ the_DT development_NN ,_, financing_NN and_CC 1.6_CD 5.2_CD completion_NN of_IN industrial_JJ and_CC infrastructure_NN projects_NNS in_IN Europe_NNP ._.
As_IN at_IN 31_CD December_NNP 2005_CD ,_, the_DT total_JJ SkyePharma_NNP As_IN at_IN As_IN at_IN holding_NN of_IN Cade_NNP Struktur_NNP ,_, a_DT Canadian_JJ company_NN ,_, was_VBD 869,086_CD shares_NNS ,_, representing_VBG approximately_RB 10.1_CD %_NN of_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD the_DT ordinary_JJ share_NN capital_NN ._.
The_DT shares_NNS were_VBD originally_RB acquired_VBN consequent_JJ upon_IN the_DT acquisition_NN of_IN the_DT assets_NNS m_VBP m_NN of_IN Hyal_NNP Pharmaceutical_NNP Corp._NNP ._.
SkyePharma_NNP has_VBZ not_RB attributed_VBN a_DT fair_JJ value_NN to_TO these_DT shares_NNS and_CC they_PRP have_VBP been_VBN 3.6_CD 16.3_CD recorded_VBN at_IN Nil_NNP 2004_CD :_: Nil_NNP ._.
14.2_CD 0.1_CD 2.0_CD 17_CD Shares_NNS in_IN and_CC loans_NNS to_TO Group_NNP undertakings_NNS 1.8_CD Shares_NNS in_IN Group_NNP Loans_NNPS to_TO Group_NNP undertakings_NNS undertakings_NNS Total_JJ 0.6_CD 0.5_CD Company_NN m_NN m_NN m_NN 1.3_CD 3.6_CD Beginning_NN of_IN the_DT year_NN 163.5_CD 237.3_CD 400.8_CD Additions_NNS 19.0_CD 19.0_CD Provision_NNP 80.0_CD 80.0_CD es_NNS :_: End_NN of_IN the_DT year_NN 163.5_CD 176.3_CD 339.8_CD Following_VBG the_DT Strategic_NNP Review_NNP the_DT Company_NN has_VBZ reviewed_VBN the_DT funding_NN of_IN its_PRP$ overseas_JJ subsidiaries_NNS and_CC tive_JJ Investment_NN Market_NN ._.
Vectura_NNP is_VBZ recorded_VBN a_DT provision_NN in_IN respect_NN of_IN recoverability_NN of_IN loans_NNS to_TO Group_NNP undertakings_NNS of_IN 80.0_CD million_CD ._.
nd_NN conditions_NNS where_WRB delivery_NN via_IN the_DT ved_VBN efficacy_NN and_CC improved_VBD tolerability_NN Principal_NN subsidiaries_NNS are_VBP detailed_VBN in_IN note_NN 35_CD :_: Principal_NN subsidiaries_NNS ._.
rdinary_JJ shares_NNS in_IN Vectura_NNP for_IN on_IN ordinary_JJ shares_NNS ._.
The_DT investment_NN 18_CD Inventories_NNS January_NNP 2006_CD the_DT Group_NNP sold_VBD the_DT As_RB at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December2004_NNP Group_NNP m_FW m_FW Raw_FW materials_NNS and_CC consumables_VBZ 2.1_CD 1.2_CD s._NN These_DT are_VBP developed_VBN for_IN Work_NN in_IN progress_NN 1.0_CD 0.2_CD upported_VBN by_IN a_DT specially_RB designed_VBN Finished_VBN goods_NNS 1.0_CD 0.1_CD up_IN received_VBN 2,101,422_CD Vital_NNP Living_VBG 4.1_CD 1.5_CD n_IN the_DT 12_CD %_NN senior_JJ secured_VBN convertible_JJ Inventory_NN provisions_NNS 0.5_CD ,_, 599_CD common_JJ shares_NNS ,_, 1_CD million_CD 3.6_CD 1.5_CD vertible_JJ notes_NNS due_JJ 2008_CD and_CC 4_CD million_CD n_JJ shares_NNS ._.
The_DT investment_NN in_IN The_DT cost_NN of_IN inventories_NNS recognized_VBN as_IN an_DT expense_NN and_CC included_VBD in_IN cost_NN of_IN sales_NNS is_VBZ disclosed_VBN in_IN Note_NN 6_CD :_: million_CD ._.
The_DT Company_NN recorded_VBN Operating_NN expenses_NNS ._.
egic_JJ Review_NNP and_CC the_DT Groups_NNS decision_NN le_FW business_NN ,_, the_DT Group_NNP no_RB longer_RB as_IN therefore_RB been_VBN impaired_VBN ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 85_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 86_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 19_CD Trade_NNP and_CC other_JJ receivables_NN Group_NNP Group_NNP Company_NNP Company_NNP As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW Trade_NNP receivables_NN 2.4_CD 3.5_CD Less_RBR provision_NN for_IN impairment_NN 0.1_CD Net_JJ trade_NN receivables_NN 2.3_CD 3.5_CD Amounts_NNS owed_VBN by_IN subsidiary_NN undertakings_NNS 5.2_CD 5.2_CD Other_JJ receivables_NN 2.2_CD 1.9_CD 0.5_CD 1.0_CD Interest_NN receivable_JJ 0.6_CD 0.4_CD Prepayments_NNS and_CC accrued_VBN income_NN 9.1_CD 12.4_CD 0.2_CD 14.2_CD 18.2_CD 5.7_CD 6.4_CD 20_CD Financial_NNP assets_NNS at_IN fair_JJ value_NN through_IN profit_NN and_CC loss_NN Group_NNP Group_NNP As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Beginning_NN of_IN the_DT year_NN 1.1_CD 1.0_CD Revaluation_NNP to_TO fair_JJ value_NN 0.7_CD 0.1_CD End_NN of_IN the_DT year_NN 0.4_CD 1.1_CD Financial_NNP assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN comprise_VBP 5_CD %_NN convertible_JJ loan_NN notes_NNS due_JJ at_IN par_NN in_IN June_NNP 2007_CD ._.
The_DT notes_NNS were_VBD received_VBN from_IN GeneMedix_NNP plc_NN in_IN 2002_CD as_IN an_DT initial_JJ payment_NN under_IN an_DT agreement_NN to_TO jointly_RB develop_VB an_DT extended_JJ release_NN formulation_NN of_IN Interferon_NNP alpha-2b_JJ using_VBG SkyePharmas_NNP DepoFoam_NNP technology_NN ._.
The_DT notes_NNS are_VBP convertible_JJ at_IN any_DT time_NN ,_, at_IN SkyePharmas_NNP option_NN ,_, into_IN between_IN approximately_RB 8.3_CD million_CD and_CC 11.2_CD million_CD GeneMedix_NNP ordinary_JJ shares_NNS ._.
There_EX are_VBP no_DT restrictions_NNS or_CC a_DT lock-up_JJ period_NN on_IN conversion_NN of_IN the_DT notes_NNS ._.
GeneMedix_NNP can_MD elect_VB to_TO redeem_VB in_IN cash_NN some_DT or_CC all_DT of_IN the_DT notes_NNS on_IN conversion_NN ._.
The_DT notes_NNS were_VBD designated_VBN as_RB at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN on_IN initial_JJ recognition_NN ._.
21_CD Cash_NN and_CC cash_NN equivalents_NNS Group_NNP Group_NNP Company_NNP Company_NNP As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW Cash_NN at_IN bank_NN and_CC in_IN hand_NN 26.8_CD 15.3_CD 24.1_CD 11.3_CD Short_JJ term_NN deposits_NNS 7.5_CD 7.5_CD 34.3_CD 15.3_CD 31.6_CD 11.3_CD The_DT short_JJ term_NN deposit_NN is_VBZ a_DT dual_JJ currency_NN deposit_NN of_IN sterling_NN versus_IN US_NNP dollars_NNS ,_, which_WDT earns_VBZ an_DT effective_JJ interest_NN rate_NN of_IN 10.5_CD %_NN ._.
If_IN the_DT sterling_NN US_NNP dollar_NN spot_NN rate_NN is_VBZ at_IN or_CC above_IN 1.75_CD at_IN expiry_NN ,_, the_DT 7.5_CD million_CD deposit_NN will_MD be_VB returned_VBN in_IN US_NNP dollars_NNS at_IN 1.75_CD $_$ 13.1_CD million_CD ,_, otherwise_RB it_PRP will_MD be_VB returned_VBN in_IN sterling_NN ._.
22_CD Trade_NNP and_CC other_JJ payables_NNS Group_NNP Group_NNP Company_NNP Company_NNP As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW Trade_NNP payables_NNS 6.8_CD 6.7_CD 0.6_CD 0.6_CD Amounts_NNS owed_VBN to_TO subsidiary_NN undertakings_NNS 89.7_CD 77.3_CD Other_JJ taxation_NN and_CC social_JJ security_NN costs_NNS 2.0_CD 1.2_CD 0.1_CD 0.1_CD Accruals_NNP 12.2_CD 12.7_CD 1.1_CD 2.5_CD 21.0_CD 20.6_CD 91.5_CD 80.5_CD 86_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 87_CD 23_CD Borrowings_NNP Company_NNP Company_NNP Group_NNP Group_NNP Company_NNP Company_NNP As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW m_FW m_FW Current_JJ Convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 9.4_CD 9.4_CD 5.2_CD 5.2_CD Bank_NNP borrowings_NNS 2.3_CD 3.5_CD 0.8_CD 1.9_CD 0.5_CD 1.0_CD Property_NN mortgage_NN 0.3_CD 0.3_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 0.7_CD 0.2_CD Finance_NNP lease_NN liabilities_NNS 0.1_CD 0.1_CD 5.7_CD 6.4_CD Other_JJ current_JJ borrowings_NNS 3.4_CD 3.9_CD 0.8_CD 1.9_CD Total_JJ current_JJ borrowings_NNS 3.4_CD 13.3_CD 0.8_CD 11.3_CD Group_NNP Group_NNP As_IN at_IN As_IN at_IN Non-current_JJ 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Convertible_JJ bonds_NNS due_JJ May_NNP 2024_CD 50.8_CD 50.4_CD 1.1_CD 1.0_CD Convertible_JJ bonds_NNS due_JJ June_NNP 2025_CD 12.8_CD 0.7_CD 0.1_CD 63.6_CD 50.4_CD 0.4_CD 1.1_CD Bank_NNP borrowings_NNS 0.6_CD 0.6_CD Property_NN mortgage_NN 6.6_CD 7.1_CD ble_NN loan_NN notes_NNS due_JJ at_IN par_NN in_IN June_NNP Paul_NNP Capital_NNP funding_VBG liabilities_NNS 43.9_CD 44.7_CD ayment_NN under_IN an_DT agreement_NN to_TO jointly_RB Finance_NNP lease_NN liabilities_NNS 0.1_CD yePharmas_NNP DepoFoam_NNP technology_NN ._.
Other_JJ non-current_JJ borrowings_NNS 51.1_CD 51.9_CD 0.6_CD en_IN approximately_RB 8.3_CD million_CD and_CC ck-up_JJ period_NN on_IN conversion_NN of_IN the_DT Total_JJ non-current_JJ borrowings_NNS 114.7_CD 102.3_CD 0.6_CD n_NN conversion_NN ._.
The_DT notes_NNS were_VBD Total_JJ borrowings_NNS 118.1_CD 115.6_CD 1.4_CD 11.3_CD Company_NN Company_NNP Bank_NNP borrowings_NNS As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD At_IN 31_CD December_NNP 2005_CD bank_NN borrowings_NNS include_VBP two_CD amounts_NNS due_JJ to_TO the_DT Basellandschaftliche_NNP Kantonalbank_NNP m_NN m_NN of_IN 0.9_CD million_CD CHF_NNP 2_CD million_CD and_CC 0.7_CD million_CD CHF_NNP 1.5_CD million_CD 2004_CD :_: 0.9_CD million_CD CHF_NNP 2_CD million_CD and_CC 24.1_CD 11.3_CD 0.7_CD million_CD CHF_NNP 1.5_CD million_CD ._.
Both_DT loans_NNS can_MD be_VB terminated_VBN with_IN six_CD weeks_NNS notice_NN by_IN either_DT party_NN and_CC bear_NN 7.5_CD interest_NN at_IN 6.5_CD %_NN and_CC 6.0_CD %_NN respectively_RB ._.
Both_DT loans_NNS are_VBP secured_VBN on_IN the_DT assets_NNS of_IN Jago_NNP and_CC the_DT 0.7_CD million_CD 31.6_CD 11.3_CD CHF_NNP 1.5_CD million_CD loan_NN is_VBZ guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
ollars_NNS ,_, which_WDT earns_VBZ an_DT effective_JJ The_DT Group_NNP had_VBD a_DT loan_NN as_IN at_IN 31_CD December_NNP 2005_CD with_IN GE_NNP Capital_NNP Corp_NNP of_IN 1.4_CD million_CD $_$ 2.4_CD million_CD 5_CD at_IN expiry_NN ,_, the_DT 7.5_CD million_CD deposit_NN 2004_CD :_: 1.9_CD million_CD $_$ 3.7_CD million_CD ._.
The_DT loan_NN is_VBZ secured_VBN by_IN certain_JJ assets_NNS of_IN SkyePharma_NNP Inc_NNP ,_, SkyePharma_NNP US_NNP Inc_NNP eturned_VBD in_IN sterling_NN ._.
The_DT loan_NN bears_VBZ interest_NN at_IN 8.0_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS until_IN September_NNP 2007_CD ._.
Convertible_JJ bonds_NNS Company_NN Company_NN Convertible_JJ bonds_NNS are_VBP disclosed_VBN in_IN Note_NN 24_CD :_: Convertible_JJ bonds_NNS ._.
As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN Property_NN mortgage_NN 0.6_CD 0.6_CD At_IN 31_CD December_NNP 2005_CD ,_, the_DT Group_NNP had_VBD a_DT property_NN mortgage_NN facility_NN with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP 89.7_CD 77.3_CD of_IN 6.9_CD million_CD CHF_NNP 15.5_CD million_CD 2004_CD :_: 7.4_CD million_CD CHF_NNP 16.1_CD million_CD ._.
The_DT mortgage_NN is_VBZ in_IN two_CD tranches_NNS ,_, both_DT 0.1_CD 0.1_CD secured_VBN by_IN the_DT assets_NNS of_IN Jago_NNP ._.
The_DT first_JJ tranche_NN of_IN 2.7_CD million_CD CHF_NNP 6.2_CD million_CD bears_NNS interest_NN at_IN 2.75_CD %_NN and_CC 1.1_CD 2.5_CD is_VBZ repayable_JJ by_IN instalments_NNS over_IN 20_CD years_NNS semi-annually_RB ._.
The_DT second_JJ tranche_NN of_IN 4.1_CD million_CD CHF_NNP 9.3_CD million_CD 91.5_CD 80.5_CD bears_NNS interest_NN at_IN 2.75_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS over_IN 50_CD years_NNS semi-annually_RB ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 87_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 88_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD Paul_NNP Capital_NNP funding_VBG liabilities_NNS The_DT Group_NNP entered_VBD into_IN two_CD transactions_NNS with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP Paul_NNP Capital_NNP in_IN 2000_CD and_CC 2002_CD ._.
Under_IN these_DT transactions_NNS Paul_NNP Capital_NNP provided_VBD a_DT total_NN of_IN $_$ 60_CD million_CD in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS on_IN a_DT selection_NN of_IN the_DT Groups_NNS products_NNS ._.
Whilst_IN the_DT contractual_JJ arrangement_NN with_IN Paul_NNP Capital_NNP is_VBZ a_DT royalty_NN agreement_NN under_IN which_WDT royalties_NNS are_VBP payable_JJ on_IN revenues_NNS earned_VBN and_CC payments_NNS received_VBD ,_, the_DT proceeds_NNS received_VBD from_IN Paul_NNP Capital_NNP meet_VBP the_DT definition_NN of_IN a_DT financial_JJ liability_NN under_IN IAS_NNP 39_CD ,_, and_CC are_VBP treated_VBN as_IN a_DT financial_JJ liability_NN ._.
Royalties_NNS paid_VBD to_TO Paul_NNP Capital_NNP are_VBP treated_VBN as_IN repayment_NN of_IN the_DT liability_NN and_CC interest_NN is_VBZ charged_VBN on_IN the_DT liability_NN using_VBG the_DT effective_JJ interest_NN rate_NN at_IN inception_NN of_IN each_DT agreement_NN ._.
The_DT estimated_JJ future_JJ payments_NNS to_TO Paul_NNP Capital_NNP are_VBP discounted_VBN using_VBG each_DT contracts_NNS original_JJ effective_JJ interest_NN and_CC any_DT adjustment_NN is_VBZ recognized_VBN as_IN income_NN or_CC expense_NN in_IN the_DT income_NN statement_NN Finance_NNP lease_NN liabilities_NNS Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS are_VBP secured_VBN upon_IN the_DT assets_NNS to_TO which_WDT they_PRP relate_VBP and_CC as_RB at_IN 31_CD December_NNP 2005_CD Nil_NNP 2004_CD :_: 0.1_CD million_CD SKR_NNP 0.9_CD million_CD is_VBZ guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
Maturity_NN analysis_NN of_IN non-current_JJ borrowings_NNS As_IN at_IN 31_CD December_NNP 2005_CD 1_CD to_TO 2_CD Years_NNS 2_CD to_TO 5_CD Years_NNS Over_IN 5_CD Years_NNS Total_JJ m_NN m_FW m_FW m_FW Convertible_JJ bonds_NNS 63.6_CD 63.6_CD Bank_NNP borrowings_NNS 0.6_CD 0.6_CD Property_NN mortgage_NN 0.3_CD 0.8_CD 5.5_CD 6.6_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 4.9_CD 22.1_CD 16.9_CD 43.9_CD Non-current_JJ borrowings_NNS 5.8_CD 22.9_CD 86.0_CD 114.7_CD As_IN at_IN 31_CD December_NNP 2004_CD 1_CD to_TO 2_CD Years_NNS 2_CD to_TO 5_CD Years_NNS Over_IN 5_CD Years_NNS Total_JJ m_NN m_FW m_FW m_FW Convertible_JJ bonds_NNS 50.4_CD 50.4_CD Property_NN mortgage_NN 0.3_CD 0.8_CD 6.0_CD 7.1_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 10.6_CD 21.5_CD 12.6_CD 44.7_CD Finance_NNP lease_NN liabilities_NNS 0.1_CD 0.1_CD Non-current_JJ borrowings_NNS 11.0_CD 22.3_CD 69.0_CD 102.3_CD Currency_NNP analysis_NN of_IN borrowings_NNS As_IN at_IN 31_CD December_NNP 2005_CD Sterling_NNP $_$ US_PRP Swiss_JJ francs_NNS Total_JJ m_NN m_FW m_FW m_FW Convertible_JJ bonds_NNS 63.6_CD 63.6_CD Bank_NNP borrowings_NNS 0.6_CD 0.6_CD Property_NN mortgage_NN 6.6_CD 6.6_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 43.9_CD 43.9_CD Total_JJ borrowings_NNS 63.6_CD 44.5_CD 6.6_CD 114.7_CD 88_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 89_CD As_IN at_IN 31_CD December_NNP 2004_CD Sterling_NNP $_$ US_PRP Swiss_JJ francs_NNS Total_JJ tion_NN Fund_NNP Paul_NNP Capital_NNP in_IN 2000_CD m_FW m_FW m_FW m_FW million_CD in_IN return_NN for_IN the_DT sale_NN of_IN a_DT Convertible_JJ bonds_NNS 50.4_CD 50.4_CD of_IN the_DT Groups_NNS products_NNS ._.
Property_NN mortgage_NN 7.1_CD 7.1_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 44.7_CD 44.7_CD ent_NN under_IN which_WDT royalties_NNS are_VBP payable_JJ Finance_NNP lease_NN liabilities_NNS 0.1_CD 0.1_CD Paul_NNP Capital_NNP meet_VBP the_DT definition_NN of_IN a_DT Total_JJ borrowings_NNS 50.4_CD 44.7_CD 7.2_CD 102.3_CD lties_NNS paid_VBN to_TO Paul_NNP Capital_NNP are_VBP treated_VBN he_PRP effective_JJ interest_NN rate_NN at_IN inception_NN Interest_NN rate_NN analysis_NN scounted_VBD using_VBG each_DT contracts_NNS As_IN at_IN 31_CD December_NNP 2005_CD expense_NN in_IN the_DT income_NN statement_NN Sterling_NNP $_$ US_PRP Swiss_JJ francs_NNS %_NN %_NN %_NN Convertible_JJ bonds_NNS 8.9_CD ._.
9.5_CD 13.3_CD assets_NNS to_TO which_WDT they_PRP relate_VBP and_CC Bank_NNP borrowings_NNS 8.0_CD anteed_NN by_IN SkyePharma_NNP PLC._NNP ._.
Property_NN mortgage_NN 2.8_CD Paul_NNP Capital_NNP Funding_NNP liabilities_NNS 24.0_CD 30.0_CD As_IN at_IN 31_CD December_NNP 2005_CD As_IN at_IN 31_CD December_NNP 2004_CD Over_IN 5_CD Years_NNS Total_JJ Sterling_NN $_$ US_PRP Swiss_JJ francs_NNS m_VBP m_JJ %_NN %_NN %_NN 63.6_CD 63.6_CD Convertible_JJ bonds_NNS 8.9_CD ._.
9.5_CD 13.3_CD 0.6_CD Property_NN mortgage_NN 2.8_CD 5.5_CD 6.6_CD Paul_NNP Capital_NNP Funding_NNP liabilities_NNS 24.0_CD 30.0_CD 16.9_CD 43.9_CD Finance_NNP lease_NN liabilities_NNS 6.5_CD 86.0_CD 114.7_CD Fair_NNP values_NNS As_IN at_IN 31_CD December_NNP 2004_CD At_IN 31_CD December_NNP 2005_CD ,_, the_DT carrying_VBG amount_NN of_IN non-current_JJ liabilities_NNS ,_, compared_VBN with_IN the_DT fair_JJ value_NN was_VBD as_IN follows_VBZ :_: Over_IN 5_CD Years_NNS Total_JJ m_NN m_NN Carrying_VBG Amount_NNP Fair_NNP Value_NNP 50.4_CD 50.4_CD m_NN m_NN 6.0_CD 7.1_CD Convertible_JJ bonds_NNS 63.6_CD 83.5_CD 12.6_CD 44.7_CD Bank_NNP borrowings_NNS 0.6_CD 0.6_CD 0.1_CD Property_NN mortgage_NN 6.6_CD 6.6_CD 69.0_CD 102.3_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 43.9_CD 43.9_CD 114.7_CD 134.6_CD As_IN at_IN 31_CD December_NNP 2005_CD At_IN 31_CD December_NNP 2004_CD ,_, the_DT carrying_VBG amount_NN of_IN non-current_JJ liabilities_NNS ,_, compared_VBN with_IN the_DT fair_JJ value_NN was_VBD as_IN follows_VBZ :_: Swiss_JJ francs_NNS Total_JJ m_NN m_NN Carrying_VBG Amount_NNP Fair_NNP Value_NNP 63.6_CD m_NN m_NN 0.6_CD Convertible_JJ bonds_NNS 50.4_CD 85.9_CD 6.6_CD 6.6_CD Property_NN mortgage_NN 7.1_CD 7.1_CD 43.9_CD Paul_NNP Capital_NNP funding_VBG liabilities_NNS 44.7_CD 44.7_CD 6.6_CD 114.7_CD Finance_NNP lease_NN liabilities_NNS 0.1_CD 0.1_CD 102.3_CD 137.8_CD Undrawn_JJ facility_NN At_IN 31_CD December_NNP 2005_CD the_DT Group_NNP had_VBD an_DT overdraft_NN facility_NN of_IN 1.3_CD million_CD CHF_NNP 3_CD million_CD 2004_CD :_: 1.4_CD million_CD ,_, CHF_NNP 3_CD million_CD with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP secured_VBN on_IN the_DT assets_NNS of_IN Jago_NNP ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 89_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 90_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 24_CD Convertible_JJ bonds_NNS In_IN June_NNP 2005_CD the_DT Group_NNP issued_VBD 20_CD million_CD 8_CD %_NN convertible_JJ bonds_NNS ,_, with_IN a_DT first_RB put_VBN after_IN five_CD years_NNS by_IN the_DT holder_NN of_IN the_DT bonds_NNS ,_, and_CC a_DT final_JJ maturity_NN of_IN June_NNP 2025_CD ._.
The_DT bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN SkyePharma_NNP Ordinary_NNP Shares_NNP at_IN an_DT initial_JJ conversion_NN price_NN of_IN 77_CD pence_NN at_IN any_DT time_NN prior_RB to_TO maturity_NN ._.
The_DT bond_NN contains_VBZ a_DT price_NN reset_VB feature_NN such_JJ that_IN if_IN on_IN 3_CD June_NNP 2006_CD the_DT Companys_NNPS average_JJ share_NN price_NN for_IN the_DT preceding_VBG 10_CD days_NNS reset_VB price_NN is_VBZ less_JJR than_IN the_DT conversion_NN price_NN ,_, then_RB the_DT conversion_NN price_NN shall_MD be_VB adjusted_VBN to_TO the_DT reset_NN price_NN subject_JJ to_TO a_DT maximum_NN reduction_NN of_IN 25_CD %_NN in_IN the_DT conversion_NN price_NN ._.
Unless_IN previously_RB redeemed_VBN or_CC converted_VBN ,_, the_DT bonds_NNS will_MD be_VB redeemed_VBN by_IN the_DT Group_NNP at_IN their_PRP$ principal_JJ amount_NN in_IN June_NNP 2025_CD ._.
The_DT convertible_JJ bonds_NNS existing_VBG at_IN 31_CD December_NNP 2005_CD ,_, due_RB in_IN May_NNP 2024_CD ,_, were_VBD not_RB affected_VBN by_IN this_DT transaction_NN ._.
On_IN 19_CD June_NNP 2005_CD 9.8_CD million_CD of_IN convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD were_VBD redeemed_VBN in_IN full_JJ by_IN the_DT Company_NN at_IN their_PRP$ principal_JJ amount_NN ._.
As_IN a_DT result_NN of_IN these_DT transactions_NNS the_DT Group_NNP has_VBZ 69.6_CD million_CD convertible_JJ bonds_NNS due_JJ May_NNP 2024_CD at_IN a_DT conversion_NN price_NN of_IN 95_CD pence_NN ,_, and_CC 20_CD million_CD convertible_JJ bonds_NNS due_JJ June_NNP 2025_CD at_IN a_DT conversion_NN price_NN of_IN 77_CD pence_NN ._.
25_CD Derivative_JJ financial_JJ instruments_NNS As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Group_NNP and_CC Company_NNP m_FW m_FW Interest_NN rate_NN swap_NN 0.2_CD Total_JJ derivative_JJ financial_JJ instrument_NN liabilities_NNS 0.2_CD The_DT Groups_NNS policy_NN is_VBZ to_TO hedge_VB interest_NN rate_NN exposures_NNS through_IN the_DT use_NN of_IN interest_NN rate_NN swaps_NNS and_CC currency_NN exposures_NNS through_IN the_DT use_NN of_IN currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS ._.
None_NN of_IN these_DT derivative_JJ financial_JJ instruments_NNS qualify_VBP to_TO be_VB treated_VBN as_IN hedges_NNS and_CC accordingly_RB gains_NNS and_CC losses_NNS are_VBP recorded_VBN in_IN the_DT income_NN statement_NN ._.
26_CD Provisions_NNPS Pension_NNP Restructuring_NNP Total_NNP Group_NNP m_FW m_FW m_FW At_IN 1_CD January_NNP 2005_CD 1.7_CD 0.3_CD 2.0_CD Actuarial_JJ gains_NNS losses_NNS 0.3_CD 0.3_CD Charge_NNP for_IN the_DT year_NN 0.1_CD 0.1_CD Utilised_NNP 0.3_CD 0.3_CD At_IN 31_CD December_NNP 2005_CD 1.9_CD 1.9_CD As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Current_JJ restructuring_NN 0.3_CD Non-Current_NNP pension_NN 1.9_CD 1.7_CD 1.9_CD 2.0_CD Pension_NN provision_NN The_DT pension_NN provision_NN relates_VBZ to_TO the_DT retirement_NN commitments_NNS under_IN its_PRP$ defined_VBN benefit_NN schemes_NNS in_IN respect_NN of_IN its_PRP$ employees_NNS in_IN Switzerland_NNP and_CC France_NNP ._.
Restructuring_NN provision_NN The_DT restructuring_NN provision_NN relates_VBZ to_TO the_DT reorganisation_NN of_IN research_NN and_CC development_NN operations_NNS and_CC other_JJ business_NN functions_NNS involving_VBG reductions_NNS in_IN staff_NN at_IN most_JJS sites_NNS ._.
90_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 91_CD 27_CD Retirement_NNP benefit_NN obligations_NNS first_RB put_VBN after_IN five_CD years_NNS by_IN the_DT holder_NN le_FW at_IN the_DT option_NN of_IN the_DT holder_NN into_IN Defined_JJ contribution_NN plans_VBZ any_DT time_NN prior_RB to_TO maturity_NN ._.
The_DT bond_NN The_DT Group_NNP operates_VBZ various_JJ defined_VBN contribution_NN plans_NNS for_IN its_PRP$ employees_NNS in_IN the_DT UK_NNP and_CC US_NNP ._.
The_DT Groups_NNS average_JJ share_NN price_NN for_IN the_DT preceding_VBG contributions_NNS to_TO these_DT plans_NNS are_VBP charged_VBN to_TO the_DT income_NN statement_NN in_IN the_DT period_NN to_TO which_WDT they_PRP relate_VBP ,_, n_JJ price_NN shall_MD be_VB adjusted_VBN to_TO the_DT reset_NN and_CC the_DT assets_NNS are_VBP held_VBN in_IN separate_JJ trustee_NN administered_VBN funds_NNS ._.
The_DT income_NN statement_NN charge_NN related_JJ ss_NN previously_RB redeemed_VBN or_CC converted_VBN ,_, to_TO defined_VBN contributions_NNS plan_VBP is_VBZ disclosed_VBN in_IN Note_NN 7_CD :_: Staff_NN costs_NNS ._.
Defined_VBN benefit_NN plan_NN The_DT Group_NNP operates_VBZ unfunded_JJ defined_VBN benefit_NN schemes_NNS in_IN respect_NN of_IN its_PRP$ employees_NNS in_IN Switzerland_NNP and_CC France_NNP ._.
deemed_VBN in_IN full_JJ by_IN the_DT Company_NN The_DT liabilities_NNS of_IN the_DT defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP are_VBP presented_VBN below_IN :_: As_IN at_IN As_IN at_IN bonds_NNS due_JJ May_NNP 2024_CD at_IN a_DT conversion_NN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD onversion_NN price_NN of_IN 77_CD pence_NN ._.
m_FW m_FW Balance_NN sheet_NN obligations_NNS for_IN :_: Defined_VBN benefit_NN pension_NN benefits_NNS 1.9_CD 1.7_CD As_IN at_IN As_IN at_IN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW The_DT amounts_NNS recognized_VBN in_IN the_DT balance_NN sheet_NN are_VBP determined_VBN as_IN follows_VBZ :_: As_IN at_IN As_IN at_IN 0.2_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 0.2_CD m_NN m_NN Present_JJ value_NN of_IN funded_JJ obligations_NNS 6.4_CD 6.3_CD interest_NN rate_NN swaps_NNS and_CC currency_NN Fair_NN value_NN of_IN plan_NN assets_NNS 5.3_CD 5.3_CD nd_NN forward_RB currency_NN contracts_NNS ._.
None_NN 1.1_CD 1.0_CD nd_NN accordingly_RB gains_VBZ and_CC losses_NNS are_VBP Present_JJ value_NN of_IN unfunded_JJ obligations_NNS 0.8_CD 0.7_CD Liability_NN in_IN the_DT balance_NN sheet_NN 1.9_CD 1.7_CD The_DT amounts_NNS recognized_VBN in_IN the_DT income_NN statement_NN are_VBP as_IN follows_VBZ :_: Restructuring_NNP Total_NNP Year_NN ended_VBD Year_NN ended_VBD m_FW m_FW 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN 0.3_CD 2.0_CD 0.3_CD Current_JJ service_NN cost_NN 0.3_CD 0.2_CD 0.1_CD Interest_NN cost_NN 0.3_CD 0.3_CD 0.3_CD 0.3_CD Expected_VBN losses_NNS on_IN assets_NNS 0.2_CD 0.2_CD 1.9_CD Total_JJ included_VBN in_IN staff_NN cost_NN 0.4_CD 0.3_CD As_IN at_IN As_IN at_IN The_DT actuarial_JJ return_NN on_IN plans_NNS assets_NNS was_VBD 0.2_CD million_CD 2004_CD :_: 0.2_CD million_CD ._.
31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 0.3_CD The_DT movement_NN in_IN the_DT defined_VBN benefit_NN obligation_NN over_IN the_DT year_NN is_VBZ as_IN follows_VBZ :_: 1.9_CD 1.7_CD Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 1.9_CD 2.0_CD m_NN m_NN Beginning_NN of_IN the_DT year_NN 7.0_CD 6.7_CD Exchange_NNP adjustment_NN 0.1_CD 0.1_CD efined_VBN benefit_NN schemes_NNS in_IN respect_NN Current_JJ service_NN cost_NN 0.3_CD 0.2_CD Contributions_NNS 0.3_CD 0.3_CD Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 0.3_CD 0.3_CD Expected_VBN losses_NNS on_IN assets_NNS 0.2_CD 0.2_CD development_NN operations_NNS and_CC other_JJ Actuarial_JJ losses_NNS recognized_VBN in_IN equity_NN 0.2_CD 0.4_CD End_NN of_IN the_DT year_NN 7.2_CD 7.0_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 91_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 92_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD The_DT movement_NN in_IN the_DT fair_JJ value_NN of_IN the_DT plan_NN assets_NNS over_IN the_DT year_NN is_VBZ as_IN follows_VBZ :_: Year_NN ended_VBD Year_NN ended_VBD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW Beginning_NN of_IN the_DT year_NN 5.3_CD 4.7_CD Exchange_NNP adjustment_NN 0.1_CD 0.3_CD Current_JJ service_NN cost_NN 0.3_CD 0.2_CD Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 0.3_CD 0.3_CD Benefits_NNS paid_VBD 0.7_CD 0.5_CD Actuarial_JJ gains_NNS recognized_VBN in_IN equity_NN 0.2_CD 0.3_CD End_NN of_IN the_DT year_NN 5.3_CD 5.3_CD At_IN 31_CD December_NNP 2005_CD and_CC 2004_CD actuarial_JJ valuations_NNS were_VBD performed_VBN by_IN professionally_RB qualified_VBN actuaries_NNS on_IN the_DT present_JJ value_NN of_IN the_DT accrued_VBN liabilities_NNS calculated_VBN under_IN the_DT projected_VBN unit_NN method_NN ._.
The_DT principal_JJ assumptions_NNS made_VBN by_IN the_DT actuaries_NNS were_VBD :_: 2005_CD 2004_CD %_NN per_IN annum_NN %_NN per_IN annum_NN Inflation_NN rate_NN 1.9_CD 2.0_CD Rate_NN of_IN increase_NN in_IN salaries_NNS 2.3_CD 2.5_CD Discount_NNP rate_NN 3.7_CD 4.0_CD Expected_VBN return_NN on_IN plan_NN assets_NNS 2.0_CD 2.4_CD Assumptions_NNS regarding_VBG future_JJ mortality_NN experience_NN are_VBP set_VBN based_VBN on_IN advice_NN in_IN accordance_NN with_IN published_VBN statistics_NNS and_CC experience_NN in_IN Switzerland_NNP and_CC France_NNP ._.
2005_CD 2004_CD years_NNS years_NNS Male_NNP 17.3_CD 17.3_CD Female_NNP 20.8_CD 20.8_CD 2005_CD 2004_CD m_NN m_NN Actuarial_JJ gains_NNS recognized_VBN in_IN equity_NN 0.3_CD Cumulative_JJ actuarial_JJ gains_NNS recognized_VBN in_IN equity_NN 0.3_CD Plan_NNP assets_NNS are_VBP comprised_VBN as_IN follows_VBZ :_: 2005_CD 2004_CD m_NN m_NN Equity_NNP 4.7_CD 4.3_CD Other_JJ 0.6_CD 1.0_CD 5.3_CD 5.3_CD Expected_VBN contributions_NNS to_TO post_VB employment_NN benefit_NN plans_NNS for_IN the_DT year_NN ending_VBG 31_CD December_NNP 2006_CD are_VBP 0.6_CD million_CD ._.
28_CD Share_NN capital_NN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD Group_NNP and_CC Company_NNP Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS m_FW m_FW Authorised_NNP Ordinary_NNP Shares_NNP of_IN 10p_CD each_DT 1,102,000_CD 1,102,000_CD 110.2_CD 110.2_CD 92_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 93_CD ws_NNS :_: Ordinary_NNP Shares_NNP of_IN Nominal_JJ value_NN Deferred_VBN B_NNP Shares_NNP Nominal_NNP value_NN Total_JJ nominal_JJ Year_NN ended_VBD Year_NN ended_VBD 10p_CD each_DT Number_NN m_NN of_IN 10p_CD each_DT Number_NN m_NN value_NN m_NN 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD At_IN 1_CD January_NNP 2004_CD 618,669,940_CD 61.9_CD 12,000,000_CD 1.2_CD 63.1_CD m_NN m_NN Exercise_NN of_IN share_NN options_NNS 478,803_CD 5.3_CD 4.7_CD Issue_NN of_IN shares_NNS to_TO Research_NNP 0.1_CD 0.3_CD Development_NNP Foundation_NNP 3,250,000_CD 0.3_CD 0.3_CD 0.3_CD 0.2_CD At_IN 1_CD January_NNP 2005_CD 622,398,743_CD 62.2_CD 12,000,000_CD 1.2_CD 63.4_CD 0.3_CD 0.3_CD Rights_NNPS issue_NN 125,627,357_CD 12.6_CD 12.6_CD 0.7_CD 0.5_CD Acquisition_NNP of_IN shares_NNS in_IN Astralis_NNP 5,482,238_CD 0.6_CD 0.6_CD 0.2_CD 0.3_CD Exercise_NN of_IN share_NN options_NNS 255,808_CD 5.3_CD 5.3_CD At_IN 31_CD December_NNP 2005_CD 753,764,146_CD 75.4_CD 12,000,000_CD 1.2_CD 76.6_CD rofessionally_RB qualified_VBN actuaries_NNS The_DT Group_NNP raised_VBD 34.8_CD million_CD net_NN of_IN expenses_NNS by_IN means_NNS of_IN a_DT rights_NNS issue_NN of_IN 125,627,357_CD new_JJ ordinary_JJ shares_NNS ._.
The_DT principal_JJ The_DT Group_NNP also_RB issued_VBD 5,482,238_CD Ordinary_NNP Shares_NNP to_TO two_CD former_JJ Astralis_NNP Directors_NNS to_TO acquire_VB 11,160,000_CD 2005_CD 2004_CD %_NN per_IN annum_NN %_NN per_IN annum_NN common_JJ shares_NNS in_IN Astralis_NNP ._.
1.9_CD 2.0_CD 2.3_CD 2.5_CD Deferred_VBN B_NNP shares_NNS 3.7_CD 4.0_CD In_IN July_NNP 2000_CD ,_, 12_CD million_CD deferred_VBN A_DT and_CC 12_CD million_CD deferred_VBN B_NNP shares_NNS were_VBD issued_VBN to_TO Dr_NNP Gonella_NNP ,_, the_DT vendor_NN of_IN 2.0_CD 2.4_CD Jago_NNP ,_, under_IN a_DT settlement_NN agreement_NN that_WDT established_VBD the_DT full_JJ and_CC final_JJ settlement_NN of_IN the_DT deferred_JJ consideration_NN payable_JJ on_IN the_DT acquisition_NN of_IN Jago_NNP ._.
The_DT holders_NNS of_IN deferred_VBN A_DT and_CC B_NNP shares_NNS have_VBP no_DT rights_NNS to_TO participate_VB in_IN the_DT profits_NNS of_IN the_DT Company_NN ,_, no_DT voting_NN rights_NNS and_CC on_IN a_DT winding_VBG up_RP or_CC other_JJ return_NN of_IN capital_NN only_RB receive_VB the_DT ce_NN in_IN accordance_NN with_IN published_VBN nominal_JJ value_NN of_IN their_PRP$ shares_NNS if_IN the_DT holders_NNS of_IN Ordinary_NNP Shares_NNP in_IN the_DT capital_NN of_IN the_DT Company_NN have_VBP received_VBN 2005_CD 2004_CD the_DT sum_NN of_IN 1_CD million_CD per_IN Ordinary_NNP Share_NNP ._.
Under_IN the_DT terms_NNS of_IN the_DT settlement_NN agreement_NN ,_, following_VBG the_DT US_NNP years_NNS years_NNS launch_NN and_CC first_JJ commercial_JJ sale_NN of_IN Paxil_NNP CR_NNP by_IN GlaxoSmithKline_NNP in_IN 2002_CD ,_, the_DT 12_CD million_CD deferred_VBN A_DT shares_NNS 17.3_CD 17.3_CD were_VBD automatically_RB converted_VBN into_IN 12_CD million_CD Ordinary_NNP Shares_NNP ._.
20.8_CD 20.8_CD The_DT 12_CD million_CD deferred_VBN B_NNP shares_NNS automatically_RB convert_VBP to_TO 12_CD million_CD Ordinary_NNP Shares_NNP on_IN the_DT Companys_NNP 2005_CD 2004_CD receipt_NN of_IN a_DT royalty_NN statement_NN under_IN the_DT current_JJ license_NN agreement_NN stating_VBG that_IN reported_VBD sales_NNS of_IN Paxil_NNP CR_NNP m_FW m_FW have_VBP exceeded_VBN $_$ 1,000_CD million_CD during_IN any_DT calendar_NN period_NN prior_RB to_TO 1_CD January_NNP 2006_CD or_CC exceeded_VBD $_$ 337_CD million_CD 0.3_CD between_IN 1_CD January_NNP 2006_CD and_CC 3_CD May_NNP 2006_CD ._.
The_DT conditions_NNS have_VBP not_RB been_VBN met_VBN and_CC the_DT deferred_VBN B_NNP shares_NNS 0.3_CD will_MD be_VB transferred_VBN to_TO the_DT Company_NNP Secretary_NNP for_IN no_DT consideration_NN for_IN him_PRP to_TO hold_VB as_IN custodian_NN ._.
2005_CD 2004_CD Warrants_NNS m_FW m_FW The_DT Company_NN has_VBZ the_DT following_JJ warrants_NNS outstanding_JJ :_: 4.7_CD 4.3_CD 0.6_CD 1.0_CD a_DT D_NNP and_CC E_NNP warrants_NNS 5.3_CD 5.3_CD The_DT D_NNP and_CC E_NNP warrants_NNS were_VBD issued_VBN in_IN March_NNP 2002_CD as_IN part_NN of_IN the_DT consideration_NN for_IN the_DT agreement_NN with_IN Paul_NNP Capital_NNP to_TO fund_VB new_JJ product_NN development_NN ._.
The_DT D_NNP and_CC E_NNP warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB g_NN 31_CD December_NNP 2006_CD are_VBP 0.6_CD million_CD ._.
for_IN a_DT total_NN of_IN 5_CD million_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN to_TO 31_CD December_NNP 2008_CD at_IN an_DT exercise_NN price_NN of_IN 73.75_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 0.3_CD million_CD ,_, deemed_VBD to_TO be_VB the_DT fair_JJ value_NN of_IN the_DT D_NNP and_CC E_NNP warrants_NNS ,_, has_VBZ been_VBN recorded_VBN in_IN Other_JJ Reserves_NNS ._.
31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_NN m_NN b_NN F_NN warrants_NNS The_DT F_NN warrants_NNS were_VBD issued_VBN in_IN December_NNP 2003_CD as_IN part_NN of_IN the_DT 2.7_CD million_CD $_$ 5_CD million_CD loan_NN with_IN GE_NNP Capital_NNP 110.2_CD 110.2_CD Corp._NNP ._.
The_DT F_NN warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB for_IN a_DT total_NN of_IN 300,000_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN until_IN the_DT repayment_NN date_NN of_IN the_DT loan_NN at_IN an_DT exercise_NN price_NN of_IN 1.20_CD per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 39,000_CD ,_, deemed_VBD to_TO be_VB the_DT fair_JJ value_NN of_IN the_DT F_NN warrants_NNS ,_, has_VBZ been_VBN recorded_VBN in_IN Other_JJ Reserves_NNS ._.
SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 93_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 94_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD c_NN Other_JJ warrants_NNS Warrants_NNS were_VBD issued_VBN in_IN December_NNP 1999_CD as_IN part_NN of_IN the_DT acquisition_NN of_IN DepoTech_NNP and_CC entitle_VB the_DT holders_NNS to_TO subscribe_VB for_IN 371,353_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN beginning_VBG 31_CD December_NNP 1999_CD and_CC ending_VBG on_IN 25_CD February_NNP 2005_CD at_IN an_DT exercise_NN price_NN of_IN $_$ 1.142_CD 59.5_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
All_DT of_IN these_DT warrants_NNS lapsed_VBD unexercised_JJ on_IN 25_CD February_NNP 2005_CD ._.
Potential_JJ Issues_NNS of_IN ordinary_JJ shares_NNS a_DT Employee_NN share_NN schemes_NNS The_DT Group_NNP encourages_VBZ employee_NN participation_NN in_IN its_PRP$ shares_NNS through_IN ownership_NN and_CC continues_VBZ to_TO operate_VB various_JJ incentive_NN schemes_NNS whereby_WRB Directors_NNS and_CC employees_NNS are_VBP to_TO able_JJ to_TO acquire_VB shares_NNS ,_, and_CC potential_JJ shares_NNS ,_, in_IN the_DT Company_NN ._.
Further_JJ details_NNS are_VBP provided_VBN in_IN Note_NN 29_CD :_: Share_NN based_VBN payments_NNS ._.
b_NN Deferred_JJ consideration_NN on_IN acquisition_NN of_IN Krypton_NNP The_NNP deferred_JJ consideration_NN on_IN the_DT acquisition_NN of_IN Krypton_NNP provides_VBZ that_IN a_DT maximum_NN of_IN 37.5_CD million_CD Ordinary_NNP Shares_NNP would_MD be_VB issued_VBN contingent_NN on_IN a_DT change_NN in_IN control_NN of_IN the_DT Company_NN at_IN a_DT share_NN price_NN of_IN not_RB less_JJR than_IN 80_CD pence_NNS compounded_VBN at_IN an_DT annual_JJ rate_NN of_IN 10_CD %_NN 2.08_CD as_RB at_IN 31_CD December_NNP 2005_CD ,_, or_CC satisfaction_NN of_IN various_JJ conditions_NNS and_CC hurdles_NNS which_WDT lapsed_VBD on_IN 31_CD December_NNP 2003_CD ._.
No_DT provision_NN for_IN deferred_JJ consideration_NN has_VBZ been_VBN recognized_VBN as_IN at_IN 31_CD December_NNP 2005_CD ._.
c_NN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP In_IN March_NNP 2002_CD the_DT Group_NNP announced_VBD a_DT second_JJ transaction_NN with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP under_IN which_WDT SkyePharma_NNP would_MD issue_VB Ordinary_NNP Shares_NNP up_IN to_TO a_DT value_NN of_IN $_$ 7.5_CD million_CD if_IN royalties_NNS and_CC milestones_NNS received_VBN by_IN SkyePharma_NNP in_IN respect_NN of_IN those_DT products_NNS included_VBD in_IN the_DT transaction_NN were_VBD not_RB in_IN excess_NN of_IN minimum_JJ annual_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ._.
During_IN 2005_CD the_DT royalties_NNS received_VBN by_IN SkyePharma_NNP were_VBD substantially_RB in_IN excess_NN of_IN the_DT minimum_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ,_, consequently_RB the_DT Company_NN has_VBZ not_RB recognized_VBN a_DT provision_NN ._.
29_CD Share_NN based_VBN payments_NNS The_DT Group_NNP operates_VBZ various_JJ share_NN based_VBN compensation_NN plans_NNS as_IN follows_VBZ :_: Option_NN schemes_NNS Options_NNS granted_VBN to_TO UK_NNP and_CC European_JJ employees_NNS are_VBP only_RB exercisable_JJ between_IN the_DT third_JJ and_CC tenth_NN anniversary_NN of_IN the_DT date_NN of_IN grant_NN ,_, and_CC are_VBP subject_JJ to_TO the_DT Companys_NNP Code_NNP of_IN Business_NNP Conduct_NNP and_CC Ethics_NNPS for_IN dealing_VBG in_IN Shares_NNP ,_, and_CC the_DT Model_NNP Code_NNP ._.
Options_NNS granted_VBN to_TO US_NNP employees_NNS prior_RB to_TO 2001_CD vest_NN at_IN 25_CD %_NN per_IN annum_NN from_IN the_DT date_NN of_IN grant_NN and_CC there_EX were_VBD no_DT performance_NN criteria_NNS ._.
UK_NNP and_CC European_JJ options_NNS granted_VBN prior_RB to_TO 2001_CD may_MD only_RB be_VB exercised_VBN if_IN the_DT growth_NN in_IN the_DT Companys_NNP share_NN price_NN over_IN a_DT consecutive_JJ three-year_JJ period_NN exceeds_VBZ the_DT growth_NN over_IN the_DT same_JJ period_NN in_IN the_DT FTSE_NNP All_NNP Share_NNP Index_NNP ._.
This_DT criteria_NNS was_VBD satisfied_VBN for_IN the_DT first_JJ time_NN in_IN March_NNP 2000_CD ._.
Employees_NNS with_IN options_NNS that_WDT are_VBP within_IN their_PRP$ exercise_NN period_NN are_VBP now_RB able_JJ to_TO exercise_VB those_DT options_NNS within_IN any_DT one-year_JJ period_NN from_IN the_DT date_NN the_DT performance_NN condition_NN is_VBZ satisfied_VBN ._.
Super_NNP Options_NNPS are_VBP exercisable_JJ after_IN five_CD years_NNS and_CC are_VBP subject_JJ to_TO higher_JJR performance_NN conditions_NNS in_IN accordance_NN with_IN those_DT recommended_VBN by_IN the_DT Association_NNP of_IN British_NNP Insurers_NNP ._.
Following_VBG changes_NNS to_TO the_DT option_NN plans_VBZ approved_VBN at_IN the_DT Annual_JJ General_NNP Meeting_VBG in_IN June_NNP 2001_CD ,_, options_NNS granted_VBN to_TO Directors_NNS and_CC senior_JJ employees_NNS since_IN that_DT date_NN are_VBP subject_JJ to_TO performance_NN conditions_NNS linked_VBN to_TO the_DT total_JJ shareholder_NN return_NN of_IN a_DT comparator_NN group_NN of_IN companies_NNS ,_, and_CC are_VBP not_RB subject_JJ to_TO retesting_VBG ._.
Options_NNS granted_VBN to_TO other_JJ US_NNP employees_NNS continue_VBP to_TO vest_NN at_IN 25_CD %_NN per_IN annum_NN with_IN no_DT performance_NN criteria_NNS ,_, and_CC other_JJ European_JJ employees_NNS who_WP are_VBP not_RB Directors_NNS or_CC senior_JJ employees_NNS can_MD exercise_VB their_PRP$ options_NNS after_IN three_CD years_NNS and_CC are_VBP not_RB subject_JJ to_TO performance_NN conditions_NNS ._.
The_DT Groups_NNS option_NN plans_NNS are_VBP detailed_VBN further_RBR in_IN the_DT Remuneration_NNP Report_NNP ._.
It_PRP is_VBZ the_DT intention_NN of_IN the_DT Group_NNP that_IN no_DT further_JJ options_NNS grants_NNS will_MD be_VB made_VBN under_IN any_DT of_IN the_DT option_NN plans_NNS ._.
94_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 95_CD The_DT following_JJ table_NN summarises_VBZ the_DT activity_NN in_IN share_NN options_NNS for_IN the_DT year_NN to_TO 31_CD December_NNP 2005_CD :_: oTech_NNP and_CC entitle_VB the_DT holders_NNS to_TO Share_NN options_NNS Option_NN price_NN nning_JJ 31_CD December_NNP 1999_CD and_CC ending_VBG At_IN 1_CD January_NNP 2004_CD 52,345,218_CD 44.8_CD p_NN 93.0_CD p_NN ary_JJ Share_NN ._.
All_DT of_IN these_DT warrants_NNS Exercised_VBN 478,803_CD 44.8_CD p_NN 66.5_CD p_NN Cancelled_VBN or_CC expired_VBN 3,883,170_CD 46.5_CD p_NN 91.3_CD p_NN At_IN 31_CD December_NNP 2004_CD 47,983,245_CD 44.8_CD p_NN 93.0_CD p_NN Exercised_VBN 255,808_CD 46.5_CD p_NN 55.6_CD p_NN Forfeited_NNP 9,654,453_CD 46.5_CD p_NN 92.0_CD p_NN Cancelled_VBN or_CC expired_VBN 2,171,974_CD 46.5_CD p_NN 92.0_CD p_NN rship_NN and_CC continues_VBZ to_TO operate_VB Rights_NNP issue_NN adjustment_NN see_VBP below_IN 1,596,534_CD 1.8_CD p_NN 3.7_CD p_NN o_NN acquire_VB shares_NNS ,_, and_CC potential_JJ At_IN 31_CD December_NNP 2005_CD 37,497,544_CD 43.0_CD p_NN 89.3_CD p_NN sed_VBD payments_NNS ._.
Exercisable_JJ 22,180,175_CD 43.0_CD p_NN 89.3_CD p_NN maximum_NN of_IN 37.5_CD million_CD Ordinary_NNP The_DT weighted_JJ average_JJ exercise_NN price_NN as_IN at_IN 31_CD December_NNP 2005_CD was_VBD 58.6_CD pence_NN ._.
y_RB at_IN a_DT share_NN price_NN of_IN not_RB less_JJR than_IN r_NN 2005_CD ,_, or_CC satisfaction_NN of_IN various_JJ The_DT market_NN value_NN of_IN Ordinary_NNP Shares_NNP as_IN at_IN 31_CD December_NNP 2005_CD was_VBD 49.75_CD pence_NN ._.
The_DT market_NN value_NN of_IN Ordinary_NNP for_IN deferred_JJ consideration_NN has_VBZ been_VBN Shares_NNS during_IN 2005_CD ranged_VBD from_IN the_DT lowest_JJS closing_NN mid-price_NN of_IN 34.25_CD pence_NN to_TO the_DT highest_JJS closing_NN mid-price_NN of_IN 66.75_CD pence_NN per_IN share_NN ._.
No_DT options_NNS were_VBD granted_VBN during_IN the_DT current_JJ year_NN ._.
At_IN 31_CD December_NNP 2005_CD the_DT following_VBG Ordinary_NNP Shares_NNP were_VBD under_IN option_NN to_TO employees_NNS or_CC former_JJ employees_NNS of_IN tal_JJ Royalty_NNP Acquisition_NNP Fund_NNP under_IN the_DT Group_NNP :_: lion_NN if_IN royalties_NNS and_CC milestones_NNS Option_NN price_NN for_IN each_DT Number_NN of_IN options_NNS over_IN saction_NN were_VBD not_RB in_IN excess_NN of_IN Normal_JJ expiry_NN date_NN Ordinary_NNP Share_NN of_IN 10p_CD Ordinary_NNP Shares_NNP of_IN 10p_CD 2005_CD the_DT royalties_NNS received_VBN by_IN 29_CD April_NNP 2006_CD 72.0_CD p_NN 930,937_CD ired_VBD to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ,_, 7_CD April_NNP 2007_CD 63.8_CD p_NN 529,100_CD 28_CD January_NNP 2008_CD 49.0_CD p_NN 129,254_CD 31_CD March_NNP 2008_CD 89.3_CD p_NN 829,615_CD 5_CD October_NNP 2008_CD 43.0_CD p_NN 570,128_CD 19_CD April_NNP 2009_CD 66.7_CD p_NN 2,272,318_CD 25_CD May_NNP 2009_CD 54.4_CD p_NN 5,076,891_CD 7_CD September_NNP 2009_CD 54.6_CD p_NN 199,044_CD ween_VBP the_DT third_JJ and_CC tenth_NN anniversary_NN 6_CD June_NNP 2010_CD 87.6_CD p_NN 442,185_CD Conduct_NNP and_CC Ethics_NNPS for_IN dealing_VBG in_IN 3_CD November_NNP 2010_CD 78.4_CD p_NN 1,411,387_CD 001_CD vest_NN at_IN 25_CD %_NN per_IN annum_NN from_IN the_DT 12_CD June_NNP 2011_CD 77.4_CD p_NN 4,066,007_CD options_NNS granted_VBN prior_RB to_TO 2001_CD may_MD 31_CD October_NNP 2011_CD 53.4_CD p_NN 913,309_CD cutive_JJ three-year_JJ period_NN exceeds_VBZ the_DT 12_CD April_NNP 2012_CD 69.4_CD p_NN 4,847,662_CD s_PRP satisfied_VBD for_IN the_DT first_JJ time_NN in_IN March_NNP 24_CD May_NNP 2012_CD 75.4_CD p_NN 447,637_CD w_NN able_JJ to_TO exercise_VB those_DT options_NNS 25_CD September_NNP 2012_CD 49.6_CD p_NN 1,114,377_CD tisfied_VBN ._.
Super_NNP Options_NNPS are_VBP exercisable_JJ 7_CD April_NNP 2013_CD 44.6_CD p_NN 13,570,809_CD dance_NN with_IN those_DT recommended_VBN by_IN 26_CD September_NNP 2013_CD 59.5_CD p_NN 146,884_CD 37,497,544_CD eeting_NN in_IN June_NNP 2001_CD ,_, options_NNS granted_VBD ance_NN conditions_NNS linked_VBN to_TO the_DT total_JJ Following_VBG completion_NN of_IN the_DT Companys_NNP Rights_NNPS Issue_NNP announced_VBD on_IN 28_CD September_NNP 2005_CD the_DT number_NN and_CC ect_VB to_TO retesting_VBG ._.
Options_NNS granted_VBN to_TO exercise_VB price_NN applicable_JJ to_TO options_NNS were_VBD adjusted_VBN to_TO take_VB account_NN of_IN the_DT dilution_NN in_IN the_DT value_NN of_IN options_NNS caused_VBD ance_NN criteria_NNS ,_, and_CC other_JJ European_JJ by_IN the_DT Rights_NNPS Issue_NNP ._.
The_DT number_NN of_IN options_NNS was_VBD increased_VBN by_IN 4_CD %_NN and_CC the_DT exercise_NN price_NN was_VBD reduced_VBN by_IN 4_CD %_NN ._.
options_NNS after_IN three_CD years_NNS and_CC are_VBP not_RB further_RB in_IN the_DT Remuneration_NNP Report_NNP ._.
As_IN stated_VBN above_IN ,_, no_DT options_NNS were_VBD granted_VBN to_TO employees_NNS in_IN 2004_CD or_CC 2005_CD ._.
For_IN those_DT options_NNS granted_VBN in_IN prior_JJ e_SYM under_IN any_DT of_IN the_DT option_NN plans_NNS ._.
years_NNS which_WDT impact_VBP the_DT income_NN statement_NN ,_, fair_JJ values_NNS were_VBD determined_VBN using_VBG an_DT option_NN pricing_NN model_NN based_VBN SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 95_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 96_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD on_IN Black-Scholes_NNP but_CC adjusted_VBN to_TO model_VB the_DT particular_JJ features_NNS of_IN the_DT options_NNS ._.
The_DT fair_JJ value_NN of_IN these_DT options_NNS is_VBZ consistent_JJ with_IN the_DT values_NNS previously_RB disclosed_VBN for_IN SEC_NNP filing_NN purposes_NNS ._.
The_DT Rights_NNPS Issue_NNP had_VBD no_DT effect_NN on_IN the_DT fair_JJ value_NN of_IN options_NNS ._.
The_DT total_JJ expense_NN relating_VBG to_TO share_VB based_VBN payments_NNS ,_, which_WDT are_VBP all_DT equity_NN settled_VBD transactions_NNS ,_, is_VBZ disclosed_VBN in_IN Note_NN 7_CD :_: Staff_NN costs_NNS ._.
Deferred_JJ Share_NN Bonus_NNP Plan_NNP DSB_NNP Under_IN the_DT rules_NNS of_IN this_DT plan_NN ,_, Directors_NNS and_CC senior_JJ employees_NNS receive_VBP conditional_JJ rights_NNS to_TO acquire_VB Ordinary_NNP Shares_NNP in_IN the_DT Company_NN ,_, at_IN the_DT prevailing_VBG market_NN rates_NNS at_IN the_DT time_NN of_IN grant_NN ._.
Eligible_JJ employees_NNS are_VBP awarded_VBN rights_NNS to_TO acquire_VB a_DT maximum_JJ number_NN of_IN shares_NNS at_IN the_DT beginning_NN of_IN a_DT three_CD year_NN period_NN ,_, a_DT proportion_NN of_IN which_WDT they_PRP will_MD be_VB entitled_VBN to_TO receive_VB at_IN the_DT end_NN of_IN that_DT period_NN depending_VBG on_IN the_DT extent_NN to_TO which_WDT the_DT performance_NN conditions_NNS set_VBN by_IN the_DT Remuneration_NNP Committee_NNP at_IN the_DT time_NN the_DT allocation_NN is_VBZ made_VBN are_VBP satisfied_VBN ._.
If_IN the_DT performance_NN conditions_NNS are_VBP not_RB satisfied_VBN the_DT share_NN award_NN will_MD lapse_NN ._.
Awards_NNS are_VBP either_RB linked_VBN to_TO the_DT deferral_NN of_IN annual_JJ bonus_NN DSB_NNP Matching_NNP Share_NNP Awards_NNPS or_CC stand_VB alone_JJ share_NN awards_NNS LTIP_NNP Awards_NNPS ._.
Further_JJ information_NN on_IN awards_NNS and_CC performance_NN conditions_NNS are_VBP detailed_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
DSB_NNP Matching_VBG LTIP_NNP Awards_NNPS Share_NNP Awards_NNPS Outstanding_JJ At_IN 1_CD January_NNP 2005_CD 3,679,499_CD 2,046,093_CD Granted_VBN 3,979,684_CD 640,103_CD Rights_NNPS Issue_NNP Adjustment_NNP 301,830_CD 90,299_CD Forfeited_NNP Cancelled_NNP or_CC expired_VBD 518,084_CD 88,801_CD Released_VBN 434,395_CD At_IN 31_CD December_NNP 2005_CD 7,442,929_CD 2,253,299_CD Following_VBG completion_NN of_IN the_DT Companys_NNP Rights_NNPS Issue_NNP announced_VBD on_IN 28_CD September_NNP 2005_CD the_DT number_NN of_IN shares_NNS comprising_VBG the_DT LTIP_NNP Awards_NNPS and_CC DSB_NNP Matching_VBG Share_NN Awards_NNS was_VBD adjusted_VBN to_TO take_VB account_NN of_IN the_DT dilution_NN in_IN the_DT value_NN of_IN conditional_JJ shares_NNS caused_VBN by_IN the_DT Rights_NNPS Issue_NNP ._.
The_DT number_NN of_IN shares_NNS under_IN award_NN was_VBD increased_VBN by_IN 4_CD %_NN ._.
For_IN the_DT purposes_NNS of_IN IFRS_NNP 2_CD the_DT fair_JJ values_NNS of_IN LTIP_NNP Awards_NNPS and_CC DSB_NNP Matching_NNP Shares_NNP Awards_NNPS have_VBP been_VBN determined_VBN using_VBG a_DT Monte_NNP Carlo_NNP Simulation_NNP model_NN ._.
The_DT Monte_NNP Carlo_NNP Simulation_NNP model_NN takes_VBZ into_IN account_NN the_DT comparative_JJ total_JJ shareholder_NN return_NN performance_NN element_NN attaching_VBG to_TO these_DT share_NN awards_NNS ._.
The_DT following_JJ table_NN sets_VBZ out_RP the_DT assumptions_NNS used_VBN in_IN determining_VBG the_DT fair_JJ value_NN of_IN these_DT share_NN awards_NNS :_: DSB_NNP Matching_VBG LTIP_NNP Awards_NNPS Share_NNP Awards_NNPS Model_NNP Monte_NNP Carlo_NNP Simulation_NNP Rationale_NNP This_DT model_NN takes_VBZ into_IN account_NN the_DT market_NN based_VBN performance_NN conditions_NNS comparative_JJ TSR_NNP attaching_VBG to_TO the_DT LTIP_NNP Awards_NNPS and_CC DSB_NNP Matching_VBG Share_NN Awards_NNS ._.
Date_NN of_IN Grant_NNP 3_CD June_NNP 2005_CD 9_CD June_NNP 2005_CD 2_CD February_NNP 2005_CD Share_NN Price_NN on_IN Grant_NNP 0.54_CD 0.53_CD 0.64_CD Exercise_NNP Price_NNP nil_NN nil_NN nil_NN Expected_NNP Dividend_NN Yield_NN n_VBD a_DT n_NN a_DT n_NN a_DT Expected_NNP Volatility_NN 47.23_CD %_NN 47.18_CD %_NN 48.96_CD %_NN Risk_NNP Free_NNP Interest_NNP Rate_NNP 4.22_CD %_NN 4.73_CD %_NN 4.57_CD %_NN Expected_NNP Life_NNP 3_CD years_NNS 3_CD years_NNS 3_CD years_NNS Fair_NNP Value_NNP 0.40_CD 0.40_CD 0.57_CD 96_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 97_CD ions_NNS ._.
The_DT fair_JJ value_NN of_IN these_DT options_NNS The_DT excepted_JJ volatility_NN is_VBZ calculated_VBN as_IN the_DT historic_JJ volatility_NN of_IN the_DT Company_NN share_NN return_NN over_IN the_DT three_CD years_NNS prior_RB to_TO each_DT grant_NN date_NN ._.
In_IN determining_VBG the_DT charge_NN to_TO the_DT income_NN statement_NN ,_, the_DT Company_NN has_VBZ assumed_VBN that_IN the_DT number_NN of_IN share_NN settled_VBN transactions_NNS ,_, is_VBZ disclosed_VBN awards_NNS that_WDT will_MD ultimately_RB vest_NN is_VBZ reduced_VBN by_IN 5_CD %_NN per_IN annum_NN ._.
The_DT Rights_NNPS Issue_NNP had_VBD no_DT effect_NN on_IN the_DT fair_JJ value_NN of_IN LTIP_NNP Awards_NNPS and_CC DSB_NNP Matching_VBG Share_NN Awards_NNS ._.
ditional_JJ rights_NNS to_TO acquire_VB Ordinary_NNP The_DT total_JJ expense_NN relating_VBG to_TO share_VB based_VBN payments_NNS ,_, which_WDT are_VBP all_DT equity_NN settled_VBD transactions_NNS ,_, is_VBZ disclosed_VBN t._IN Eligible_JJ employees_NNS are_VBP awarded_VBN in_IN Note_NN 7_CD :_: Staff_NN costs_NNS ._.
e_LS year_NN period_NN ,_, a_DT proportion_NN of_IN which_WDT extent_NN to_TO which_WDT the_DT performance_NN International_NNP Share_NNP Purchase_NNP Plan_NNP ISPP_NNP is_VBZ made_VBN are_VBP satisfied_VBN ._.
If_IN the_DT All_NNP employees_NNS are_VBP eligible_JJ to_TO participate_VB in_IN the_DT ISPP_NNP whereby_WRB employees_NNS buy_VBP shares_NNS in_IN the_DT Company_NN ._.
rds_NNS are_VBP either_RB linked_VBN to_TO the_DT deferral_JJ These_DT shares_NNS are_VBP called_VBN Partnership_NNP Shares_NNP and_CC are_VBP held_VBN in_IN trust_NN on_IN behalf_NN of_IN the_DT employee_NN ._.
For_IN every_DT rds_NNS LTIP_NNP Awards_NNPS ._.
Further_JJ Partnership_NNP Share_NNP bought_VBD by_IN the_DT employee_NN the_DT Company_NN will_MD give_VB the_DT employee_NN one_CD share_NN free_JJ of_IN charge_NN muneration_NN Report_NNP ._.
The_DT employees_NNS have_VBP to_TO take_VB their_PRP$ shares_NNS out_IN of_IN the_DT plan_NN on_IN leaving_VBG the_DT Company_NN and_CC will_MD not_RB be_VB entitled_VBN to_TO the_DT Matching_NNP Shares_NNP if_IN they_PRP leave_VBP within_IN three_CD years_NNS of_IN buying_VBG the_DT Partnership_NNP Shares_NNP ._.
DSB_NNP Matching_VBG In_IN addition_NN ,_, the_DT Company_NN can_MD also_RB award_NN employees_NNS rights_NNS to_TO acquire_VB up_RP to_TO a_DT maximum_NN of_IN 3,000_CD of_IN shares_NNS LTIP_NNP Awards_NNPS Share_NNP Awards_NNPS Free_NNP Shares_NNP ._.
There_EX are_VBP no_DT vesting_NN conditions_NNS attaching_VBG to_TO the_DT Free_NNP Shares_NNP other_JJ than_IN being_VBG continuously_RB 3,679,499_CD 2,046,093_CD employed_VBN by_IN a_DT Group_NNP company_NN on_IN the_DT third_JJ anniversary_NN of_IN the_DT date_NN of_IN grant_NN ._.
3,979,684_CD 640,103_CD 301,830_CD 90,299_CD Matching_NNP Shares_NNP Free_NNP Shares_NNP Outstanding_JJ At_IN 1_CD January_NNP 2005_CD 348,831_CD 30,411_CD 518,084_CD 88,801_CD Granted_VBN 211,460_CD 434,395_CD Rights_NNPS Issue_NNP Adjustment_NNP n_VBD a_DT 2,723_CD 7,442,929_CD 2,253,299_CD Forfeited_NNP Cancelled_NNP or_CC expired_VBD 41,109_CD 7,855_CD ptember_NN 2005_CD the_DT number_NN of_IN shares_NNS Released_VBN 88,347_CD ed_VBD to_TO take_VB account_NN of_IN the_DT dilution_NN in_IN At_IN 31_CD December_NNP 2005_CD 430,835_CD 25,279_CD f_SYM shares_NNS under_IN award_NN Following_VBG the_DT completion_NN of_IN the_DT Companys_NNP Rights_NNPS Issue_NNP announced_VBD on_IN 28_CD September_NNP 2005_CD the_DT number_NN of_IN shares_NNS applicable_JJ to_TO Free_NNP Shares_NNP was_VBD adjusted_VBN to_TO take_VB account_NN of_IN the_DT dilution_NN in_IN the_DT value_NN of_IN conditional_JJ shares_NNS ing_VBG Shares_NNP Awards_NNPS have_VBP been_VBN caused_VBN by_IN the_DT Rights_NNPS Issue_NNP ._.
ulation_NN model_NN takes_VBZ into_IN account_NN to_TO these_DT share_NN awards_NNS ._.
For_IN the_DT purposes_NNS of_IN IFRS_NNP 2_CD the_DT fair_JJ value_NN of_IN these_DT Matching_NNP Shares_NNP and_CC Free_NNP Shares_NNP is_VBZ determined_VBN as_IN the_DT value_NN of_IN these_DT share_NN awards_NNS :_: market_NN value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN grant_NN ._.
In_IN determining_VBG the_DT charge_NN to_TO the_DT income_NN statement_NN ,_, the_DT Company_NN has_VBZ assumed_VBN that_IN the_DT number_NN of_IN share_NN awards_NNS that_WDT will_MD ultimately_RB vest_NN is_VBZ reduced_VBN by_IN 10_CD %_NN per_IN annum_NN ._.
DSB_NNP Matching_VBG LTIP_NNP Awards_NNPS Share_NNP Awards_NNPS The_NNP Rights_NNPS Issue_NNP had_VBD no_DT effect_NN on_IN the_DT fair_JJ value_NN of_IN the_DT Free_NNP Shares_NNP ._.
Monte_NNP Carlo_NNP Simulation_NNP model_NN takes_VBZ into_IN account_NN the_DT market_NN based_VBN ce_NN conditions_NNS comparative_JJ TSR_NNP attaching_VBG to_TO The_DT total_JJ expense_NN relating_VBG to_TO share_VB based_VBN payments_NNS ,_, which_WDT are_VBP all_DT equity_NN settled_VBD transactions_NNS ,_, is_VBZ disclosed_VBN P_NNP Awards_NNPS and_CC DSB_NNP Matching_VBG Share_NN Awards_NNS ._.
9_CD June_NNP 2005_CD 2_CD February_NNP 2005_CD 0.53_CD 0.64_CD nil_NN nil_NN n_VBD a_DT n_NN a_DT 47.18_CD %_NN 48.96_CD %_NN 4.73_CD %_NN 4.57_CD %_NN 3_CD years_NNS 3_CD years_NNS 0.40_CD 0.57_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 97_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 98_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 30_CD Reserves_NNS Share_NN premium_NN Translation_NN reserve_NN Fair_NNP value_NN reserve_NN Retained_VBN losses_NNS Group_NNP m_FW m_FW m_FW m_FW At_IN 1_CD January_NNP 2004_CD 319.3_CD 1.6_CD 364.3_CD On_IN issue_NN of_IN shares_NNS to_TO Research_NNP Development_NNP Foundation_NNP 1.5_CD Exercise_NN of_IN share_NN options_NNS 0.2_CD Exchange_NNP adjustments_NNS 2.5_CD Revaluation_NNP deficit_NN transfer_NN 0.5_CD Loss_NN for_IN the_DT year_NN 18.6_CD Share_NN based_VBN payments_NNS charge_VBP 4.1_CD Pension_NNP actuarial_JJ losses_NNS 0.1_CD At_IN 31_CD December_NNP 2004_CD 321.0_CD 0.9_CD 0.5_CD 378.9_CD Rights_NNPS issue_NN 25.1_CD Expenses_NNS of_IN rights_NNS issue_NN 2.9_CD Acquisition_NNP of_IN shares_NNS in_IN Astralis_NNP 2.3_CD Exercise_NN of_IN share_NN options_NNS 0.1_CD Exchange_NNP adjustments_NNS 0.3_CD Impairments_NNP 0.5_CD Revaluation_NNP surplus_NN transfer_NN 0.2_CD Loss_NN for_IN the_DT year_NN 50.9_CD Share_NN based_VBN payments_NNS charge_VBP 2.4_CD Purchase_NNP of_IN own_JJ shares_NNS 0.4_CD Repayment_NN of_IN convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 0.7_CD At_IN 31_CD December_NNP 2005_CD 345.6_CD 1.2_CD 0.2_CD 427.1_CD Share_NN premium_NN Fair_NNP value_NN reserve_NN Retained_VBN losses_NNS Company_NN m_NN m_FW m_FW At_IN 1_CD January_NNP 2004_CD 319.3_CD 18.4_CD On_IN issue_NN of_IN shares_NNS to_TO Research_NNP Development_NNP Foundation_NNP 1.5_CD Exercise_NN of_IN share_NN options_NNS 0.2_CD Revaluation_NNP deficit_NN transfer_NN 0.5_CD Loss_NN for_IN the_DT year_NN 32.0_CD Share_NN based_VBN payments_NNS charge_VBP 1.1_CD At_IN 31_CD December_NNP 2004_CD 321.0_CD 0.5_CD 49.3_CD Rights_NNPS issue_NN 25.1_CD Expenses_NNS of_IN rights_NNS issue_NN 2.9_CD Acquisition_NNP of_IN shares_NNS in_IN Astralis_NNP 2.3_CD Exercise_NN of_IN share_NN options_NNS 0.1_CD Impairments_NNP 0.5_CD Revaluation_NNP surplus_NN transfer_NN 0.2_CD Loss_NN for_IN the_DT year_NN 98.3_CD Share_NN based_VBN payments_NNS charge_VBP 1.3_CD Purchase_NNP of_IN own_JJ shares_NNS 0.4_CD Repayment_NN of_IN convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 0.7_CD At_IN 31_CD December_NNP 2005_CD 345.6_CD 0.2_CD 146.0_CD As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Income_NNP Statement_NNP of_IN the_DT Company_NN is_VBZ not_RB presented_VBN ._.
The_DT loss_NN of_IN the_DT Company_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD was_VBD 98.3_CD million_CD 2004_CD :_: 32.0_CD million_CD ._.
98_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 99_CD 31_CD Other_JJ reserves_NNS Fair_NNP value_NN reserve_NN Retained_VBN losses_NNS Equity_NN of_IN m_NN m_NN Merger_NNP reserve_NN Warrants_NNS reserve_NN convertible_JJ bonds_NNS Total_JJ other_JJ reserves_NNS Group_NNP m_FW m_FW m_FW m_FW 364.3_CD At_IN 1_CD January_NNP 2004_CD 9.0_CD 0.4_CD 0.7_CD 10.1_CD Exchange_NNP and_CC issue_NN of_IN convertible_JJ bonds_NNS due_JJ May_NNP 2024_CD 22.3_CD 22.3_CD At_IN 31_CD December_NNP 2004_CD 9.0_CD 0.4_CD 23.0_CD 32.4_CD Issue_NN of_IN convertible_JJ bonds_NNS due_JJ June_NNP 2025_CD 6.1_CD 6.1_CD 0.5_CD Repayment_NN of_IN convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 0.7_CD 0.7_CD 18.6_CD At_IN 31_CD December_NNP 2005_CD 9.0_CD 0.4_CD 28.4_CD 37.8_CD 4.1_CD 0.1_CD The_DT merger_NN reserve_NN relates_VBZ to_TO the_DT acquisition_NN of_IN Krypton_NNP Limited_NNP during_IN 1996_CD ._.
The_DT warrant_NN reserve_NN relates_VBZ to_TO 0.5_CD 378.9_CD the_DT D_NNP ,_, E_NNP and_CC F_NN warrants_NNS described_VBN in_IN note_NN 28_CD :_: Share_NN capital_NN ._.
The_DT equity_NN element_NN of_IN the_DT convertible_JJ bonds_NNS reserve_NN relates_VBZ to_TO the_DT convertible_JJ bonds_NNS due_JJ May_NNP 2024_CD and_CC June_NNP 2025_CD ._.
Equity_NN of_IN Merger_NNP reserve_NN Warrants_NNS reserve_NN convertible_JJ bonds_NNS Total_JJ other_JJ reserves_NNS Company_NN m_NN m_FW m_FW m_FW 0.5_CD At_IN 1_CD January_NNP 2004_CD and_CC 31_CD December_NNP 2004_CD 9.0_CD 0.4_CD 0.7_CD 10.1_CD 0.2_CD Repayment_NN of_IN convertible_JJ bonds_NNS due_JJ June_NNP 2005_CD 0.7_CD 0.7_CD 50.9_CD At_IN 31_CD December_NNP 2005_CD 9.0_CD 0.4_CD 9.4_CD 2.4_CD 0.4_CD 32_CD Commitments_NNP Group_NNP Group_NNP Company_NNP Company_NNP 0.7_CD As_IN at_IN As_IN at_IN As_IN at_IN As_IN at_IN 0.2_CD 427.1_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD 31_CD December_NNP 2005_CD 31_CD December_NNP 2004_CD m_FW m_FW m_FW m_FW Fair_NN value_NN reserve_NN Retained_VBN losses_NNS Commitments_NNS under_IN operating_VBG leases_NNS m_FW m_FW Operating_NN leases_NNS on_IN land_NN and_CC buildings_NNS :_: 18.4_CD In_IN one_CD year_NN or_CC less_JJR 2.3_CD 2.5_CD 0.6_CD In_IN two_CD to_TO five_CD years_NNS 10.4_CD 10.7_CD In_IN five_CD years_NNS or_CC more_JJR 14.6_CD 15.6_CD 0.3_CD 0.5_CD 27.3_CD 28.8_CD 0.3_CD 0.6_CD 32.0_CD 1.1_CD Other_JJ operating_NN leases_NNS :_: 0.5_CD 49.3_CD In_IN one_CD year_NN or_CC less_JJR 0.1_CD 0.1_CD In_IN addition_NN the_DT Group_NNP has_VBZ committed_VBN to_TO undertake_VB certain_JJ clinical_JJ trials_NNS on_IN behalf_NN of_IN its_PRP$ partners_NNS under_IN development_NN and_CC licensing_NN agreements_NNS ._.
0.5_CD 0.2_CD The_DT Group_NNP is_VBZ committed_VBN to_TO make_VB certain_JJ payments_NNS to_TO third_JJ parties_NNS contingent_JJ upon_IN future_JJ events_NNS such_JJ 98.3_CD as_IN the_DT approval_NN and_CC launch_NN of_IN products_NNS ._.
1.3_CD 0.4_CD 0.7_CD 0.2_CD 146.0_CD ement_NN of_IN the_DT Company_NN er_NN 2005_CD was_VBD 98.3_CD million_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 99_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 100_CD Notes_NNP to_TO the_DT Financial_NNP Statements_NNP continued_VBD 33_CD Contingencies_NNS At_IN 31_CD December_NNP 2005_CD the_DT Company_NN had_VBD provided_VBN guarantees_NNS on_IN various_JJ bank_NN borrowings_NNS of_IN its_PRP$ subsidiaries_NNS as_IN set_VBN out_RP in_IN Note_NN 23_CD :_: Borrowings_NNS ._.
In_IN common_JJ with_IN most_JJS business_NN enterprises_NNS ,_, Group_NNP companies_NNS are_VBP subject_JJ to_TO a_DT number_NN of_IN claims_NNS from_IN third_JJ parties_NNS ,_, the_DT outcome_NN of_IN which_WDT can_MD not_RB at_IN present_JJ be_VB determined_VBN but_CC which_WDT are_VBP not_RB considered_VBN to_TO be_VB material_NN in_IN the_DT context_NN of_IN these_DT financial_JJ statements_NNS ._.
Provisions_NNS have_VBP been_VBN made_VBN in_IN these_DT financial_JJ statements_NNS for_IN any_DT liabilities_NNS which_WDT are_VBP expected_VBN to_TO materialise_VB from_IN such_JJ claims_NNS ._.
34_CD Related_VBN Parties_NNS Group_NNP Directors_NNS transactions_NNS At_IN the_DT end_NN of_IN December_NNP 1998_CD ,_, Ian_NNP Gowrie-Smith_NNP through_IN a_DT family-owned_JJ trust_NN acquired_VBD a_DT 51_CD %_NN interest_NN in_IN 10_CD East_NNP 63rd_NNP Street_NNP Inc._NNP the_DT company_NN which_WDT owns_VBZ 10_CD East_NNP 63rd_NNP Street_NNP ,_, a_DT property_NN in_IN New_NNP York_NNP ._.
In_IN December_NNP 2002_CD Mr._NNP Gowrie-Smith_NNP acquired_VBD a_DT further_JJ 49_CD %_NN interest_NN ._.
SkyePharma_NNP PLC_NNP has_VBZ been_VBN in_IN occupation_NN of_IN approximately_RB half_DT of_IN that_DT property_NN since_IN January_NNP 1997_CD ,_, subject_JJ to_TO tenancy_NN agreements_NNS based_VBN upon_IN independent_JJ valuation_NN ._.
In_IN August_NNP 2003_CD the_DT Company_NN took_VBD occupation_NN of_IN the_DT entire_JJ building_NN under_IN an_DT eight-year_JJ tenancy_NN agreement_NN ,_, at_IN which_WDT time_NN the_DT annual_JJ rent_NN was_VBD increased_VBN from_IN $_$ 420,000_CD per_IN annum_NN to_TO $_$ 720,000_CD per_IN annum_NN until_IN August_NNP 2008_CD ,_, and_CC $_$ 942,500_CD per_IN annum_NN from_IN August_NNP 2008_CD to_TO August_NNP 2011_CD ._.
A_DT portion_NN of_IN these_DT premises_NNS is_VBZ currently_RB sub-let_JJ by_IN the_DT Group_NNP ._.
Company_NN The_DT Company_NN has_VBZ issued_VBN share_NN options_NNS to_TO employees_NNS of_IN subsidiary_NN undertakings_NNS and_CC in_IN accordance_NN with_IN IFRS_NNP 2_CD has_VBZ made_VBN a_DT charge_NN of_IN 1.3_CD million_CD 2004_CD :_: 1.1_CD million_CD ._.
The_DT Company_NN has_VBZ charged_VBN 1.6_CD m_NN 2004_CD :_: 1.9_CD m_NN to_TO subsidiary_NN undertakings_NNS and_CC the_DT Company_NN was_VBD charged_VBN 0.5_CD m_NN 2004_CD :_: 0.3_CD m_NN by_IN subsidiary_NN undertakings_NNS for_IN corporate_JJ services_NNS provided_VBN ._.
The_DT Company_NN has_VBZ intercompany_NN loans_NNS and_CC accounts_NNS with_IN its_PRP$ subsidiary_NN undertakings_NNS and_CC details_NNS can_MD be_VB found_VBN in_IN notes_NNS 17_CD :_: Shares_NNP in_IN and_CC loans_NNS to_TO Group_NNP undertakings_NNS ,_, 19_CD :_: Trade_NNP and_CC other_JJ receivables_NN and_CC 22_CD :_: Trade_NNP and_CC other_JJ payables_NNS ._.
Interest_NN is_VBZ charged_VBN on_IN inter_NN company_NN loans_NNS and_CC accounts_NNS at_IN 0.5_CD %_NN above_IN one_CD month_NN LIBOR_NNP or_CC 1.0_CD %_NN above_IN three_CD month_NN LIBOR_NNP and_CC totalled_VBD 7.5_CD m_NN for_IN the_DT year_NN 2004_CD :_: 9.1_CD m._FW The_DT Groups_NNS key_JJ management_NN comprises_VBZ only_RB Directors_NNS and_CC Director_NNP remuneration_NN for_IN the_DT year_NN is_VBZ shown_VBN in_IN the_DT audited_JJ part_NN of_IN the_DT Remuneration_NNP Report_NNP ._.
There_EX are_VBP no_DT material_NN balances_NNS held_VBN with_IN associates_NNS at_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD or_CC 2004_CD ._.
100_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 101_CD 35_CD Principal_NN subsidiaries_NNS ank_VBP borrowings_NNS of_IN its_PRP$ subsidiaries_NNS Subsidiary_NNP undertakings_NNS %_NN held_VBN of_IN Country_NN of_IN nominal_JJ value_NN t_NN to_TO a_DT number_NN of_IN claims_NNS from_IN third_JJ Company_NN incorporation_NN and_CC voting_NN rights_NNS Principal_NN activities_NNS are_VBP not_RB considered_VBN to_TO be_VB material_JJ SkyePharma_NNP Canada_NNP Inc._NNP ._.
Canada_NNP 100_CD %_NN Research_NN and_CC development_NN n_NN these_DT financial_JJ statements_NNS for_IN SkyePharma_NNP Production_NNP SAS_NNP France_NNP 100_CD %_NN Manufacturing_NNP of_IN pharmaceuticals_NNS SkyePharma_NNP Jersey_NNP Limited_NNP Jersey_NNP 100_CD %_NN Issue_NN of_IN bonds_NNS Krypton_NNP Limited_NNP Gibraltar_NNP 100_CD %_NN Exploitation_NN of_IN intellectual_JJ property_NN SkyePharma_NNP AB_NNP Sweden_NNP 100_CD %_NN Research_NN and_CC development_NN Jago_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD %_NN Holding_VBG company_NN Jagotec_NNP AG_NNP Switzerland_NNP 100_CD %_NN Exploitation_NN of_IN intellectual_JJ property_NN trust_NN acquired_VBD a_DT 51_CD %_NN interest_NN in_IN SkyePharma_NNP AG_NNP Switzerland_NNP 100_CD %_NN Research_NN and_CC development_NN perty_NN in_IN New_NNP York_NNP ._.
In_IN December_NNP 2002_CD SkyePharma_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD %_NN Holding_VBG company_NN een_NN in_IN occupation_NN of_IN approximately_RB SkyePharma_NNP Holding_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Holding_VBG company_NN ased_VBD upon_IN independent_JJ valuation_NN ._.
US_NNP 100_CD %_NN Development_NNP of_IN pharmaceuticals_NNS an_DT eight-year_JJ tenancy_NN agreement_NN ,_, SkyePharma_NNP US_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Development_NNP of_IN pharmaceuticals_NNS and_CC licensing_NN o_VBP $_$ 720,000_CD per_IN annum_NN until_IN August_NNP Directly_RB held_VBN by_IN the_DT Company_NN ._.
on_IN of_IN these_DT premises_NNS is_VBZ currently_RB Associates_NNPS %_NN held_VBN of_IN Country_NN of_IN nominal_JJ value_NN Company_NN incorporation_NN and_CC voting_NN rights_NNS Principal_NN activities_NNS takings_NNS and_CC in_IN accordance_NN with_IN Astralis_NNP Limited_NNP US_NNP 40_CD %_NN Research_NN and_CC development_NN 36_CD Subsequent_JJ event_NN gs_NNS and_CC the_DT Company_NN was_VBD charged_VBN In_IN May_NNP 2006_CD SkyePharma_NNP announced_VBD that_IN it_PRP had_VBD entered_VBN into_IN an_DT agreement_NN with_IN Kos_NNP Pharmaceuticals_NNP Inc_NNP rovided_VBD ._.
Kos_NNS will_MD have_VB exclusive_JJ rights_NNS to_TO market_NN Flutiform_NN in_IN the_DT US_NNP and_CC a_DT right_NN of_IN first_JJ negotiation_NN in_IN Canada_NNP ._.
SkyePharma_NNP could_MD receive_VB up_IN to_TO $_$ 165_CD million_CD in_IN milestone_NN payments_NNS on_IN achievement_NN ndertakings_NNS and_CC details_NNS can_MD be_VB found_VBN of_IN all_DT regulatory_JJ and_CC revenue_NN targets_NNS of_IN which_WDT $_$ 25_CD million_CD has_VBZ been_VBN paid_VBN up_RP front_JJ together_RB with_IN royalties_NNS her_PRP$ receivables_NN and_CC 22_CD :_: Trade_NNP and_CC starting_VBG in_IN the_DT mid_JJ teens_NNS on_IN sales_NNS by_IN Kos_NNP ._.
at_IN 0.5_CD %_NN above_IN one_CD month_NN LIBOR_NNP 9.1_CD m._NN muneration_NN for_IN the_DT year_NN is_VBZ shown_VBN December_NNP 2005_CD or_CC 2004_CD ._.
SkyePharma_NNP Annual_JJ Report_NNP 20051018155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 102_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 37_CD Transition_NN from_IN accounting_VBG practices_NNS generally_RB accepted_VBN in_IN the_DT UK_NNP to_TO International_NNP Financial_NNP Reporting_NNP Standards_NNP The_NNP Group_NNP reported_VBD under_IN UK_NNP GAAP_NNP in_IN its_PRP$ financial_JJ statements_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
The_DT Group_NNP is_VBZ required_VBN under_IN the_DT Listing_NNP Rules_NNPS to_TO report_VB under_IN IFRS_NNP for_IN the_DT year_NN ending_VBG 31_CD December_NNP 2005_CD and_CC present_JJ comparatives_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
Consequently_RB ,_, the_DT Groups_NNS date_NN of_IN transition_NN to_TO IFRS_NNP is_VBZ 1_CD January_NNP 2004_CD ._.
Set_VBN out_RP below_IN are_VBP reconciliations_NNS of_IN total_JJ equity_NN and_CC reserves_NNS and_CC income_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP ._.
Total_JJ equity_NN and_CC reserves_NNS 31_CD December_NNP 2004_CD 1_CD January_NNP 2004_CD Notes_NNP m_FW m_FW Total_JJ equity_NN and_CC reserves_NNS as_IN reported_VBN under_IN UK_NNP GAAP_NNP 63.6_CD 84.9_CD Adjustments_NNS to_TO conform_VB to_TO IFRS_NNP Revenue_NNP recognition_NN a_DT 6.7_CD 19.6_CD Sale_NNP of_IN royalty_NN interests_NNS to_TO Paul_NNP Capital_NNP b_NN 39.0_CD 36.1_CD Goodwill_NNP amortisation_NN d_SYM 4.1_CD Convertible_JJ bonds_NNS e_LS 16.4_CD 1.5_CD Fixed_VBN assets_NNS investments_NNS f_LS 0.5_CD Other_JJ financial_JJ instruments_NNS g_VBP 0.2_CD 0.4_CD Pensions_NNS h_VBP 1.2_CD 1.3_CD Total_JJ equity_NN and_CC reserves_NNS under_IN IFRS_NNP 36.5_CD 29.8_CD Loss_NN for_IN the_DT year_NN Year_NN ended_VBD 31_CD December_NNP 2004_CD Notes_NNP m_NN Loss_NN for_IN the_DT year_NN as_IN reported_VBN under_IN UK_NNP GAAP_NNP 24.3_CD Adjustments_NNP to_TO conform_VB to_TO IFRS_NNP Revenue_NNP recognition_NN a_DT 13.1_CD Sale_NNP of_IN royalty_NN interests_NNS to_TO Paul_NNP Capital_NNP b_NN 1.7_CD Share_NN based_VBN payments_NNS c_NN 2.8_CD Goodwill_NNP amortisation_NN d_SYM 4.1_CD Convertible_JJ bonds_NNS e_LS 6.5_CD Other_JJ financial_JJ instruments_NNS g_VBP 0.5_CD Loss_NN for_IN the_DT year_NN under_IN IFRS_NNP 18.6_CD Cash_NN flow_NN statement_NN The_DT transition_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP does_VBZ not_RB change_VB any_DT of_IN the_DT cash_NN flows_VBZ of_IN the_DT Group_NNP ._.
The_DT IFRS_NNP cash_NN flow_NN statement_NN is_VBZ similar_JJ to_TO UK_NNP GAAP_NNP ,_, but_CC presents_VBZ various_JJ cash_NN flows_NNS in_IN different_JJ categories_NNS and_CC in_IN a_DT different_JJ order_NN from_IN the_DT UK_NNP GAAP_NNP cash_NN flow_NN statement_NN ._.
All_DT of_IN the_DT IFRS_NNP accounting_NN adjustments_NNS net_JJ out_IN within_IN cash_NN generated_VBD from_IN operations_NNS ,_, except_IN for_IN the_DT inclusion_NN of_IN the_DT repayment_NN of_IN the_DT Paul_NNP Capital_NNP funding_VBG liabilities_NNS ._.
102_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 103_CD The_DT IFRS_NNP adjustments_NNS set_VBD out_RP in_IN the_DT reconciliations_NNS are_VBP explained_VBN below_IN :_: ar_NN ended_VBD 31_CD December_NNP 2004_CD ._.
a_DT Revenue_NN recognition_NN e_SYM year_NN ending_VBG 31_CD December_NNP 2005_CD Under_IN UK_NNP GAAP_NNP SkyePharma_NNP has_VBZ generally_RB recognized_VBN up_RP front_JJ payments_NNS immediately_RB in_IN full_JJ where_WRB there_EX uently_RB ,_, the_DT Groups_NNS date_NN of_IN transition_NN are_VBP no_DT material_NN future_NN obligations_NNS and_CC the_DT payments_NNS are_VBP non-refundable_JJ ,_, on_IN the_DT basis_NN that_IN the_DT up_RP front_JJ payment_NN relates_VBZ to_TO past_JJ services_NNS ._.
Under_IN IFRS_NNP up_IN front_JJ payments_NNS will_MD generally_RB be_VB deferred_VBN and_CC amortised_VBN on_IN a_DT systematic_JJ basis_NN over_IN the_DT period_NN of_IN product_NN development_NN to_TO filing_NN ._.
However_RB ,_, the_DT accounting_NN for_IN each_DT from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP ._.
agreement_NN will_MD continue_VB to_TO be_VB determined_VBN on_IN an_DT individual_JJ basis_NN ._.
The_DT IFRS_NNP restatement_NN increases_VBZ revenue_NN in_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD by_IN 13.1_CD million_CD so_IN reducing_VBG 31_CD December_NNP 2004_CD 1_CD January_NNP 2004_CD operating_NN and_CC retained_VBD loss_NN by_IN 13.1_CD million_CD ._.
This_DT relates_VBZ to_TO up_RB front_JJ payments_NNS that_WDT have_VBP been_VBN previously_RB m_FW m_FW recognized_VBN in_IN the_DT UK_NNP GAAP_NNP financial_JJ statements_NNS in_IN earlier_JJR years_NNS but_CC which_WDT under_IN IFRS_NNP would_MD not_RB have_VB been_VBN 63.6_CD 84.9_CD recognized_VBN in_IN full_JJ ,_, but_CC deferred_VBN across_IN the_DT period_NN of_IN development_NN to_TO filing_NN ._.
The_DT restatement_NN increases_VBZ deferred_JJ income_NN at_IN 31_CD December_NNP 2004_CD by_IN 6.7_CD million_CD 2003_CD :_: 19.6_CD million_CD ._.
6.7_CD 19.6_CD 39.0_CD 36.1_CD b_NN Sale_NNP of_IN royalty_NN interests_NNS to_TO Paul_NNP Capital_NNP 4.1_CD The_NNP Group_NNP entered_VBD into_IN two_CD transactions_NNS with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP Paul_NNP Capital_NNP in_IN 2000_CD and_CC 16.4_CD 1.5_CD 2002_CD ._.
Under_IN these_DT transactions_NNS Paul_NNP Capital_NNP provided_VBD a_DT total_NN of_IN $_$ 60_CD million_CD in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN 0.5_CD of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS on_IN a_DT selection_NN of_IN the_DT Groups_NNS products_NNS ._.
Under_IN UK_NNP GAAP_NNP the_DT 0.2_CD 0.4_CD proceeds_NNS received_VBN from_IN Paul_NNP Capital_NNP are_VBP treated_VBN as_IN a_DT sale_NN and_CC recorded_VBN as_IN operating_NN income_NN and_CC the_DT royalties_NNS 1.2_CD 1.3_CD are_VBP expensed_VBN when_WRB incurred_VBN ._.
36.5_CD 29.8_CD Under_IN IFRS_NNP the_DT proceeds_NNS received_VBD from_IN Paul_NNP Capital_NNP meet_VBP the_DT definition_NN of_IN a_DT financial_JJ liability_NN under_IN IAS_NNP 39_CD ,_, and_CC are_VBP treated_VBN as_IN such_JJ ._.
No_DT operating_NN income_NN is_VBZ recognized_VBN ,_, royalties_NNS paid_VBD to_TO Paul_NNP Capital_NNP are_VBP treated_VBN as_IN Year_NN ended_VBD 31_CD December_NNP 2004_CD repayment_NN of_IN the_DT liability_NN and_CC in_IN addition_NN interest_NN is_VBZ imputed_JJ on_IN the_DT liability_NN using_VBG the_DT effective_JJ rate_NN as_IN at_IN Notes_NNP m_NN inception_NN of_IN the_DT agreement_NN ._.
The_DT contractual_JJ arrangement_NN with_IN Paul_NNP Capital_NNP is_VBZ unaffected_JJ by_IN this_DT change_NN in_IN 24.3_CD accounting_NN and_CC the_DT arrangement_NN remains_VBZ a_DT royalty_NN agreement_NN under_IN which_WDT royalties_NNS are_VBP payable_JJ on_IN revenues_NNS earned_VBN and_CC payments_NNS received_VBD ._.
The_DT liability_NN has_VBZ no_DT face_NN amount_NN but_CC represents_VBZ the_DT net_JJ present_JJ value_NN of_IN a_DT 13.1_CD royalties_NNS we_PRP expect_VBP to_TO pay_VB Paul_NNP Capital_NNP over_IN the_DT term_NN of_IN the_DT agreement_NN ,_, discounted_VBN at_IN the_DT effective_JJ rate_NN at_IN b_NN 1.7_CD inception_NN of_IN the_DT agreement_NN ._.
c_NN 2.8_CD d_SYM 4.1_CD The_DT IFRS_NNP restatement_NN increases_VBZ the_DT loss_NN in_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD by_IN 1.7_CD million_CD and_CC decreases_VBZ e_SYM 6.5_CD net_JJ assets_NNS at_IN 31_CD December_NNP 2004_CD by_IN 39.0_CD million_CD 2003_CD :_: 36.1_CD million_CD ._.
g_RB 0.5_CD 18.6_CD c_NN Share_NN based_VBN payments_NNS IFRS_VBP 2_CD requires_VBZ that_IN for_IN share_NN option_NN awards_NNS to_TO employees_NNS ,_, the_DT fair_JJ value_NN of_IN the_DT employee_NN services_NNS received_VBD should_MD be_VB measured_VBN by_IN reference_NN to_TO the_DT fair_JJ value_NN of_IN the_DT share_NN option_NN at_IN the_DT grant_NN date_NN ._.
This_DT differs_VBZ ws_NNS of_IN the_DT Group_NNP ._.
The_DT IFRS_NNP cash_NN flow_NN significantly_RB from_IN the_DT treatment_NN under_IN UK_NNP GAAP_NNP where_WRB the_DT charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN was_VBD based_VBN rent_NN categories_NNS and_CC in_IN a_DT different_JJ on_IN the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN grant_NN and_CC the_DT exercise_NN price_NN ._.
Since_IN adjustments_NNS net_JJ out_IN within_IN cash_NN SkyePharma_NN has_VBZ historically_RB granted_VBN employee_NN options_NNS where_WRB the_DT share_NN price_NN at_IN the_DT date_NN of_IN grant_NN equals_VBZ he_PRP Paul_NNP Capital_NNP funding_VBG liabilities_NNS ._.
the_DT exercise_NN price_NN ,_, there_EX has_VBZ been_VBN no_DT charge_NN recorded_VBN under_IN UK_NNP GAAP_NNP ._.
SkyePharma_NNP has_VBZ adopted_VBN full_JJ retrospective_NN application_NN of_IN IFRS_NNP 2_CD ._.
The_DT IFRS_NNP restatement_NN results_NNS in_IN an_DT additional_JJ charge_NN to_TO the_DT income_NN statement_NN in_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD of_IN 2.8_CD million_CD ,_, increasing_VBG both_DT operating_NN and_CC retained_VBD loss_NN ._.
The_DT restatement_NN has_VBZ no_DT impact_NN on_IN net_JJ assets_NNS ._.
d_LS Goodwill_NNP amortisation_NN Under_IN UK_NNP GAAP_NNP goodwill_NN has_VBZ been_VBN amortised_VBN over_IN its_PRP$ estimated_VBN expected_VBN useful_JJ life_NN which_WDT the_DT Directors_NNS determined_VBD as_IN 20_CD years_NNS ._.
Under_IN IFRS_NNP ,_, goodwill_NN is_VBZ considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC so_RB is_VBZ not_RB amortised_VBN ,_, but_CC is_VBZ subject_JJ to_TO annual_JJ impairment_NN testing_NN ._.
Therefore_RB the_DT annual_JJ goodwill_NN charge_NN made_VBN under_IN UK_NNP GAAP_NNP will_MD SkyePharma_NNP Annual_JJ Report_NNP 20051038155_CD LR_NNP Back_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:41_CD Page_NNP 104_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD not_RB be_VB recorded_VBN under_IN IFRS_NNP from_IN 1_CD January_NNP 2004_CD ,_, the_DT IFRS_NNP transition_NN date_NN ._.
The_DT IFRS_NNP restatement_NN results_NNS in_IN a_DT reduction_NN in_IN the_DT amortisation_NN charge_NN in_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD of_IN 4.1_CD million_CD thereby_RB reducing_VBG both_DT operating_NN and_CC retained_VBD loss_NN ._.
e_LS Convertible_JJ bonds_NNS Under_IN UK_NNP GAAP_NNP the_DT total_JJ net_JJ proceeds_NNS of_IN the_DT convertible_JJ bond_NN issues_NNS in_IN 2000_CD due_JJ in_IN 2005_CD and_CC 2004_CD due_JJ in_IN 2024_CD were_VBD recorded_VBN as_IN debt_NN ._.
Under_IN IFRS_NNP the_DT conversion_NN feature_NN of_IN each_DT of_IN the_DT bonds_NNS must_MD be_VB split_VBN from_IN the_DT debt_NN and_CC classified_VBN as_IN equity_NN ._.
The_DT net_JJ impact_NN of_IN the_DT changes_NNS to_TO IFRS_NNP and_CC in_IN particular_JJ the_DT split_NN of_IN the_DT equity_NN component_NN of_IN each_DT bond_NN has_VBZ led_VBN ,_, at_IN 31_CD December_NNP 2004_CD ,_, to_TO a_DT reduction_NN in_IN the_DT carrying_VBG value_NN of_IN convertible_JJ debt_NN of_IN 16.4_CD million_CD 2003_CD :_: 1.5_CD million_CD and_CC a_DT corresponding_JJ increase_NN in_IN equity_NN ._.
While_IN the_DT carrying_VBG value_NN of_IN the_DT convertible_JJ debt_NN in_IN the_DT balance_NN sheet_NN is_VBZ reduced_VBN ,_, the_DT amount_NN of_IN debt_NN repayable_NN at_IN maturity_NN is_VBZ unchanged_JJ and_CC consequently_RB under_IN IFRS_NNP the_DT Group_NNP records_NNS higher_JJR interest_NN charges_NNS in_IN each_DT year_NN to_TO maturity_NN or_CC conversion_NN ._.
In_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD ,_, the_DT impact_NN of_IN these_DT factors_NNS led_VBD to_TO an_DT additional_JJ interest_NN charge_NN of_IN 0.3_CD million_CD ._.
The_DT terms_NNS of_IN the_DT debt_NN are_VBP unaffected_JJ and_CC the_DT physical_JJ cash_NN payments_NNS due_JJ remain_VBP the_DT same_JJ :_: as_IN such_JJ the_DT cost_NN of_IN the_DT debt_NN in_IN cash_NN terms_NNS is_VBZ unaffected_JJ ._.
During_IN the_DT year_NN to_TO 31_CD December_NNP 2004_CD the_DT Group_NNP exchanged_VBD 49.6_CD million_CD of_IN the_DT convertible_JJ bonds_NNS due_JJ 2005_CD for_IN bonds_NNS due_JJ 2024_CD in_IN the_DT same_JJ amount_NN ,_, leaving_VBG 9.8_CD million_CD 2005_CD bonds_NNS outstanding_JJ ._.
Under_IN UK_NNP GAAP_NNP no_DT gain_NN or_CC loss_NN arose_VBD on_IN the_DT exchange_NN ._.
However_RB un-amortised_JJ issue_NN costs_NNS of_IN 0.3_CD million_CD were_VBD written_VBN off_RP under_IN UK_NNP GAAP_NNP as_IN exceptional_JJ interest_NN charge_NN ._.
Under_IN IFRS_NNP the_DT refinancing_NN of_IN the_DT 49.6_CD million_CD convertible_NN is_VBZ treated_VBN as_IN an_DT extinguishment_NN of_IN the_DT original_JJ debt_NN and_CC the_DT issue_NN of_IN new_JJ debt_NN recorded_VBN at_IN fair_JJ value_NN since_IN the_DT discounted_JJ present_JJ value_NN of_IN the_DT cash_NN flows_VBZ of_IN the_DT two_CD instruments_NNS differ_VBP by_IN more_JJR than_IN 10_CD %_NN 2005_CD Bond_NNP replaced_VBN by_IN a_DT 2024_CD Bond_NN ._.
The_DT extinguishment_NN and_CC debt_NN issue_NN costs_NNS lead_VBP to_TO the_DT additional_JJ charge_NN of_IN 6.2_CD million_CD recorded_VBN in_IN the_DT IFRS_NNP income_NN statement_NN in_IN 2004_CD ._.
In_IN total_JJ the_DT IFRS_NNP adjustments_NNS on_IN the_DT convertible_JJ bonds_NNS result_VBP in_IN an_DT additional_JJ interest_NN charge_NN in_IN the_DT 2004_CD income_NN statement_NN of_IN 6.5_CD million_CD and_CC an_DT increase_NN in_IN net_JJ assets_NNS at_IN 31_CD December_NNP 2004_CD by_IN 16.4_CD million_CD ._.
Of_IN the_DT 6.5_CD m_NN additional_JJ interest_NN charge_NN ,_, 0.3_CD m_NN relates_VBZ to_TO the_DT IFRS_NNP accounting_NN for_IN convertible_JJ bonds_NNS in_IN general_JJ and_CC 6.2_CD million_CD is_VBZ an_DT additional_JJ charge_NN caused_VBN by_IN the_DT 2004_CD refinancing_NN of_IN SkyePharmas_NNP convertible_JJ bond_NN due_JJ 2005_CD ._.
f_LS Fixed_VBN assets_NNS investments_NNS Under_IN UK_NNP GAAP_NNP fixed_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Under_IN IFRS_NNP most_JJS of_IN SkyePharmas_NNP investments_NNS are_VBP classified_VBN as_IN Available-for-sale_JJ financial_JJ assets_NNS and_CC as_IN such_JJ stated_VBN at_IN fair_JJ value_NN with_IN any_DT unrealised_JJ gains_NNS or_CC losses_NNS recorded_VBN in_IN equity_NN ._.
The_DT IFRS_NNP restatement_NN reduces_VBZ net_JJ assets_NNS at_IN 31_CD December_NNP 2004_CD by_IN 0.5_CD million_CD 2003_CD :_: Nil_NNP and_CC does_VBZ not_RB effect_VB the_DT income_NN statement_NN ._.
g_NN Other_JJ financial_JJ instruments_NNS Under_IN UK_NNP GAAP_NNP ,_, periodic_JJ gains_NNS and_CC losses_NNS on_IN interest_NN and_CC foreign_JJ currency_NN derivatives_NNS designated_VBN as_IN hedges_NNS are_VBP not_RB recognized_VBN until_IN the_DT operational_JJ transactions_NNS to_TO which_WDT they_PRP are_VBP linked_VBN occur_VBP ._.
No_DT derivatives_NNS have_VBP qualified_VBN as_IN hedges_NNS under_IN IFRS_NNP and_CC therefore_RB in_IN accordance_NN with_IN IAS_NNP 39_CD such_JJ instruments_NNS have_VBP been_VBN recognized_VBN at_IN fair_JJ value_NN at_IN the_DT balance_NN sheet_NN date_NN with_IN gains_NNS and_CC losses_NNS being_VBG recorded_VBN in_IN the_DT income_NN statement_NN ._.
104_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Covers_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:44_CD Page_NNP 2_CD Contents_NNS 01_CD Our_PRP$ Mission_NNP SkyePharma_NNP is_VBZ adopting_VBG full_JJ retrospective_JJ application_NN of_IN IAS_NNP 32_CD and_CC IAS_NNP 39_CD and_CC has_VBZ therefore_RB restated_VBN 02_CD Corporate_JJ Highlights_NNS its_PRP$ opening_NN balance_NN and_CC 2004_CD result_NN accordingly_RB ._.
This_DT restatement_NN has_VBZ led_VBN to_TO an_DT additional_JJ charge_NN in_IN the_DT year_NN 03_CD Financial_NNP Highlights_NNS to_TO 31_CD December_NNP 2004_CD of_IN 0.5_CD million_CD ,_, increasing_VBG both_DT operating_NN and_CC retained_VBD loss_NN ._.
As_IN at_IN 31_CD December_NNP 2004_CD 04_CD Chairmans_NNPS Statement_NNP the_DT IFRS_NNP restatement_NN reduces_VBZ net_JJ assets_NNS by_IN 0.2_CD million_CD 2003_CD :_: 0.4_CD million_CD increase_NN ._.
06_CD Our_PRP$ Strategy_NNP 07_CD Review_NNP of_IN Operations_NNP h_VBP Pensions_NNS 12_CD Product_NNP Pipeline_NNP The_NNP IFRS_NNP adjustment_NN on_IN pensions_NNS relates_VBZ to_TO the_DT Companys_NNPS pension_NN schemes_NNS in_IN Switzerland_NNP and_CC France_NNP ._.
14_CD Products_NNPS on_IN the_DT Market_NN In_IN accordance_NN with_IN IFRS_NNP 1_CD ,_, the_DT Group_NNP has_VBZ fully_RB recognized_VBN all_DT actuarial_JJ gains_NNS and_CC losses_NNS on_IN its_PRP$ pension_NN 15_CD Upcoming_NNP Products_NNPS schemes_NNS in_IN Switzerland_NNP and_CC France_NNP at_IN 1_CD January_NNP 2004_CD ,_, its_PRP$ transition_NN date_NN ._.
Ongoing_JJ actuarial_JJ gains_NNS and_CC 16_CD Flutiform_NN losses_NNS will_MD be_VB recognized_VBN in_IN the_DT Statement_NN of_IN Recognised_NNP Income_NNP and_CC Expenditure_NNP ._.
17_CD The_DT Shares_NNP 20_CD Corporate_JJ Social_NNP Responsibility_NNP i_FW Other_JJ 22_CD Financial_NNP Review_NNP Under_IN IFRS_NNP the_DT Group_NNP is_VBZ required_VBN to_TO capitalize_VB research_NN and_CC development_NN costs_NNS when_WRB the_DT criteria_NNS laid_VBN out_RP in_IN 26_CD Directors_NNS and_CC Officers_NNS IAS_NNP 38_CD are_VBP met_VBN ._.
The_DT Group_NNP has_VBZ reviewed_VBN its_PRP$ historical_JJ research_NN and_CC development_NN projects_NNS and_CC determined_VBD that_IN 28_CD Report_NNP of_IN the_DT Directors_NNS no_DT expenditure_NN incurred_VBN to_TO date_NN meets_VBZ the_DT criteria_NNS for_IN capitalization_NN in_IN IAS_NNP 38_CD ._.
However_RB the_DT Group_NNP will_MD continue_VB 30_CD Corporate_JJ Governance_NN to_TO review_VB its_PRP$ development_NN expenditure_NN against_IN the_DT relevant_JJ criteria_NNS and_CC will_MD capitalize_VB such_JJ expenditure_NN when_WRB 36_CD Statement_NN of_IN Directors_NNS '_POS Responsibility_NN it_PRP is_VBZ appropriate_JJ ._.
in_IN Relation_NN to_TO the_DT Accounts_NNPS 37_CD Remuneration_NNP Report_NNP Company_NNP 53_CD Independent_NNP Auditors_NNS Report_NNP to_TO the_DT Members_NNS of_IN SkyePharma_NNP PLC_NNP Total_NNP equity_NN and_CC reserves_NNS 31_CD December_NNP 2004_CD 1_CD January_NNP 2004_CD 55_CD Consolidated_NNP Income_NNP Statement_NNP m_NN m_NN 56_CD Consolidated_NNP Balance_NNP Sheet_NNP Total_NNP equity_NN and_CC reserves_NNS as_IN reported_VBN under_IN UK_NNP GAAP_NNP 349.6_CD 373.1_CD 57_CD Company_NN Balance_NNP Sheet_NNP Adjustments_NNP to_TO conform_VB to_TO IFRS_NNP 58_CD Consolidated_NNP Statement_NNP of_IN Recognised_NNP Share_NNP based_VBN payments_NNS 1.1_CD Income_NN and_CC Expense_NNP Convertible_NNP bonds_NNS 3.1_CD 1.5_CD 58_CD Company_NN Statement_NN of_IN Recognised_NNP Income_NNP Fixed_NNP assets_NNS investments_NNS 0.5_CD and_CC Expense_NNP Other_JJ financial_JJ instruments_NNS 0.2_CD 0.4_CD 59_CD Consolidated_NNP Cash_NNP Flow_NNP Statement_NNP Total_NNP equity_NN and_CC reserves_NNS under_IN IFRS_NNP 344.7_CD 375.0_CD 61_CD Company_NN Cash_NNP Flow_NNP Statement_NNP 63_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP Loss_NN for_IN the_DT year_NN Year_NN ended_VBD 31_CD December_NNP 2004_CD m_NN Loss_NN for_IN the_DT year_NN as_IN reported_VBN under_IN UK_NNP GAAP_NNP 26.9_CD Adjustments_NNP to_TO conform_VB to_TO IFRS_NNP Share_NNP based_VBN payments_NNS 1.1_CD Convertible_JJ bonds_NNS 3.8_CD Other_JJ financial_JJ instruments_NNS 0.2_CD Loss_NN for_IN the_DT year_NN under_IN IFRS_NNP 32.0_CD SkyePharma_NNP Annual_JJ Report_NNP 2005_CD 8155_CD LR_NNP Covers_NNP 22_CD 05_CD ._.
qxp_NN 28_CD 5_CD 06_CD 22:44_CD Page_NNP 1_CD Registered_NNP Head_NNP Office_NNP 105_CD Piccadilly_NNP London_NNP W1J_NNP 7NJ_NNP Telephone_NNP :_: 02074911777_CD Fax_NNP :_: 02074913338_CD Registered_NNP No_NNP :_: 107582_CD Company_NNP Secretary_NNP :_: Douglas_NNP Parkhill_NNP Auditors_NNS LLP_NNP Chartered_NNP Accountants_NNPS 1_CD Embankment_NNP Place_NNP London_NNP WC2N_NNP 6RH_NNP Solicitors_NNPS UK_NNP Stringer_NNP Saul_NNP 17_CD Hanover_NNP Square_NNP London_NNP W1S_NNP 1HU_NNP US_NNP Sullivan_NNP &_CC Cromwell_NNP 1_CD New_NNP Fetter_NNP Lane_NNP London_NNP EC4A_NNP 1AN_NNP Corporate_NNP Broker_NNP and_CC Financial_NNP Adviser_NNP Credit_NNP Suisse_NNP First_NNP Boston_NNP 20_CD Columbus_NNP Courtyard_NNP London_NNP E14_NNP 4DA_NNP Bankers_NNP National_NNP Westminster_NNP Bank_NNP plc_NN Bishopsgate_NNP Business_NNP Centre_NNP PO_NNP Box_NNP 34_CD 15_CD Bishopsgate_NNP London_NNP EC2P_NNP 2AP_NNP Registrars_NNPS Capita_NNP Registrars_NNPS The_DT Registry_NNP 34_CD Beckenham_NNP Road_NNP Beckenham_NNP Kent_NNP BR3_NNP 4TU_NNP Depositary_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP 101_CD Barclay_NNP Street_NNP New_NNP York_NNP NY_NNP 10286_CD USA_NNP Annual_JJ Report_NNP 2005_CD Making_VBG Good_JJ Drugs_NNS Better_RBR SkyePharma_NNP Annual_JJ Report_NNP 2005_CD
